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ABSTRACT 
This study aims at tackling some of the problems often encountered in photostability testing 
and liquid formulation development. Three anti-cancer drugs will be employed as models; 
Dacarbazine (DBZ) has well established photostability issues, Axitinib (AXI) and Sunitinib (SUT) 
are two new drugs only commercially available in solid dosage forms. 
In ethanol, the photokinetics of these drugs were well described by the newly proposed Φ-
order kinetic mathematical model. This has confirmed the photoreversible character of AXI 
and SUT’s and unimolecular photoreaction of DBZ’s photodegradations. Also, the Φ-order 
kinetics is proven to describe them better than the usually used classic thermal reaction 
orders. 
In aqueous solution, the drugs were found to undergo thermal and photochemical complex 
degradations, involving at least 3 photoproducts. A new photokinetic approach has been 
proposed in this work to solving and unravelling the attributes of such complex mechanisms. 
For the first time, the quantum yields (QY) of the three drugs were determined and found to 
increase with irradiation wavelength. SUT’s QY were comparable in ethanol and water (QY460 = 
0.02), DBZ was found to be more photoefficient in water (QY330 = 0.04 and 0.1, respectively) 
and AXI in water (QY330 = 0.06 and 0.03). 
Φ-order kinetics’ potential for the development of reliable actinometers of the three drugs, 
without prior knowledge of unknown reaction parameters, has also been established. 
A general equation to describe the isotherm of a (Gn:Hm) guest-host multicomponent complex 
was proposed in this work to palliate the lack of a strategy for characterising nanosponge-drug 
complexes. It provides information on both stiochiometry and association constant of the 
complex. The results indicate that hydrophobic AXI forms a 1:0.8 complex, indicating the 
possibility of multiple association sites and/or different types of binding. 
The newly developed AXI/nanosponge liquid formulation has significantly increased solubility 
(5000-fold) and thermal stability. Furthermore, the photostability of DBZ and SUT were 
considerably improved by using a strategy based on light-absorption competitors. Their initial 
velocities reduced from 10 and 3 s-1 (respectively) to 1 and 0.13 s-1. 
The successful application of these methods to the model anti-cancer drugs has set out new 
approaches that might be found useful for future treatments of photodegradation data, 
development of drug-actinometers and liquid formulations of drugs. 
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GLOSSARY AND ABBREVIATIONS 
Atot  Total absorbance of the sample 
𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜(𝑦𝑦)  the total absorbance of the reaction medium at reaction time (𝑦𝑦 = 0,∞) when 
irradiated at certain wavelength and observed at another wavelength 
𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(𝑧𝑧) the total absorbance of the reaction medium at reaction time (z= 0,∞) when 
irradiated at certain wavelength and at the same wavelength 
𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜(𝑤𝑤) the total absorbance of the reaction medium at reaction time (𝑤𝑤 = 0,∞) 
when irradiated at the isosbestic point and observed at another wavelength 
AXI  Axitinib 
AB(1Φ) a unimolecular photoreaction mechanism, where the initial species (A) photo-
transforms into a product (B) with an efficiency ΦA→B 
AB(2Φ) a mechanism which involves two reversing photochemical reactions between 
the drug and its photoisomer 
β-Ca  Beta-Carotene 
𝐶𝐶𝑋𝑋(ℎ)  Concentration of species X at the reaction time (h = 0, pss, ∞) 
CD  Cyclodextrin 
DBZ  Dacarbazine 
DMSO  Dimethysulfoxide 
EMA  European Medicines Agency 
E-S  E-isomer of species S 
𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(𝑡𝑡) the photokinetic factor including the absorbance recorded at the reaction time 
𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜  Total fluorescence intensity at a specific wavelength of observation, with 
nanosponge “j” concentration and “i” guest concentration 
𝐹𝐹𝐹𝐹0,(𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚)
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜  the fluorescence intensity of the medium when every guest molecule is 
complexed 
𝐹𝐹𝐹𝐹0,𝐺𝐺,𝑖𝑖
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜   the native fluorescence of the guest at “i” concentration 
𝐺𝐺𝑛𝑛: �𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚 guest (G):cycldoextrin (CD) complex containing “n” number of guest species 
and  a polymer “m” (one or more) cyclodextrin chain-molecules that may 
encompass each up to “p” cyclodextrin monomer–units 
HP-β-CD 2-Hydroxypropyl- Beta-Cyclodextrin 
𝐾𝐾𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜  the equilibrium constant which expresses the ratio of species’ concentrations 
at pss for the isosbestic irradiation 
𝑘𝑘𝑋𝑋𝑚𝑚 the overall rate constant of the reaction of species X (e.g A→B or 𝐴𝐴 ⇋ 𝐵𝐵), 
where m is photochemical (λ irr) or thermal (Δ) 
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𝐹𝐹𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜   the optical path length of the monitoring light inside the sample 
𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖   the optical path length of the irradiation beam inside the sample 
PA Peak Area 
PP Photoproduct, product formed through photoreaction 
PSS Photostationary State, where the reaction have reached equilibrium. 
OHCl  Ondansetron Hydrochloride 
𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖   the radiant power 
RK  Runge-Kutta 
RMM  Relative Molecular Mass 
S0  Switch off time 
SSY  Sunset Yellow 
SUT  Sunitinib Malate 
S/x-CDP Formulation containing species S and α- or β-CDP  
TRZ  Tartrazine 
VAN  Vanillin 
x-CD  Cyclodextrin monomer, where x is α, β or γ 
x-CDP  Cyclodextrin  Polymer, where x is α, β or γ 
Z-S  Z-isomer of species S 
Φ𝑖𝑖→𝑗𝑗
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖   The quantum yield at the irradiation wavelength between species 
𝜀𝜀𝑋𝑋
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖   the extinction coefficients of species X 
λ irr  Wavelength of Irradiation, the wavelength used to irradiate the sample 
λobs Wavelength of Observation, the wavelength at which the sample was 
observed 
λ isos Wavelength of Isosbestic point, wavelength where the total absorbance of the 
reactive medium does not change because the absorbance of the species are 
the same 
λ irr/λobs Irradiated at a wavelength and observed at another  
𝛽𝛽𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  Proportionality factor between the overall rate-constant and the radiant 
power 
𝜈𝜈0(𝑛𝑛)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜⁄  the reaction’s initial velocity, where n is cld. (calculated from theoretical 
equation) or mod. (determined from differential equation of the Φ-order 
kinetic model equation). 
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1.1. INTRODUCTION 
The process of pharmaceutical formulation development involves many stages and testing that 
leads to a final product which is suitable for patient use. However, many limitations are 
encountered, such as the evaluation and quantification of drugs’ photostability data, the 
suitability of the actinometers used for photostability studies and the development of liquid 
formulations that are soluble and stable. This study aims to address these issues through the 
use of three anti-cancer drugs: Dacarbazine, Axitinib and Sunitinib. 
Photostability testing is an integral part of drug development as specified by the International 
Conference on Harmonisation (ICH) [1]. However, the lack of a standardised methodology or 
comparative measure for determining a drug’s photokinetics means that the photoreactivity of 
different drugs, or the same drug measured at different irradiation conditions, cannot be 
directly compared. 
Furthermore, it is often questioned whether the quinine hydrochloride chemical actinometer 
recommended by the ICH [1] for use with photostability studies meets the generally accepted 
requirements of a chemical actinometer [2-4]. Not only must it be calibrated for each type of 
light source that might be used for photostability testing, but also its response is temperature 
dependent [4]. 
In the pharmaceutical industry, the lack of commercially available oral liquid dosage forms is 
an on-going problem [5] – limiting their availability to paediatric and geriatric patients, and 
those with dysphagia who require medicines to be delivered via nasogastric or gastrostomy 
tubes [5]. However, challenges with the solubility and stability (including light stability) of 
active compounds of liquid drug preparations often means that new drugs are only available in 
solid dosage forms [6]. Consequently, drugs are often prepared extemporaneously as oral 
liquid formulations by crushing or opening marketed tablets and capsules. In many cases, the 
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stability of these extemporaneous preparations, which may affect their tolerability, are yet to 
be established [5]. 
These issues will be discussed and solutions to solve them proposed in the 10 chapters of this 
thesis. 
Chapter 1 to 3 provides an overview of the work to be presented, current literature in the 
subject and the methods employed in this study. 
An overview of the current literature on the three model drugs can be found in chapter 4. To 
the best of our knowledge, there are no published photokinetic studies on the three drugs. In 
addition, a stable liquid formulation does not currently exist for these drugs.  
The following chapters (Chapter 5-10) can be divided into two main sections.  
The first section seeks to quantify photokinetic data obtained from drug photodegradation 
reactions. For simple, thermally stable, unimolecular AB(1Φ) and photoreversible AB(2Φ) drug 
photodegradations, the recently developed Φ-order kinetics model can be applied (Chapter 5). 
Successful application of this approach strongly suggests that drug photodegradations are 
better described by Φ-order than the classic zero, first and second thermal reaction orders.  
In aqueous solution, the degradation of these three drugs was found to obey much more 
complex mechanisms and thus required other means of evaluation. Chapter 6 presents a new, 
alternative method which circumvents the limitations of published chemometric approaches, 
to elucidate, quantify and evaluate complex drug photodegradation. This new approach 
enabled the determination of different aspects of the reaction, with a better performance 
compared to classic separation techniques (including the elucidation of all species’ spectra). 
New techniques for the development of drug actinometers are described in chapter 5 and 6. 
The methods presented here can easily be applied to many other photolabile drugs for 
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development of reliable actinometers, even without prior knowledge of other reaction 
parameters.  
The second part of this study focuses on the quantification of the effect of both cyclodextrin 
monomer and polymers with the aim to developing stable liquid formulations of three very 
light-sensitive anti-cancer drugs – one of which is practically insoluble in water.  
However, the means of evaluating the interaction/association between drug and cyclodextrin 
polymers does not currently exist in the literature and so a new mathematical framework 
proposed will be presented in Chapter 7. Not only does it does not require precise knowledge 
of the species’ masses, it does not impose preselected stoichiometries, to provide reliable 
information on both stiochiometry and association constant of the complex. 
For the first time, a comprehensive approach is presented to address these issues by 
considering both inclusion complexation with cyclodextrins (Chapter 8) and the use of light 
absorption competitors (Chapter 9). Until now, a systematic study of the effect of cyclodextrin 
monomers and polymers has never been presented for these drugs.  
Chapter 10 proposes soluble aqueous formulations for the three drugs that present improved 
thermal and/or photochemical stabilities. It offers potential solutions to the problems that 
stand in the way of making these and other similar drugs more widely available. 
The final chapter (Chapter 11) represents the main conclusions from the work presented and 
the results of this study. 
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DRUG PHOTODEGRADATION AND 
PHOTOSTABLIZATION OVERVIEW 
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2.1. DRUG PHOTODEGRADATION 
Exposure of certain materials to light can cause various changes to their properties. This is 
often seen as a change in colour, such as the colour of products fading or glasses that darken 
when exposed to sunlight [1]. 
Light can also have an effect on pharmaceuticals. There are a large number of drugs that 
require protection from light as outlined by the European Pharmacopoeia [2]. The number of 
drugs identified as photochemically unstable (photoreactive or photolabile) is steadily 
increasing as new drugs are discovered and existing drugs re-examined [3]. However, drugs 
that are being labelled sensitive to light do not necessary all carry the same consequence; as 
some drugs, after weeks of exposure, only a small percentage is lost, while others degrade in 
just a few minutes [4]. 
The loss of therapeutic potency of the pharmaceutical is inevitable but the photodegradation 
of drugs should not be considered just as a decomposition process. It involves phenomena, 
such as generation of free radicals, transfers of energy and luminescence, which could result in 
the formation of photoproducts. Some of these could have toxic effect on the patient [5].  
It is true that the stability of drugs can also be influenced by other factors such as temperature, 
moisture and oxidation; but photochemical processes can have severe pharmaceutical and 
medicinal consequences. Due to the fact that most drugs absorbed within the UV and Visible 
region of light, the matter should not be considered trifling as light can essentially change the 
properties of many therapeutic agents during production, storage, handling, administration 
and even in the patient after their administration (in vivo) [3].  
In general, the drug substance would mainly experience exposure to visible light, from cool 
white fluorescent tubes. Many drug substances are white in colour, meaning little or no visible 
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light are absorbed by these compound. But it is important to note that all lamps emit some 
radiation in the UV region of the spectrum [6]. 
In modern hospital pharmacies, drugs are often stored in unit-dose containers on open shelves 
[6]. In many cases, the protective commercial pack is removed – leaving the drug product 
unprotected. They can then be exposed to fluorescence tubes and/or filtered daylight for 
several days or weeks [7]. Moreover, in accordance to the Food and Drug Administration’s 
(FDA) Compliance Policy [8], repackaged drugs can utilize an expiration date up to 6 months 
from date of repackaging without conducting stability studies. 
Therefore, knowledge about the photostability of the drug substance in vitro is essential to 
evaluate any precautions needed and ensure good quality over the entire life span of the drug. 
 
2.2. PHOTOSTABILITY TESTING 
In January 1998, the International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) made photostability testing of all new 
drug substances and products an "integral part of stress testing" [9]. Their Q1B guideline [9] on 
photostability testing provides guidance on the basic information required to characterise the 
drug's light sensitivity and stability, for submission in registration applications. It also gives 
instructions to help applicants identify the likelihood of degradation, which in turn helps 
establish the degradation pathways, products and the intrinsic stability of the molecule.  
However, despite the regulation's insistence in generating photostability data in accordance to 
its instructions (or set in comparison to them), it contains issues that are unclear including the 
design of the testing protocol, which is left to the applicant's discretion. The applicant must 
establish how the product will be used, to devise appropriate photostability studies and so 
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allowing alternative approaches "to demonstrate that light exposure does not results in 
unacceptable change". 
The lack of a standardised methodology or comparative measure for determining drugs’ 
photokinetics means that the photoreactivity of different drugs, or the same drug measured at 
different irradiation conditions, cannot be directly compared. 
 
2.3. KINETICS OF DRUG PHOTOREACTIONS 
In the literature [6,10-29], photochemical reaction data are commonly treated with 
conventional thermal reaction kinetic zero-, first- and second-order models.  
In many cases [10-29], only part of the kinetic data of photodegradation is used for such 
classical treatments. In some cases, it was found that no kinetic model can be accurately 
applied to the reaction kinetic data [26-29]. Piechocki and Thoma [10] showed that partial 
reaction data could equally be fitted with both zero and first order models (Fig 2.1).   
 
 
Fig 2.1: Partial photodegradation data of benzydamine hydrochloride (5 x 10-5 M) that was 
fitted with (A) first-order kinetics and later a good fit was also obtained for (B) a zero-order 
model [10] 
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However, only poor fitting is found when the full photodegradation data was fitted with the 
conventional (classical thermal) models [30]. This clearly shows that the kinetics models 
developed for thermal reactions may not be suitable for photochemical reactions.  
In contrast to thermal reactions, the different equations depends on three parameters – the 
intensity of the irradiation (P), the extinction coefficient (ε) and quantum yield (Φ) of the drug 
at a specific wavelengths. The quantum yield for photoreaction can be defined as the number 
of drug molecules that undergo photoreaction divided by the number of photons absorbed 
[10]. Without first defining these parameters, the photoreactivity of different drugs, or the 
same drug measured at different irradiation conditions, cannot be directly compared.  
The differential equation (Eq.1) for the photochemical reaction AB(1Φ), that is species A 





𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐶𝐶𝐴𝐴(𝑡𝑡) × 𝑃𝑃
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(𝑡𝑡)                     Eq.1 
Where CA(t) is the concentration of A at any time, 𝜀𝜀𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  the extinction coefficient of A, 𝛷𝛷𝐴𝐴𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  
the quantum yield of the reaction, 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  the light intensity received and 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  the path length of 







  Eq.2 
in which 𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  is the total absorbance of the reaction medium. 
In the general case, Eq.1 cannot be integrated due to the time-variation of the photokinetic 
factor, which is dependent on the total absorbance of the medium at the irradiation 
wavelength.  
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However, recently, it has been successfully integrated in closed-form and was shown that a 
drug following the AB(1Φ) photodegradation mechanism obeys well a Φ-order kinetic [30-32]. 
The Φ-order kinetic described well the whole set of AB(1Φ) photodegradation data and readily 
allowed the determination of the reaction photochemical quantum yield from the reaction 
overall rate-constant. Nevertheless, it has a limited application as they are specific to 
unimolecular AB(1Φ) drug photodegradations. 
 
2.3.1. Computational Techniques  
In some studies, data analysis of complex photodegradation mechanisms are overcome by the 
use of computational techniques, which involves the use of mathematical software procedures 
to analyse data obtained from dynamic and unstable systems [33]. Common chemometrics 
techniques used in combination with UV-Vis spectrophotometry are spectral curve 
deconvolution multivariate curve resolution (MCR) methods, Principal Component Regression 
(PCR) and non-linear iterative partial least squares (NIPALS) [33]. These models enable 
complex drug photodegradation pathways to be resolved, the number of species, their 
individual spectra, their concentration profiles and rate-constant to be extracted from mixed 
spectral photokinetic data [34-41]. The NIPALS method will also provide the equilibrium 
constant [40].  
However, these methods do not provide a unique answer and is only applicable to systems 
where two correlated spectra can be recorded on each sample [40]. Otherwise, 
chromatographic data is required to determine the component spectral profiles and 
concentrations. 
More importantly, these models are based on the thermal differential equations - which are 
completely different to that of photokinetic. Thus, the current methods of resolving 
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photokinetic data gives thermal rate constants for photochemical reaction and do not provide 
information of Φ. 
 
2.4. EFFECT OF SOLVENT 
When comparing photostability data, the choice of solvent is vital as this may significantly 
affect the results of photodegradation processes [10].  Systematic studies on the effect of 
solvents on a range of pharmaceutics have been carried out and many reviews available [41-
53]. All of which were found to give different mechanisms, different number of photoproducts 
and different rate of photodegradation in different media [50-53]. 
 
Table 2.1: Apparent first-order rate constants (kobs) for the photodegradation of various 
drugs in water and organic solvents using chromatographic assays 
 kobs x 103 (min-1) ± SD 
Solvents Riboflavin [50] Norfloxacin [51] Moxifloxacin [52] Levofloxacin [53] 
Water 4.61 ± 0.25 1.59 ± 0.13 32.6 ± 0.13 99.8 ± 0.35 
Acetonitrile 3.81  ± 0.16 0.80 ± 0.12 20.4 ± 0.10 76.6 ± 0.31 
Methanol 3.64  ± 0.17 0.61 ± 0.09 18.1 ± 0.11 71.4 ± 0.33 
Ethanol 3.45 ± 0.15 0.45 ± 0.05 15.5 ± 0.09 68.0 ± 0.23 
1-Propanol 3.34 ± 0.16 0.37 ± 0.11 13.5 ± 0.05 63.2 ± 0.27 
1-Butanol 3.28 ± 0.13 0.34 ± 0.08 12.4  ± 0.08 61.6 ± 0.20 
 
Even minor addition of one solvent to another can alter the photoreactivity of the drug [6]. 
Addition of 6.5 mM carbon tetrachloride to a sample of 6-methoxy-2-naphthylacetic acid 
prepared in acetonitrile caused the photodegradation rate to increase nearly 10 times [54]. 
Thus, these considerations are important in the formulation of drugs where organic solvents 
are used as cosolvents [55,56]. 
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It should also be noted that 92 percent of blood plasma is water and that drugs are taken with 
water, some pharmaceutical excipients releases moisture or strongly absorbs water from the 
air [55]. 
Thus photochemical studies in both polar and apolar media provides useful information for 
predicting drug photoreactivity in lipophilic environment. 
 
2.5. CYCLODEXTRINS 
Cyclodextrins (CD) are cyclic oligosaccharides consisting of glucopyranose units linked by α-
(1,4) bonds (Fig 2.2). They possess the unique ability to accommodate hydrophobic ‘guests’ 
within the cavity of their bucket-shaped structure. Since its discovery, cyclodextrin’s ability to 
form inclusion complexes has been found to have profound effects on the properties of guest 
molecules [57]. 
There are different pharmaceutical products containing cyclodextrins that are now available 
on the market worldwide and numerous food products, cosmetics and other commercial 
products contain cyclodextrins [58,59] In the pharmaceutical industry, cyclodextrins are most 
commonly used to aid the dissolution of poorly soluble drugs [60-64].   
There are three main types of cyclodextrins: α-, β- and γ-CD. They are referred to as the first 
generation cyclodextrins. They consist of six, seven and eight α-(1,4) linked glycosyl units 
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Table 2.2: Natural cyclodextrins and their properties. 
Cyclodextrin α-CD β-CD γ-CD 
No. of Glucose Units 6 7 8 
Molecular Mass (g mol-1) 972 1135 1297 
Cavity Diameter (nm) 0.47 - 0.53 0.60 - 0.65 0.75 - 0.83 
Solubility (25°C, %w/v) 14.5 1.85 23.2 
 
 
Fig 2.2: The Molecular structure of β-cyclodextrin, cross-section of a cyclodextrin molecule 
showing the arrangement of the glucose units and conical representation showing 
hydrophilic exterior and hydrophobic cavity [65]. 
 
Due to their unique property, the use of cyclodextrins as pharmaceutical excipients has grown 
rapidly over the last two decades [66]. They have also been used to improve the stability of 
drugs, including photostability. When highly photolabile pharmaceutics are entrapped within 
the cavity of cyclodextrins, their photodegradation rates could be reduced [67-71] - such as 
ibuprofen [68], shikon [69], nicardipine [70] and doxorubicin [71].  
However, formation of an inclusion complex does not necessarily lead to a stabilization of the 
guest molecule. This was reported for the case of midazolam [72], molsidomine [73], naproxen 
[74], and flutamide [75]. A 20-fold increase in photodecomposition quantum yield of the latter 
was reported [75]. No kinetics were given for the others. 
Nonetheless, the low water solubility and toxicity of parent CDs limit their further application 
in pharmaceutical formulations [76]. 
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2.5.1. Cyclodextrin Polymers 
Apart from the naturally occurring cyclodextrins, many cyclodextrin derivatives have been 
synthesised.  Depending on the substituent, the properties (stability and solubility) of the 
cyclodextrin derivatives are usually slightly different from that of their parent cyclodextrins. 
Of particular interest are products containing two or more covalently linked cyclodextrin-units 
called cyclodextrin polymers (CDP).  
 
 
Fig. 2.3: Schematic representation of the three main types of cyclodextrin polymers. (A) 
soluble, (B) insoluble, (C) immobilised cyclodextrin polymer [77] 
 
However, the slow development of CD polymers over the last 40 years has moderated their 
true potential. But, recent advances in nanotechnology has increased attention paid to 
cyclodextrin polymers for applications in the field of nanomedicines. Nanomedicine proposes 
the use of these systems to improve many current cancer treatments by increasing aqueous 
solubility of poorly water-soluble drugs, sustaining delivery of drugs and modifying 
pharmacokinetics, biodistribution and cellular trafficking of the active substances included 
within the nanostructure [78].  
 
2.5.2. Characterisation of Cyclodextrin Polymers 
Most guest/cyclodextrin complexes are thought to be inclusion complexes but cyclodextrins 
are also known to form non-inclusion complexes in which the guest molecule is linked at the 
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external part of the cyclodextrin [79]. Depending on the size of the guest and the host 
molecules, one guest molecule can interact with more than one host molecules (Fig. 2.4); or 
one CD interacting with one or two guest molecules.  
 
 
Fig 2.4: Diagrammatic representation of a 1:1 guest-CD inclusion complexes formed 
 
 
In some instances, depending on the size of the CD size, only parts of the guest can be 
included. Thus, multiple inclusion equilibria can coexist in one solution [79]. 
Several methods can be used for characterisation of a CD inclusion complex: circular dichroism 
[80], fluorescence spectroscopy [81], 1HNMR [82], IR and Raman spectroscopies [83]. 
Stoichiometry and association (or binding) constant of the complexes can be determined from 
all methods, but information on the structure can only be obtained from 1HNMR [82]. 
Determination of complex parameters (stoichiometry and association constant) is often 
achieved by applying Benesi-Hildebrand or Job’s method to experimental data [80, 82, 83]. 
However, Job’s method only gives indication of the stoichiometry, not association constant. 
Benesi-Hildebrand assumes a 1:1 stiochiometry, lacks sensitivity for low concentrations and 
accuracy drops rapidly as K increases [84]. Furthermore, multiple types of inclusion complex 
(1:1, 1:2 or 2:1) can be found in one solution as stoichiometries are assume and experimental 
data are fitted to the corresponding model [85]. 
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Thus, despite its growing popularity, method for characterising complexes with CD polymers 
are not yet as extensively examined as the monomers. Current methods of determining the 
stoichiometry and association constant of inclusion complexes are, as discussed, limited in 
itself and more so when applied to cyclodextrin polymers. So, often the stoichiometry for CD-P 
complexes are assumed or not stated [79,80]. 
 
2.6. PHOTOSTABILIZATION WITH CYCLODEXTRIN POLYMERS 
In many cases, suitable light-resistant packaging can prevent or reduce photodecomposition of 
drugs [4]. However, very often drugs are removed from their original packaging and stored in 
unit-dose containers, leaving them unprotected. Furthermore, exposure to light during 
administration is unavoidable and so it might be necessary to photostabilize the drug itself.  
Cyclodextrin polymer’s ability of encapsulate molecules have been used to improve drug 
photostability. They protect the photolabile drug by physically quenching the electronic 
excited states of drug molecules, draining off the energy from absorption of light before the 
drug molecule has the opportunity to undergo photodegradation [10]. Therefore, when 
unstable molecules are entrapped within the cavity of cyclodextrins, their decomposition rates 
could be reduced [68-71] or increased [72-75]. 
Even with the growth of nanomedicine, there have been very few examples of where CDPs 
have been used to protect the encapsulated molecules from light [78, 86-90] or from chemical 
and enzyme-induced degradation [92]. Nanosponges are mainly used for increasing drug 
solubility. 
5-fluoroucil (5-FU) is a chemotherapy drug known to be very light-sensitive. Encapsulation of 
the drug in β-CDP protected the drug for 6 months and maintained its cytoxicity [90].  
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β-CDP has been used in buccal formulations of Resveratrol - a polyphenolic compound 
endowed with multiple health benefits. However, its limited bioavailability and poor 
photostability in solution hinders its use in pharmaceutical applications. Complexation of the 
drug with β-CDP significantly improved its solubility, permeation of the active pharmaceutical 
ingredient (API) and photostability (Fig. 2.5) [86]. However, little detail were provided for the 
photodegradation study other than that complexation with CDP improved the drug’s 




Fig. 2.5: Photodegradation of resveratrol and complex when exposed to UV lamp at 10 cm 
distance and quantitatively analysed by HPLC [86] 
 
 
Gamma-oryzanol, a ferulic acid ester mixture used as sunscreen in the cosmetics industry, is 
another pharmaceutic whose use was limited by its photochemical instability [87]. 
Encapsulation of the compound in cyclodextrin-based nanosponges was found to provide good 
protection from UV-induced oxidation (Table 2.3). 
Another example is when camptomethecin (CPT) was also encapsulated in β-CDP. CPT is a 
potent anti-tumour agent but has poor water-solubility and high chemical instability - limiting 
its therapeutic use. However, encapsulation in β-CD nanosponges enable large amounts of the 
drug to be solubilised and increased its thermal stability [88]. Thus, prolonging its shelf life. 
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Table 2.3: rate constant (k) values obtained using pseudo-first order kinetic model and 
correlation coefficient (R2) of free gamma-oryzanol (GO) or complexed (GO/NS) 
photodegradation in different media under UVA irradiation (6.0 × 10-4 W cm-2) for 60 min at 
10 cm distance. [87] 
 
 
2.7. LIGHT ABSORPTION COMPETITORS 
Alternative to microencapsulation, inactive substances (pharmaceutical excipients) can be 
added to the drug to provide photoprotection [6,10,90-93]. However, for this the excipient 
must have an absorption spectrum that overlays the photolabile drug [90-93]. The idea is that 
the excipient will compete with the drug for the energies from the light source and as a result, 
reducing the amount of damage done to the drug by reducing the amount of light absorbed 
[90-93].  
Excipients with similar absorption spectra to the drug can be incorporated into the 
formulation, film coating or capsule shell. This was shown to be effective when addition of 
curcumin and riboflavin 5-phosphate significantly enhanced the photostability of nifedipine 
[93] or when red iron oxide was added to the film coating of Axitinib tablets [94]. 
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Fig. 2.6: Principle of photostabilzation through spectral overlay with absorbing excipients [6] 
 
Obviously, not only does the excipient requires the appropriate absorption spectrum for 
overlay, but it must also be pharmaceutically inactive, non-toxic and be photostable itself. 
Hence, the potentially useful materials is limited [90]. 
 
2.8. FORMULATION 
There are two main goals of pharmaceutical formulation [58,95,96]. First, to produce a drug 
that is stable to ensure that efficacy and safety characteristics of the active substance are 
maintained. Second, to make drug administration easier and more convenient to the patient 
who will use it. 
As mentioned above, photochemical reaction are affected by the medium and so exposure of 
drug formulations to light can impact its stability. Thus, the excipient and preparation type (i.e. 
solid dosage, liquid and topical forms) can influence the photostability of the active ingredient. 
The effect of excipients on the stability of drug formulation is often difficult to predict [58]. 
They can initiate, propagate or participate in photochemical reactions. 
Common excipients such as sugar, starches, polyvinylpyrrolidone (PVP), mannitol and lactose 
are all vulnerable to free radical attacks, which in many cases destabilizes the formulation [6, 
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56, 57]. Furthermore, non-ionic surfactants for emulsions of oral or topical preparations 
susceptible to oxidation could influence the photoreactivity of drugs.  
Although in solid state, photodegradation takes place on the surface, the degree of 
degradation depends very much on the excipients, the colour, thickness, coating, source and 
intensity of the light. 
Similarly, sample close to the surface of a solution will absorb most of the light.  
 
2.9. CONCLUSION 
Photodecomposition of unstable drug formulations could lead to undesirable side effects. A 
loss of potency of the drug and the development of adverse effects may be due to the 
formation of photoproducts during storage or administration. Therefore, photostability testing 
of drug substances is important for the evaluation of the overall photosensitivity of the 
material for development. Hence, the photostability of drug substances has developed into an 
important area of research, especially as more drugs are considered photolabile.  
When enclosed in the packaging, the drug is normally well protected from light exposure. 
However, it is also important to note those periods of time when the dosage forms are not 
covered by packaging - i.e. both during the process of manufacturing itself and during handling 
by the patient on application at home or in hospital. In this respect, the kinetics of degradation 
are strongly dependent on light intensity and spectral distribution of the light source used. 
Thus, the need to know the photochemistry of the drugs used is essential to provide important 
information to evaluate precautions required for handling and packaging, potential adverse 
effects, therapeutic aspects and new drug delivery systems 
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The ICH made photostability testing of all new drug substances and products an "integral part 
of stress testing", but fails to provide clear protocols on the treatment and analysis of 
photokinetic data. Thus, very often the zero-, first- and second-order thermal kinetic model are 
implemented. These were used irrespective of the drug’s photochemical mechanism or the 
influence of the irradiation wavelength and intensity of the light source. 
Recent advances in nanotechnology increased interest in the use of cyclodextrin polymers for 
stable drug delivery systems. They have been shown to improve many current cancer 
treatments by increasing aqueous solubility of poorly water-soluble drugs, sustaining delivery 
of drugs and modifying pharmacokinetics, biodistribution and cellular trafficking of the active 
substances included within the nanostructure. Although it is not as extensively examined as 
the other areas, nanosponges have been shown to improve the thermal and photo-stability of 
drugs. 
Overall, there are many aspects in photochemistry of pharmaceutics that are lacking and in 
this study they will be examined through the use of three very light-sensitive anti-cancer 
drugs: Dacarbazine, Axitinib and Sunitinib. 
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3.1. MATERIALS AND EQUIPMENTS 
3.1.1. CHEMICAL, SOLVENTS AND DRUGS 
3.1.1.1. Drugs 
Dacarbazine (DBZ, ≥98%), 5-(3,3-dimethyltriazen-1-yl)imidazole-4-carboamide, was purchased 
from Sigma-Aldrich (Dorset, UK).  
Axitinib (AXI, >99%), N-Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-
yl)sulfanyl)benzamide, was purchased from Selleck Chemicals (Suffolk, UK).  
Sunitinib Malate (SUT, >99%), N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-
ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (2S)-2-hydroxybutanedioic acid, was 
purchased from Selleck Chemicals (Suffolk, UK).  
8-Anilino-1-naphthalenesulfonic acid ammonium salt (ANS, ≥90%) was purchased from Sigma-
Aldrich (Dorset, UK). 
 
3.1.1.2. Solvents 
Ethanol (99.8%), methanol (99.8%), acetonitrile (99.9%) and formic acid (99.8%) were from 
Fisher Scientific (Loughborough, UK). Distilled water was also used as solvent. 
 
3.1.1.3. Chemicals 
Tartrazine (TRZ, ≥85%), Sunset Yellow (SSY, ≥90%), Quinoline Yellow (QY, ≥95%), β-Carotene 
(β-Ca, 95%), Ondansetron Hydrochloride (OHCl, ≥98%) and Vanillin (VAN, ≥98%) were 
purchased from Sigma-Aldrich (Dorset, UK) as powders.   
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Cyclodextrin monomers (α-CD, 2-Hydroxypropyl-β-CD and γ-CD) and β-cyclodextrin polymer 
(β-CDP) were purchased from Sigma-Aldrich (Dorset, UK) in powder form. 
α-Cyclodextrin polymer (α-CDP) and γ-Cyclodextrin polymer (γ-CDP) were purchased from 
CycloLab (Hungry) in powder form. 
All solvents and chemicals were of analytical grade or higher. 
 
Table 3.1: Molecular weight of cyclodextrin monomers and polymers 
 CYCLODEXTRIN 
 α-CD HP-β-CD γ-CD α-CDP β-CDP γ-CDP 
Mw (g/mol) 972.84 1460 1297.12 -a 15000 - 




For monochromatic irradiation studies, absorption spectra were recorded with an Agilent 8453 
Diode Array Spectrophotometer, using the Agilent ChemStation kinetics software provided by 
Agilent Technologies. Measurements were done with a thermostatically controlled Peltier 
cuvette holder designed for a 1 cm cuvette. 
For polychromatic studies, a ThermoScientificTM Helios Omega Spectrophotometer was used. It 
operated on remote setting for reading the absorbance, the absorbance data was collated 
using VISIONliteTM software. The scan speed was 600 nm/min at 0.5 nm interval.  
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3.1.2.2. Monochromatic Irradiation set-up  
The irradiation light for monochromatic irradiation was an Ushio 1000 W xenon arc-lamp 
housed within a shell (model A6000) and was powered by a power supply (model LPS-1200). 
The whole equipment was manufactured by Photon Technology International Corporation. 
The lamp was connected to a monochromator (model 101), a f/2.5 monochromator with a 





Fig 3.1: Monochromatic photolysis set-up for continuous and steady-state irradiations 
 
3.1.2.3. Radiant Power Meter 
The radiant power was measured using a Radiant Power/Energy meter (Oriel Model 70260). 
Light intensity is expressed as milliwatts per centimetre square (mW/cm2) by the radiant 
power meter.  
 
Optical fibre which guides the irradiation beam 
from the monochromator (model 101) to the 
sample within the Peltier-controlled cuvette 
holder for continuous irradiation. 
Computer 
program 
DAD Spectrophotometer Magnetic stirring plate placed in front 
of the monochromator opening used 
for steady-state irradiation. 
Water Inlet 
Water Outlet 
Ushio 1000 W Xenon 
Arc-Lamp housed 
within a shell (Model 
A6000) 
Power Supply (Model 
LPS-1200) 
 
36 | P a g e  
 
3.1.2.4. Fluorescence Spectrometer 
Fluorescence spectra were measured using a PerkinElmer LS 55 Fluorometer controlled via the 
FL Win Lab program as provided by PerkinElmer (USA). 
Light from an excitation source passes through a filter or monochromator and hits the sample. 
A proportion of the excitation light is absorbed by the sample, and molecules in the sample 
fluoresce. The fluorescent light is emitted in all directions. Some of this fluorescent light passes 
through a second filter or monochromator and reaches a detector, which is usually placed at 
90° to the incident light beam to avoid the risk of interference of the transmitted or reflected 
excitation light reaching the detector. 
 
 
Fig 3.2: Illustration of the key components of a fluorometer. 
 
3.1.2.5. High Performance Liquid Chromatography 
Separation was achieved on a Gemini C18 reverse phase column 5 µm, 2.1 x 50 mm 
(Phenomenex, UK) fitted to a PerkinElmer Series 200 Pump and UV/Vis Detector, and a 600 
Series Link interface; all of which were controlled remotely using TotalChrom software 
(PerkinElmer, USA).  
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3.1.2.6. Rotary Evaporator 
Evaporation of solvents for Drug/CDP formulation were achieved on the Büchi Rotavapor R-
210 (Büchi, Switzerland) fitted with a Büchi Rotavapor R-114 Vacuum. The rotary evaporation 
setup consists of a motor unit, which is attached to the evaporation flask containing the 
sample to be dried. 
 
3.1.2.7. ATR-FTIR Spectroscopy 
Infrared spectra were recorded with Bruker’s ALPHA Attenuated Total Reflection (ATR) Fourier 
Transform Infrared (FTIR) Spectrometer using the OPUS software. 
 
3.1.2.8. Scanning Electron Microscope 
An Evo 15 Scanning Electron Microscope (SEM, Zeiss, Cambridge) analysis was used for 
visualising the surface texture of the samples. The instrument was controlled through the 
program SmartSEM V05.07 provided by Zeiss. 
 
3.2. METHODS 
3.2.1. Preparation of Solutions 
Stock solutions of each compound were prepared by weighing accurately an amount of 
powder in a volumetric flask using an analytical balance. The powder was then dissolved using 
either ethanol or distilled water. This was immediately wrapped in aluminium foil to prevent 
light exposure and placed in an ultrasonic bath (FB11024, Fisherbrand, UK) to ensure complete 
dissolution. Stock solutions were kept refrigerated at T<5°C. 
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The concentration of the solutions was calculated using the following: 
  𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑡𝑡𝐶𝐶𝐶𝐶𝑡𝑡𝐶𝐶𝐶𝐶𝐶𝐶 (𝑀𝑀) = 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑡𝑡𝑜𝑜 𝑚𝑚𝑡𝑡𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠 (𝑔𝑔)
𝑅𝑅𝑅𝑅𝑅𝑅 � 𝑔𝑔𝑚𝑚𝑜𝑜𝑚𝑚�×𝐹𝐹𝑖𝑖𝑛𝑛𝑚𝑚𝑠𝑠 𝑉𝑉𝑡𝑡𝑠𝑠𝑠𝑠𝑚𝑚𝑠𝑠 (𝐿𝐿)
     Eq. 1 
Dilutions of the solutions were prepared by transferring a specific volume of the stock solution 
into another volumetric flask using a Gilson® pipette. The diluted solutions were stored and 
protected from light in the same conditions as above until used. 
 
3.2.2. Calibration Graph 
For spectrophotomeric calibrations, the blank experiment consisted of 2 mL of the solvent. 
Then specific volumes (μL) of the stock solution was added to 2 mL of solvent using a 50 μL 
microsyringe (Phenomenex, UK). The spectrum of the diluted solutions were measured and 
recorded. The calibration graph were built by plotting absorbance readings at a specific 
wavelength of observation against increasing concentrations. 
For calibration on HPLC, increasing concentrations of the drug was injected. The 
chromatogram of this solution was measured and the peak area recorded. Calibration graph of 
the analyte was obtained by plotting peak area (PA) against increasing concentrations. 
The blank experiment for fluorimeter was 2 mL of water. Specific volumes (μL) of AXI was 
spiked into the 2 mL solvent and the excitation and emission spectra of each solution was 
measured and recorded. Calibration graph of the analyte was obtained by plotting relative 
fluorescence intensity at a specific wavelength of observation (𝐹𝐹𝐹𝐹𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜) against increasing 
concentrations.  
For each, a line of best fit was drawn, correlation co-efficient (r2) calculated and the linear 
range determined (Table 3.2). 
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Table 3.2: The linear range of DBZ, AXI and SUT in ethanol and water, the equation of the 
line and correlation co-efficient (r2) 






Ethanol  x 10-6 –  x 10-5 𝐴𝐴330 =   
Water 5.37 x 10-6 – 9.27 x 10-5 𝐴𝐴330 = 19749 x C0 + 0.0062 0.9988 
Axitinib 
Ethanol 1.03 x 10-6 – 6.32 x 10-5 𝐴𝐴332 = 35712 x C0 – 0.0008 0.9995 
Water 1.03 x 10-6 – 3.98 x 10-5 𝐴𝐴330 = 29995 x C0 + 0.0007 0.9991 
Sunitinib 
Ethanol 4.68 x 10-7 – 6.26 x 10-5 𝐴𝐴430 = 26279 x C0 + 0.0064 0.9999 
Water 2.34 x 10-6 – 7.22 x 10-5 𝐴𝐴430 = 24948 x C0 + 0.0136 0.9986 
HPLC 
Dacarbazine Ethanol 4.82 x 10-5 – 5.49 x 10-4 PA = 1x10
10 x C0 - 
497703 0.995 
Axitinib Ethanol 2.76 x 10-6 – 2.33 x 10-5 PA = 1x10
11 x C0 + 
15215 0.9971 
Sunitinib Ethanol 4.99 x 10-6 – 2.15 x 10-4 PA = 5x109 x C0 + 15376 0.9973 
Fluorimeter (λex = 332 nm ; λem = 418 nm) 
Axitinib Water 2.58 x 10-6 – 3.62 x 10-6 𝐹𝐹𝐹𝐹419 = 2x10
6 x C0 + 
0.0793 0.9895 
 
3.2.3. Monochromatic Photolysis Procedure 
3.2.3.1. Continuous Irradiation 
The monochromator was set to a specific wavelength for irradiation (λ irr) and the excitation 
beam was guided through an optical fibre impinging upon the top of the sample cuvette. 
Accordingly, the direction of the irradiation and analysis light were perpendicular (Fig. 3.1). 
2 mL of solvent was placed in the 1 cm quartz cuvette and a blank (zero concentration) is taken 
on the spectrophotometer. Pure ethanol was used for studies in organic solvent and distilled 
water was used for studies in aqueous media. For studies in ethanol/water solutions, specific 
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volumes (µL) of ethanol were spiked into 2 mL of water as the blank for these studies – the 
percentage of ethanol not exceeding 2.5% v/v. Studies in the presence of CDs, TRZ, SSY, QY, β-
Ca, OHCl and VAN, 2 mL solutions containing the excipient (no drug) were the blank; so that 
only the drug’s absorbance is observed.  
The intensity of light at the end of the optical fibre was measured by placing the end of the 
optical fibre perpendicularly onto the radiometer probe. The reading was recorded before and 
after each photolysis. 
Specific volumes (µL) of the drug solution - taken with a 50 µL Hamilton Microsyringe - were 
added to 2 mL of solvent.  
UV-Visible spectra were recorded set intervals throughout the set time of photolysis, using the 
Agilent 8453 ChemStation kinetics computer program.  
The sample was stirred continuously with a magnetic flea during all experiments to ensure 
homogenisation of solution and maximum exposure, a temperature of 22°c was maintained 
(unless stated otherwise) and the sample was shielded from ambient light. 
Due to limit of the temperature controller and the sensitivity of SUT to temperature in water, 
an ice bath was employed for photolysis. The sample was placed in a small beaker containing 
ice and placed on top of a Fisher ScientificTM magnetic stirrer (FB65312). The solution shielded 
from ambient light by a covering with a much larger beaker that has been completely wrapped 
in foil.  
SUT sample was removed from the ice bath and placed into the UV spectrometer (with 
thermostat set at the lowest possible, 6°C) at 5 minutes intervals and irradiated 
monochromatically using the optical fibre for 1 minute. This was repeated until a plateau was 
achieved – i.e. the end of the reaction was reached. 
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3.2.3.2. Steady-State Photolysis Procedure 
General analysis was carried out as described above. However, instead of irradiating using the 
optical fibre, the sample was placed directly in front of the monochromator opening, clamped 
into place by a lab stand (Fig. 3.1).  
 The intensity of light behind and in front of the cell were measured and recorded before and 
after each photolysis. Thus, the amount of light absorbed by the sample is known. 
A magnetic stirring plate was placed under the sample cell to ensure the sample was stirred 
continuously with a magnetic flea. 
At regular intervals the sample would be removed from the clamp and its absorption spectrum 
measured using the spectrophotometer until the end of the reaction. 
 
3.2.4. Polychromatic Ambient Photolysis Procedure 
The blank experiment was carried out as described above. 
During preparation of the analytical sample, the cuvette was covered in aluminium foil to 
avoid light exposure.  The sample was stirred to ensure homogeneity and then the initial 
absorbance spectrum was taken. The cuvette was then placed on a magnetic stirrer on a 
laboratory worktop without any light protection (foil removed), positioned to allow adequate 
ambient light exposure. A plastic lid was placed on top of the cuvette to prevent evaporation 
of the sample. 
The sample was stirred continuously with a magnetic flea, on a magnet stirrer, during all 
experiments to ensure homogenisation of solution and maximum exposure, ambient room 
temperature in the range 20°C-25°C were recorded. 
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Absorbance spectra were recorded at regular intervals until the end of the photoreaction, 
which was indicated by no/little change in absorbance. 
For HPLC analysis, injections were made at regular intervals until the end of the reaction. The 
peak areas plotted against time. 
 
3.2.5. Stability Of The Drugs In The Absence Of Light 
Instrumental set-up and sample preparation were carried out as above, except the contents of 
the cuvette were protected by a cap which completely covered the top of the cuvette. The 
analytical sample was continuously stirred and thermalstatically maintained at a set 
temperature.  
Under ambient conditions, the cuvette was covered with aluminium foil. This was only 
removed when the sample was analysed at intervals. The sample was continuously stirred on a 
stirring plate. 
UV-Visible spectra were recorded using a computer program as described above. 
 
3.2.6. Chromatographic Conditions 
Separation of the drugs and their products were achieved with mobile phase of water and 
acetonitrile or methanol (Table 3.3). An injection loop of 20 µl was used and the detector was 
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water (adjusted to 
pH 3 with glacial 
acetic acid) 
acetonitrile 70 30 0.5 236 10 
AXI water (0.1 % v/v formic acid) methanol 40 60 2.0 332 4 
SUT 
water (adjusted to 
pH 3 with glacial 
acetic acid) 
acetonitrile 67 33 1.0 350 6 
 
3.2.7. Kinetic Data Treatment Using MathCad 
Differential equations obtained based on the proposed photodegradation mechanism are 
entered into the computer program (MathCad 2000) which uses the numerical method of 
Runge-Kutta 5th order (RK-5) to generate values of the integral at specific times. Therefore, the 
values obtained describe the behaviour of the reaction through variation of concentration of 
all reaction species over time.  
These values were converted into absorbance and fitted with experimental data in excel. The 
input data corresponding to unknown reaction parameters are optimised until a unique fit 
between theoretical RK-5 traces and experimental data is achieved. 
  




Insert differential equations into MathCad with all required parameters (i.e. ε, k, Φ, P, C0 and 
reaction time) for one set of experiment irradiated and observed at one wavelength. 
Input values for known parameters (i.e. εA, P, C0 and reaction time) 
Input values for unknown parameters (i.e. εx, k∆, Φ) 







Using values determined for this set of unknown parameters, apply to 
a different set of experimental data observed at a different wavelength 
- altering only the epsilon of the new observation wavelength. 
Using values determined, apply to a different set of experimental data irradiated and 
observed at a different wavelength to propose the Φ for these λirr/λobs conditons 
Yes 
No 
Write the differential equations to the considered reaction mechanism 
Does the calculated and 
experimental curves fit? 
Does the calculated and 
experimental curves fit? 
Identified unknown 
parameters (εx, k∆, Φ) 
Does the calculated and 
experimental curves fit? 
Propose 10 other 
values for Φ 
No 
Yes 
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3.2.8. Fluorescence Analysis 
Solution of α-CD, HP-β-CD, α-CDP, β-CDP and γ-CDP were made in various concentrations. 
The fluorescence spectrum of a cuvette containing 2 mL of water (no sample) was measured. 
This is then spiked with a known volume of sample stock solution and its excitation and 
emission spectra was determined.  
The cuvette is then washed and replaced with 2 mL of CD at increasing concentrations (0 - 25 
mg/mL). For each CD concentration, the initial excitation and emission spectra of the CD were 
measured before adding the analytical sample and the spectra recorded again.  
The fluorescence emission intensities for each were then plotted against CD concentrations in 
excel to give one isotherm. This is then repeated for different AXI concentrations and then 
different CDs. 
 
3.2.9. Formulation of AXI/CDP Complex 
Ensuring that all solutions are protected from light at all-time using foil, 5 mg of AXI was 
dissolved in 0.5 mL ethanol in a small vial. In a 25 mL round-bottomed flask, 50 mg α-CDP or 
200 mg β-CDP were dissolved in 1 mL. The AXI solution was then added to the flask containing 
the CDP solution.  
If the solution becomes cloudy, either β-CDP or AXI had precipitated back into solution; one of 
the two solvents was not of sufficient quantity. Cautious additions of both solvents brought 
both solutes back into solution – i.e. a clear solution has achieved.  
The complex solution was then evaporated, ensuring that exposure to light and heat is limited 
at all-time by covering with foil and storing and evaporating at low temperature. 
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Once the AXI/CDP complex had dried, 1 mL of double distilled water was added, ensuring 
complete dissolution by using an ultrasonic bath. If complete complexation (a clear solution) 
was not achieved, then 20 mg of CDP was added into the solution, dissolved with water and 
ethanol and evaporated. This was again tested with 1 mL of water. The process was repeated 
until a clear solution was achieved when 1 mL of double distilled water was added to the dried 
AXI/CDP complex.  
 
3.2.10. Solubility limit Testing of Formulations 
Double distilled water in aliquots of 0.1 mL were added to the dried AXI/CDP complex until a 
clear solution was achieved. An ultrasonic bath was used in-between each addition for water 
to ensure complete dissolution.  
As AXI is not water soluble, a clear solution would be a strong indication that a water soluble 
complex was achieved. However, if the solution was cloudy and ethanol is required to achieve 
a clear solution, then a water soluble complex was not formed and more cyclodextrin was 
needed to be added. 
Small aliquots were used to determine the minimum volume of water required to completely 
solubilize the formulation.  
 
3.2.11. Photostability Testing of Formulations 
Instrumental set-up were as described in 3.2.3. 
 
The blank experiment for this was carried out with a specific amount of CDP (Table 3.4) 
dissolved in 2 mL water.  
Specific amount of the AXI/CDP formulation was then dissolved in a certain amount of double 
distilled water (Table 3.4) (Cell 1). AXI/α-CDP samples were dissolved in 0.8 mL and AXI/β-CDP 
47 | P a g e  
 
samples were dissolved in 1 mL of water. An initial absorption spectrum of the sample was 
taken, by spiking 40 μL of sample from Cell 1 into 2 mL of water (cell 2) to get a measurable 
concentration.  
 























sample 300 5 305 
- - - - 
Cell 1 24 0.4 24.4 - 0.8 30.5 0.2 
Cell 2 0.96 0.016 0.976 0.04 2 0.488 0.008 
 AXI/β-CDP Formulation 
Dry 
Sample 770 5 775 
- - - - 
Cell 1 59.6 0.4 60 - 1 77.5 0.2 
Cell 2 0.92 0.0154 0.9354 0.04 2 0.4677 0.0077 
  
Specific amount of the AXI/CDP formulation was then dissolved in a certain amount of double 
distilled water (Table 3.3) (Cell 1). AXI/α-CDP samples were dissolved in 0.8 mL and AXI/β-CDP 
samples were dissolved in 1 mL of water. An initial absorption spectrum of the sample was 
taken, by spiking 40 μL of sample from Cell 1 into 2 mL of water (cell 2) to get a measurable 
concentration.  
Cell 1 was then placed into the spectrophotometer’s sample holder with a magnetic flea and 
irradiated monochromatically at 360 nm using the optical fibre, whilst stirred and 
thermostatically maintained at 22°C.  
At timed intervals sample analysis was carried out by stopping the irradiation of Cell 1, 
removed the cell from the sample holder of the spectrophotometer and placed on the bench 
shielded from light with a large beaker covered in aluminium foil. Than 40 μL of Cell 1 was 
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spike into 2 mL of water (cell 2) for analysis. This continued until a plateau was reached – i.e. 
the reaction has stopped.  
Changes in absorbance at two specific wavelengths (330 nm and 380 nm) were recorded and 
plotted against time. 
Ambient photostability tests were carried out in the same way, except the sample was 
exposed to polychromatic ambient fluorescent light and temperature. Experiments where the 
sample was stirred and not stirred were also carried out under ambient conditions. 
 
3.2.12. Thermal Stability Testing Of Formulations 
Instrumental set-up and sample preparation were carried out as above (Section 3.2.11), except 
the sample was not irradiated. The analytical sample was continuously stirred and 
thermalstatically maintained at a set temperature.  
UV-Visible spectra were recorded using a computer program as described above. 
 
3.2.13. Samples for FTIR and SEM Characterisation 
Analysis were carried out directly on the powder samples of AXI, αCD-P, AXI/αCD-P 
formulation, AXI/αCD-P physical mixture, β-CDP, AXI/ β-CDP formulation and AXI/β-CDP 
physical mixture were used. Physical mixtures were prepared by mixing AXI and α-CDP or β-









DRUG LITERATURE SURVEY 
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4.1. INTRODUCTION 
Cancer is one of the most serious health problems in the Western Hemisphere [1]. Overall, the 
last 65 years have seen a significant progress in the discovery and development of anti-cancer 
drugs. Even though the treatments devised for some forms of cancer have a high success rate, 
patients often tolerate unpleasant side effects. In the last decade, however, there has there 
been more success in developing targeted drugs and therapies [1]. 
Amongst the large variety of cancer treatments, some involve the use of photodynamic 
therapy (PDT) and photochemical internalisation (PCI) to activate light-sensitive drugs and to 
facilitate intracellular delivery [2].  
Despites these advances, the delivery of anti-cancer drugs is still a challenging problem [3]. 
Recent advances in nanotechnology have opened new venues for anti-cancer nanomedicine 
and stable delivery systems [4].  
Overall, there are very few published studies on the photostability of anti-cancer drugs both in 
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In this study, photostability aspects of three different drugs: Dacarazbine (DBZ), Axitinib (AXI) 
and Sunitinib (SUT) (Fig. 4.1 and Table 4.1), will be investigated as examples of recent and old 
anti-cancer medication.  
DBZ was proposed in the late 1970’s as the most effective single agent in the treatment of 
metastatic malignant melanoma and Hodgkin’s disease [7] and is sometimes used in 
combination with other drugs for soft tissue sarcomas [8]. Dacarbazine is supplied as a sterile, 
lyophilized powder for injection, which is reconstituted with water before use [9]. Due to its 
hydrophilicity, DBZ is incompletely absorbed when dispensed orally [10]. 
However, its usefulness is limited by adverse side effects such local venous pain, nausea, 
haematotoxicity and influenza-like syndrome and more importantly its sensitivity to light [11]. 
The majority of the side effects, in particular local venous pains, were found to be caused by its 
photodegradation products and not dacarbazine itself [9,12-19]. 
 
Table 4.1: Manufacturer and brand names of dacarbazine, axitinib and suntinib and the year 





Year Approved for Use 











Bayer 1975 2002 2001 
Axitinib 
(Inlyta) 
Pfizer 2012 2012 2015 
Sunitinib 
(Sutent) 
Pfizer 2006 2006 2009 
 
AXI and SUT are oral multi-targeted tyrosine kinase inhibitors part of a new emerging cancer 
targeted therapies [20]. SUT is the first-line treatment of advanced and/or metastatic renal cell 
carcinoma as appraised by NICE in 2009 [21]. In the case where the treatment with SUT is 
unsuccessful, AXI is given [22]. Some results suggested that Z-SUT might be active against 
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breast cancer and its efficacy and toxicity do not appear to be affected by patient age, 
including children and elderly [23]. AXI is currently on clinical trial for treatment of thyroid 
cancer [24]. 
Suntinib and Axtinib are commercially available only as a capsule and red tablet (respectively). 
No liquid formulations of the drugs were available for clinical use. However, pharmacist and 
nurses frequently encounter patients with nasogastric tube or those unable to swallow oral 
medications for other reasons [25]. Even though it is advised against, current practice is to 
crush the tablet and administering it as a suspension [25].  
During early clinical development, the powder-in-bottle (PIB) approach was tested. It consists 
of using apple juice to constitute SUT extemporaneously in the clinic as a solution or a 
suspension [26]. However, after exposure to ambient light and room temperature, 
degradation was observed but not quantified. 
There have been some attempts to address the issue of liquid formulations through the use of 
commercially available vehicle Ora-Plus® and Ora-Sweet® [27]. Suspensions were prepared in 
amber plastic bottles, three were stored at room temperatures and three were refrigerated. 
All suspensions were found to be chemically and physically stable over the experimental 
period of 60 days. 
However, SUT is still limited to oral administration and the needs of patients requiring 
alternative routes of administration (such as parenteral or nasogastric intubation) is not met. 
Yet, crushing/disintegrating tablets in water to prepare AXI suspensions can hugely impact on 
the drug’s stability, especially when exposed to light, and the safety of pharmacists and nurses 
who would require protection from inadvertent exposure. 
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4.2. THERMAL STABILITY 
DBZ was reported to be stable for in many conditions as when stored in the dark in aqueous 
solutions (prepared from DBZ’s commercial formulation which also contains a pH 3.5 citrate 
buffer and 37.5 mg of mannitol, at least 24 hours at room temperature and at least 96 hours at 
2-6°C) [28], following cycles of freeze-thawing in human plasma and urine [29,30] or when 
prepared in 50 % (v/v) methanol/water, even when subjected to dry heat degradation at 105°C 
for 60 min, only 4.05 % degradation was observed. 
Many authors [31-34] reported AXI and SUT to be thermally stable at room temperature either 
after 24 hours of storage in human plasma or when stored in a solution of 
acetonitrile/water/formic acid (20:80:0.1, v/v/v), sweat, human plasma and methanol. 




Photodecomposition of DBZ in aqueous solutions by both natural and fluorescence light has 
been confirmed and proven by a number of studies. Most of which reported 10% loss after 24 
hours of exposure to fluorescent light at room temperature and a higher loss if exposed to 
direct sunlight [12,19,36-44]. When photodecomposition was forced (i.e. exposing the drug to 
intensive light), 0.1 mg/mL DBZ rapidly deteriorated, the reaction completing in just 1 hour 
[12, 42, 43]. 
Exposure of AXI and SUT (Fig. 4.1) to light has been reported to induce photoisomerization of 
the compounds, E- to Z- [31,34,45-47] and Z- to E- [26,32,33,48-51], respectively. One study 
has reported a dimer in addition to the Z-AXI isomer [35], Fig 4.2.   




To the best of our knowledge, there are no published kinetic studies on the photodegradation 
of E-AXI and Z-SUT [5,52,53]. Despite the fact that skin reactions are recognised side effects of 
sunitinib therapy with an adverse impact on quality of life. Its presence in patients’ skin and 
sweat was evidenced [54], and its effects in skin photoirritation and phototoxicity have also 
been reported [55]. 
Noticeably, despite a large number of studies reported, so far, on the photodegradation and 
photostabilization of DBZ, only a few included kinetic studies. Nevertheless, the 
photodegradation reaction order of DBZ is still controversial as it was reported to obey both 
pseudo-first-order [39] and zero-order [42] kinetics in solution. 
For the three drugs, the quantum yields of the photoreaction steps have not yet been reported 
in the literature. 
 
4.4. PHOTOSTABILIZATION 
Protection methods of using opaque [11,12,14] and light filtering [13] infusion sets showed to 
be effective in protecting DBZ from photodegradation. Yet, this does not protect the drug from 
























Fig 4.1: Reversible photoisomerisation 
of Z-SUT and E-SUT 
 
 
Fig 4.2: Axitinib’s photoproducts identified by Pfizer in 
solid dosage form: (A) cis-isomer, (B) asymmetric dimer 
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Thus far, only one study [42] attempted to photoprotect DBZ solutions with the use of 
excipients, glutathione (GSH). GSH is a natural antioxidant produced in the human liver. 
Unfortunately, it inhibits DBZ-induced cell apoptosis [56]. Therefore, although GSH has been 
shown to increase DBZ’s photostability [42], it is not commercially used. Therefore, there is still 
a need for studies in that area.  
During formulation development of AXI, the conventional hypromellose white coating system 
was found to provide the drug with no protection against light [34]. This was then adjusted to 
include red iron oxide and was found to give better protection against light [34,45]. There are 
no other examples to protect AXI from light, especially in solution.  
In the case of SUT, there are no reports on any attempts to photostabilize it in any form.   
 
4.5. CONCLUSION 
Cancer is one of the most serious health problems that generally require heavy medical 
treatments. It is important to ensure that no additional burden is put on patients by 
administration modes and/or low quality of drugs. In this respect, understanding, quantifying 
and improving photostability of drugs is one important element that may enhance the quality 
of life of the patients. At least, such information can provide precautions for handling, 
packaging and administering drugs. It also fulfils one of the ICH Q1b recommendations for 
these drugs. 
As discussed in the previous and this chapter, there are many aspects of drugs’ 
photodegradation that are lacking in the specialized literature. This study will be looking at 
some of them through the use of new photokinetic approaches using the three anti-cancer 
drugs DBZ, AXI and SUT, as template examples. 
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5.1. INTRODUCTION 
Dacarbazine (DBZ), Axitinib (AXI) and Sunitinib Malate (SUT) are anti-cancer drugs known to be 
photolabile in solution (Scheme 5.1). In the literature, there are no studies on the stability of 
DBZ in organic media and those reporting the observation of photodegradation of AXI and SUT 
studied the drugs in either dimethysulfoxide (DMSO) or plasma. However, no data on kinetics 


























Scheme 5.1: Molecular structures of Dacarbazine (DBZ), Axitinib (E-AXI) and Sunitinb (Z-SUT) 
 
This study aims to shed light on the photokinetic behaviour of DBZ, AXI and SUT in organic 
media through the application of the new Φ-order kinetic mathematical strategy for  
unimolecular (AB(1𝛷𝛷), 𝐴𝐴 → 𝐵𝐵) and photoreversible reactions (AB(2𝛷𝛷), 𝐴𝐴 ⇋ 𝐵𝐵) [1,2], where A is 
the initial compound and B the photoproduct. 
 
5.2. Φ-ORDER KINETIC MODEL  
In the literature, photochemical reaction data are commonly treated with conventional 
thermal reaction kinetic models [3-13]. These models are used regardless of the presence of 
light in the reaction and the photodegradation pathway of the drug.  In some cases, it was 
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In contrast to thermal kinetics, the rate constant of a photoreaction is dependent on three 
important factors – the intensity of the irradiation (P), the extinction coefficient (ε) and 
quantum yield (Φ) of the drug at specific wavelengths. Therefore, without first quantitatively 
defining the reaction kinetics, as well as the reaction parameters, the photoreactivity of 
different drugs, or the same drug measured at different irradiation conditions, cannot be 
directly compared. 
Recently, a newly developed approach based on Φ-order kinetics has been proven to 
successfully describe the time evolution of the species concentrations when the reactive 
medium is subjected to non-isosbestic and monochromatic irradiation at constant 
temperature [14-18].  
The Φ-order approach allows a unique characterisation of the kinetic data, provides an 
analytical equation for the overall reaction rate-constant and enables the quantification of the 
extinction coefficient and quantum yields. Thus, in great contrast to the thermal kinetic 
models, there is no possibility of multiple interpretations (more than one reaction order) of 
the same set of data. It also aids the determination a drug’s suitability to act as actinometers. 
 
5.2.1. Φ-order kinetic model for non-isosbestic irradiations 
The model equation describing Φ-order kinetics for the photoreversible degradation of initial 
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𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(∞) are the total 
absorbance of the reaction medium at reaction time (t), at the start of the reaction (t = 0) and 
at infinity (∞), when irradiated at a certain wavelength and observed at the same wavelength 
(λ irr/λ irr) or irradiated and observed at different wavelengths (λ irr/λobs). 
The rate constant 𝑘𝑘𝐴𝐴⇋𝐵𝐵






𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖� × 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(∞) =  𝛽𝛽𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖            Eq.2 
where Φ𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  and Φ𝐵𝐵→𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  are the forward and reverse quantum yields at the irradiation 
wavelength (λ irr), 𝜀𝜀𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖and 𝜀𝜀𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  the extinction coefficients of A and B, 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  the light intensity 
received, 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  the path length of the irradiation light and 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(∞) the photokinetic factor 
expressed as: 











    Eq.3 
Eq.1 can be used to describe the kinetic behaviour of any AB photoreaction at any 
observation/irradiation conditions. Thus, for an AB(2Φ) system where both species absorb at 
the irradiation wavelength , the absorbance at infinity will be represented by the 
photostationary state (pss). As a result,  𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜(∞) and 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(∞) becomes  𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜(𝑝𝑝𝑝𝑝𝑝𝑝) 
and 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(𝑝𝑝𝑝𝑝𝑝𝑝). For an unimolecular AB(1Φ) system where only the A absorbs at the 
irradiation wavelength, 𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜(∞) , Φ𝐵𝐵→𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  and 𝜀𝜀𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  = 0 and 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(∞) = ln(10) = 2.3. This 
returns Eq.1 to the model equations obtained through closed-form integration for this AB(1Φ) 
system [1].  
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The 𝛽𝛽𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  in Eq.2 is a proportionality factor between the overall rate-constant and the radiant 
power. 
The details of the kinetic elucidation method [15] that allows the complete set of system 
unknowns to be worked out from the kinetic traces are presented in Annex A5.1. 
 
5.3. STABILITY OF DBZ, AXI AND SUT IN ETHANOLIC SOLUTION 
5.3.1 Electronic Spectral Characteristics of the Drugs 
The UV-Vis spectra indicating the absorption characteristics of DBZ (1.37 x 10-5 M), E-AXI (1.77 
x 10-5 M) and Z-SUT (8.94 x 10-6) in Fig 5.1. 
The electronic absorption spectrum of DBZ (1.37 x 10-5 M) in ethanol is characterised by two 
peaks situated at 235 nm and 325 nm attributing to the S0 -> S2 and S0 -> S1 (π -> π*) 
transitions [19]. The electronic absorption spectra of AXI and SUT are characterised by four 
peaks. While, SUT’s has a shoulder at 395 nm. As can be seen in Fig. 5.1, only SUT absorbs 
beyond the UV region (380 nm) into the visible region, which causes its powder and solutions 
to be yellow in colour. 
 
 
Fig. 5.1: UV/Vis Spectrum of 1.37 x 10-5 M DBZ, 1.77 x 10-5 M AXI and 8.94 x 10-6 M SUT in 
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5.3.2 Thermal Stability of the Drugs in Ethanol 
In the literature, thermal stability of the three drugs in pure organic solution has never been 
reported, however our results correlate well with the few literature reports that mentions 
thermal stability for the three drugs. DBZ was reported to be stable for at least 24 hours at 
room temperature and at least 96 hours at 2-6°C when stored in the dark in aqueous solutions 
(prepared from DBZ’s commercial formulation which also contains a pH 3.5 citrate buffer and 
37.5 mg of mannitol) [21]. DBZ were also reported to be stable following cycles of freeze-
thawing in human plasma and urine [22, 23].  These were confirmed by Lal Prasanth et al. [24] 
who prepared solutions of DBZ in 50 % (v/v) methanol/water, subjected it to dry heat 
degradation at 105°C for 60 min and found only 4.05 % degradation. 
Many authors [25-28] reported AXI and SUT to be thermally stable at room temperature either 
after 24 hours of storage in human plasma or when stored in sweat, human plasma, methanol 
and a solution of acetonitrile/water/formic acid (20:80:0.1, v/v/v) mix.  
In this study, no changes in absorbance were recorded for any of the drugs. Therefore, they 
can all be considered thermally stable in the given experimental conditions used in this study.  
 
5.3.3 Photostability of the Drugs in Ethanol 
There are currently no photostability studies on DBZ in pure organic solution in the literature.  
Although AXI and SUT have been studied in DMSO and plasma, full photochemical studies have 
never been carried out. Therefore, the kinetics and quantum yields for all three drugs are still 
unknown. 
The continuous irradiation of the three drugs induced a decrease of a section of the spectrum 
and an increase of absorbance is in another section.  
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For all three drugs, a decrease of the main peak and formation of a new peak were observed. 
However, unlike the peaks for SUT and AXI, the DBZ peak at 325 nm depletes completely. No 
peaks and/or changes in absorbance were observed beyond 400 nm. SUT and its photoproduct 
share the same overall shape of the absorption spectra, as they totally overlap and no new 





Fig 5.2: Evolution of the electronic absorption spectra of 5.47 x 10-6 M DBZ, 2.65 x 10-5 M E-
AXI and .94 x 10-6 M Z-SUT in ethanol, when irradiated continuously with a monochromatic 
beam at 325 nm (1.84 x 10-6 einstein s-1 dm-3), 355 nm (3.12 x 10-6 einstein s-1 dm-3) and 430 
nm (4.10 x 10-6 einstein s-1 dm-3), repectively. Isosbestic points indicated by vertical lines. 
 
The spectral evolution of DBZ produced only one identifiable isosbestic point, unlike AXI and 
SUT, where five and three isosbestic points can be seen, respectively (Table 5.1). The presence 
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HPLC analysis showed only two peaks (the mother compound and its product) for all drugs 
(Fig. 5.3). This indicated an AB mechanism for all three drugs. The HPLC peaks representing AXI 
and SUT do not completely deplete, indicating the occurrence of an equilibrium between the 
drug and its photoproduct (PP).  These features correspond to an AB(2Φ) photoreversible 
reaction mechanism. DBZ's peak, however, completely depletes suggesting a unimolecular 
AB(1Φ) reaction mechanism. 
 
Table 5.1: Spectral changes observed when the drugs were monochromatically irradiated in 
ethanolic solution 
a underlined wavelengths represent the maximum 
b values in brackets corresponds to shoulders 
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Fig 5.3: Chromatographic evolution of DBZ and its photoproduct (Left chromatogram), AXI 
and its photoproduct (middle chromatogram) and SUT and its photoproduct (right 
chromatogram) 
 
The initial AXI and SUT were "E" and "Z" in conformations, respectively. The results obtained 
and the structure of the two drugs strongly suggests that upon irradiation, they transform into 
their E- and Z-isomers, respectively.  
This conclusion matches well that reported in the literature where the E/Z photoisomerisation 
of AXI in the solid state [29] and in solution [25, 30, 31]; and SUT in solution [32] 
HPLC analysis of the irradiated 5.49 x 10-4 M DBZ in 50% methanol/water solution [24] showed 
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Table 5.2: Retention time of the three drugs (A) and their photoproducts (B), calibration 
equation for the drugs, correlation coefficients (r2) and linearity range of the drug. 
Drug 
Retention Times  




Linearity Range of A 
/ M 
A B 
DBZ 3.89 4.24 y = 1 x 1010 – 497703 0.995 
4.82 x 10-5 – 
5.49 x 10-4 
AXI 2.52 1.70 y = 1 x 1011 + 15215 0.997 
2.76 x 10-6 – 
2.33 x 10-5 
SUT 2.17 1.84 y = 5 x 109 + 15376 0.997 1.25 x 10
-6 –   
2.15 x 10-4 
 
 
5.3.4 Effect of irradiation wavelength on photodegradation traces 
Photodegradation of drug substances strongly depends on the spectral properties of the drug 
substance and the spectral distribution of the light source [33, 34].  Knowledge of the drug’s 
absorption spectra does not suffice to predict the causative wavelength range, since not all 
light absorbed induces photodegradation [35]. In the case of vitamin A, maximum rates of 
photolysis were observed over the range 330–350 nm [36]; and irradiation wavelength of 254 
nm (UVC) was found to be most effective for vitamin E, whilst it remained stable under UVA 
(366 nm) irradiation [37].  
In addition, it has been reported that irradiation of different wavelengths trigger different 
photochemical pathways leading to the formation of different photoproducts [38, 39].    
Thus, it is important to consider the variation of drugs’ reactivity with the irradiation 
wavelength range of the source.  
In this context we studied the effect of the wavelength of the irradiation beam on the drugs’ 
photodegradation reaction. For each drug, the kinetic traces of the degradation when 
irradiated at different irradiation wavelength were recorded at a specific observation 
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wavelength. The same kinetic behaviour was observed, indicating that the reaction is governed 
by the same mechanism. 
At the longest wavelengths, the kinetic traces follows a smooth descend of the absorbance (at 
the λmax of the longest wavelength peak) reaching zero or a photostationary state (pss) in the 
cases for AXI and SUT (Fig. 5.4). The behaviour of the traces agrees well with the Φ-order 
AB(1Φ) mechanism for DBZ and AB(2Φ) mechanism for AXI and SUT. 
For the photodegradation of all three drugs, the experimental traces were all well fitted by Eq. 










Fig. 5.4: (Left) Photokinetic traces of DBZ (5.47 x 10-6 M), AXI (2.65 x 10-5 M) and SUT (8.94 x 
10-6 M) in ethanol at different irradiation wavelengths. Circles represent experimental data 
and the solid lines are the fitting of the traces to the Φ-order model. (Right) The 
unimolecular AB(1Φ) degradation mechanism of DBZ and AB(2Φ) photoreversible reaction 
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Table 5.3: Overall Photoreaction rate-constants, spectroscopic and kinetic parameter values 
of DBZ, AXI and SUT for a set of monochromatic irradiations performed in ethanol at 22°C 




/einstein s-1 dm-3 
𝑨𝑨𝒕𝒕𝒕𝒕𝒕𝒕
𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊/𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊(∞) 𝒌𝒌𝑨𝑨⇋𝑩𝑩
𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊  / s-1 
DBZ  (𝜆𝜆𝑡𝑡𝑜𝑜𝑚𝑚 = 325 𝐶𝐶𝑛𝑛) 
350 0.094 2.80 0.002 0.006200 
345 0.093 2.17 0.000 0.005550 
325 0.097 1.79 0.000 0.003300 
300 0.109 1.30 0.010 0.001200 
275 0.102 1.49 0.004 0.000455 
250 0.106 1.55 0.007 0.000233 
236 0.103 1.65 0.023 0.000195 
221 0.105 1.28 0.013 0.000130 
AXI (𝜆𝜆𝑡𝑡𝑜𝑜𝑚𝑚 = 332 𝐶𝐶𝑛𝑛) 
400 0.437 3.56 0.020 0.00700 
380 0.404 3.04 0.124 0.01000 
332 0.447 1.80 0.258 0.02100 
300 0.415 1.15 0.216 0.00710 
277 0.408 1.18 0.192 0.00260 
258 0.403 1.20 0.234 0.00125 
235 0.435 1.31 0.343 0.00070 
SUT (𝜆𝜆𝑡𝑡𝑜𝑜𝑚𝑚 = 332 𝐶𝐶𝑛𝑛) 
480 0.229 4.85 0.058 0.0155 
460 0.229 4.30 0.145 0.0195 
440 0.228 4.07 0.221 0.0225 
420 0.233 3.93 0.237 0.0230 
400 0.239 3.48 0.219 0.0210 
380 0.243 2.97 0.167 0.0130 
360 0.247 2.67 0.085 0.0094 
340 0.240 1.98 0.028 0.0030 
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The overall rate-constants obtained (𝑘𝑘𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 ) for DBZ and 𝑘𝑘𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  for AXI and SUT), appeared to 
increase with wavelength (Table 5.3). However, as discussed earlier (Section 5.1), these values 
must be considered with care because they all depend on the intensity of the irradiation (P), 
optical path length of the irradiation beam inside the sample (lirr), the extinction coefficients of 
both species (εA and εB) and quantum yields (Φ) of the drug at specific wavelengths, as shown 
by the equation of the rate constant (Eq. 2). Hence, it is necessary to determine all the 
parameters – in particular, the quantum yields – to allow comparison. Some literature reports 
that quantum yield is wavelength-dependent as it is the measure of the extent of a reaction 
relative to the number of radiation quanta absorbed [40]. In one study, the quantum yield of 
domoic acid photodegradation in seawater decreased with increasing wavelength and 
decreasing energy of incoming radiation, with the average value ranging from 0.03 to 0.20 in 
the wavelength range 280–400 nm. [41].  
The rate constant of its photoreaction is given by Eq.2. Unlike AXI and SUT, DBZ follows an 
unimolecular AB(1Φ) reaction. Accordingly, Eq.1 (with Φ𝐵𝐵→𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 = 0 ) can be used to calculate the 
Φ𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  values for DBZ at different irradiation wavelengths (Table 5.6). 
However, for AXI and SUT, obeying an AB(2Φ) reaction, there are three unknown parameters 
(𝛷𝛷𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 , 𝛷𝛷𝐵𝐵→𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  and 𝜀𝜀𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖) that need to be determined through a stepwise method as described 
in Annex A5.2.  
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5.3.5 Determination of the Reaction Quantum Yields for an Isosbestic 
Irradiation 
Firstly, the photodegradation reaction is subjected to a monochromatic irradiation at the 
isosbestic point (where 𝜀𝜀𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜 = 𝜀𝜀𝐴𝐴
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜  ). Hence, reducing the number of unknowns to just 
𝛷𝛷𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  and 𝛷𝛷𝐵𝐵→𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 . 
This reaction is monitored by HPLC and the change in concentration of the species over time 
obtained (Table A5.1 in Annex A5.3).   
 
 
Fig. 5.5: Kinetic trace of the three drugs over photodegradation time and formation of the 
photoproduct monitored by HPLC when irradiated continuously with a monochromatic 
beam: DBZ (C0 = 1.32 x 10-4 M) and its photoproduct (λ irr = 325 nm, 1.02 x 10-6 einstein s-1 dm-
3, 22°C); E-AXI (C0 = 8.13 x 10-5 M, C∞ = 1.82 x 10-5 M) and its photoproduct (Z-AXI, C∞ = 6.31 x 
10-5 M)(λ irr = 355 nm, 1.38 x 10-6 einstein s-1 dm-3, 22°C). E-SUT (C0 = 7.53 x 10-5 M, C∞ = 5.73 x 
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The concentration profiles (Fig. 5.5) were well fitted with the first-order equations (Table A5.2 
in Annex A5.4). The values of their overall photodegration rate-constant (𝑘𝑘𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜) was obtained 
as a fitting parameter, allowing the determination of the absolute quantum yields values for 
forward (𝛷𝛷𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜) and reverse (𝛷𝛷𝐵𝐵→𝐴𝐴
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜) reaction steps and therefore, the equilibrium constant 
(𝐾𝐾𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜). 
The results found that, for both AXI and SUT, the E-isomers were much more photoreactive 
than the Z-isomer (Table 5.4). This is possibly due to steric effect, because in the Z-isomer 
form, the two large groups are closer to each other so they interfere more with each other 
than in the E-form. 
Table 5.4: AXI's and SUT's quantum yield values at the isosbestic wavelength and their 
equilibrium constant (𝑲𝑲𝑨𝑨⇋𝑩𝑩
𝝀𝝀𝒊𝒊𝒐𝒐𝒕𝒕𝒐𝒐 ) 
 λ isos  / nm 𝚽𝚽𝑨𝑨→𝑩𝑩
𝝀𝝀𝒊𝒊𝒐𝒐𝒕𝒕𝒐𝒐  𝚽𝚽𝑩𝑩→𝑨𝑨
𝝀𝝀𝒊𝒊𝒐𝒐𝒕𝒕𝒐𝒐  𝑲𝑲𝑨𝑨⇋𝑩𝑩
𝝀𝝀𝒊𝒊𝒐𝒐𝒕𝒕𝒐𝒐   / s-1 
AXI 355 0.068 ± 4.61 x 10-3 0.020 ± 1.53 x 10-3 3.46 
SUT 345 0.020 ± 6.47 x 10-4 0.064 ± 2.05 x 10-3 0.315 
 
5.3.6 Reconstruction of the whole spectrum of the photoproduct 
The whole spectrum of the photoproduct could therefore be reconstructed using the value of 
𝐾𝐾𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜  and eq.9 (Fig. 5.6). 
The spectrum of DBZ’s photoproduct is obtained at the end of DBZ photodegradation. It is 
characterised by two peaks at 210 nm and 232 nm and does not absorbed at all beyond 290 
nm.  
AXI, SUT and their respective photoproducts have overlapping electronic spectra, with the 
mother compound being characterised by higher values of absorption coefficient values 
everywhere, except where new absorption bands corresponding to the photoproduct appear. 
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For all three drugs, the formation of these new peaks belonging to the photoproduct are 
observed irrespective of the irradiation wavelength. Such features clearly point to the 
occurrence of a photochemical change and further confirms the reaction is governed by the 
same mechanism - as the same evolution is observed irrespective of the irradiation 
wavelength.  
Unlike E-AXI, whose main absorption band tails off by 390 nm, its photoproduct (Z-AXI) 
absorbs in the visible region (400 – 800 nm). 
 
5.3.7 Determination of the reaction quantum yields at different wavelengths 
Once the absorption coefficients of the photoproducts are known for all wavelengths, the 
photochemical quantum yields at any irradiation wavelength can be determined. 
  
 
Fig. 5.6: Native and reconstructed electronic absorption spectra (absorption coefficient units) 
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The forward quantum yields for DBZ and AXI (E → Z) have been found to be wavelength 
dependent. Their quantum yields increased with irradiation wavelength (Fig. 5.7) with a similar 
sigmoidal pattern. For DBZ, a 24.5-fold increase was recorded for 𝛷𝛷𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖
R  values between 221 
nm and 350 nm, and in the case of Z-AXI, a 226-fold increase between 235 nm and 400 nm 
(Table 5.5). This confirms that the photodegradation of DBZ and AXI is mainly driven by UVA–
Visible light. However, the variation of AXI's 𝛷𝛷𝐵𝐵→𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖
R values was just 17.5-fold – suggesting that 
the reverse reaction is less affected by the variation of the irradiation wavelength. 
In contrast, the forward (Z → E) reaction of Z-SUT is less affected by the variation of the 
irradiation wavelength – having fairly similar 𝛷𝛷𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖
R  values between 340 nm and 480 nm – than 
its reverse reaction (E → Z), in which a 2.69-fold increase in its 𝛷𝛷𝐵𝐵→𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖
R values within the same 
wavelength range was recorded.  
In the case of AXI and SUT, the fact that phototransformation of E-AXI and E-SUT is more 
efficient than that of Z-AXI and Z-SUT (Table 5.5) is probably due to geometric strain of the 
species. In the Z-isomer form, the two large groups are closer to each other. They potentially 
interfere more with each other than in the E-form, where the larger groups are farther apart 
and have a higher degree of freedom [42]. 
Excellent sigmoid correlation of the calculated quantum yield values (Φcld.) against 
experimental values (Φexp.) for these irradiation wavelengths (Fig. 5.7) was found. The sigmoid 
equation can be used to determine the quantum yield values at any wavelength in which the 
drug is photochemically reactive (Table 5.6). 
It is evident from the quantum yield values of DBZ and AXI that these drugs are most 
photochemically reactive in the UVA-Visible range and that Z-SUT is equally reactive across the 
spectrum (Fig. 5.7). This poses great cause for concern as, of UV radiation reaching the Earth’s 
surface, 95 % of it is UVA [43]. 
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Fig. 5.8: Spectral distribution of sunlight compared with an incandescent lamp [3]. 
 
DBZ and AXI’s maxima (325 nm and 330 nm, respectively) are located in the middle of the UVA 
region and SUT's main absorption band (340-500 nm, maximum at 430 nm) spans all the way 
from UVA to Visible light. UVA penetrate deep into the lower skin layers [3], increasing the 
possibility of photosensitivity and phototoxicity caused by the photodegradation of these 
drugs at skin surface level [3]. 
SUT was reported to be "probably phototoxic" in the European Medicines Agency's (EMA) 
European Public Assessment Reports (EPAR) [44]. Unfortunately, no further details were 
provided. 
In another EMA report, the Committee for Medicinal Products for Human Use (CHMP), 
recognised AXI's potential to cause phototoxicity in eye and skin tissue [31]. However, negative 
phototoxicity and lack of photosensitive reaction was reported. 
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Fig 5.7: Sigmoid relationship obtained for the photochemical quantum 

































































Table 5.6: Proposed sigmoid equation for the calculation of DBZ’s, AXI's and SUT's 
quantum yield values at each irradiation wavelength (λirr) and the correlation coefficient 
(r2) of the calculated quantum yield values (Φcld.) against the experimental values (Φexp.) 
Drug λirr Range  / nm 
Correlation of Φcld. 
against Φexp. 
Proposed Sigmoid Equation 





AXI 235 – 400 0.9954 𝛷𝛷𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 =
1.80
1 + 4 × 105𝐶𝐶−0.042×(𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖−150)
 













Table 5.5: Quantum yield values for DBZ, AXI and SUT at different wavelengths of irradiation 















/ M-1 cm-1 
𝜺𝜺𝑩𝑩
𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊 




DBZ (λobs = 325) 
350 2.993 1.50 x 10-3 0.00663 -* 9896 -* 2.295 0.049 ± 1.11 x 10-3 -* 
345 2.168 6.99 x 10-5 0.00555 - 12580 - 2.303 0.042 ± 1.85 x 10-3 - 
325 2.156 8.04 x 10-5 0.00417 - 18864 - 2.303 0.026 ± 5.51 x 10-3 - 
300 1.446 6.11 x 10-3 0.00137 - 12469 - 2.271 0.014 ± 1.98 x 10-3 - 
275 1.440 3.51 x 10-3 0.00045 - 7068 - 2.284 0.009 ± 2.20 x 10-3 - 
250 1.265 6.97 x 10-3 0.00023 - 7157 - 2.266 0.006 ± 1.04 x 10-3 - 
236 1.493 2.23 x 10-2 0.00020 - 14639 - 2.188 0.002 ± 2.43 x 10-4 - 
221 1.529 1.29 x 1023 0.00013 - 9476 - 2.236 0.002 ± 3.72 x 10-4 - 
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AXI (λobs = 332) 𝜱𝜱𝒁𝒁→𝑬𝑬
𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊  𝜱𝜱𝑬𝑬→𝒁𝒁
𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊  
400 3.60 0.350 0.0063 -5.85 x 10-4 154 3822 2.294 0.871 ± 2.04 x 10-1 0.070 ± 9.68 x 10-3 
380 3.08 0.288 0.0097 -1.35 x 10-3 753 15244 2.209 0.495 ± 7.97 x 10-2 0.034 ± 2.14 x 10-4 
355 2.88 0.307 0.0192 -2.28 x 10-3 16059 37064 1.326 0.068 ± 4.61 x 10-3 0.020 ± 1.53 x 10-3 
332 1.78 0.265 0.0197 -2.28 x 10-3 37064 16455 1.053 0.062 ± 9.88 x 10-3 0.110 ± 2.83 x 10-2 
300 1.13 0.267 0.0074 -9.3 x 10-4 23434 15116 1.324 0.051 ± 4.64 x 10-3 0.0699 ± 2.14 x 10-3 
277 1.22 0.273 0.0026 -3.8 x 10-4 16215 15683 1.525 0.029 ± 5.65 x 10-3 0.0195 ± 1.87 x 10-3 
258 1.16 0.269 0.00124 -1.8 x 10-4 20299 19939 1.404 0.010 ± 6.91 x 10-4 0.009 ± 1.45 x 10-4 
235 1.44 0.297 0.00073 -9.8 x 10-5 28113 27607 1.170 0.004± 3.63 x 10-4 0.004 ± 7.17 x 10-4 
SUT (λobs = 445) 𝜱𝜱𝑬𝑬→𝒁𝒁
𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊  𝜱𝜱𝒁𝒁→𝑬𝑬
𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊  
480 4.85 0.198 0.0155 -4.74 x 10-4 9234 2911 1.93 0.026 ± 7.39 x 10-4 0.175 ± 1.26 x 10-2 
460 4.30 0.208 0.0195 -4.09 x 10-4 19048 8657 1.60 0.020 ± 3.63 x 10-3 0.124 ± 1.26 x 10-2 
440 4.07 0.211 0.0225 -3.76 x 10-4 27078 16133 1.39 0.015 ± 2.44 x 10-3 0.097 ± 2.56 x 10-3 
420 3.93 0.233 0.023 -3.52 x 10-4 26882 19993 1.37 0.016 ± 2.68 x 10-3 0.087 ± 2.60 x 10-3 
400 3.48 0.239 0.021 -3.56 x 10-4 24202 19116 1.43 0.022 ± 7.87 x 10-3 0.089 ± 2.79 x 10-3 
380 2.97 0.243 0.013 -2.51 x 10-4 18084 15922 1.59 0.017 ± 2.77 x 10-3 0.074 ± 4.94 x 10-3 
360 2.67 0.226 0.0094 -1.92 x 10-4 8993 8276 1.90 0.014 ± 4.06 x 10-3 0.067 ± 1.78 x 10-2 
345 2.04 0.209 0.0035 -7.49 x 10-5 4021 3863 2.12 0.020 ± 6.47 x 10-4 0.064 ± 2.05 x 10-3 
340 1.98 0.221 0.003 -5.89 x 10-5 2950 2817 2.17 0.020 ± 8.79 x 10-4 0.065 ± 2.79 x 10-3 
320 1.33 0.211 0.0018 -4.46 x 10-5 1307 1208 2.24 0.046 ± 3.79 x 10-3 0.145 ± 1.20 x 10-2 
300 0.94 0.211 0.0013 -3.53 x 10-5 4070 2151 2.15 0.020 ± 1.75 x 10-3 0.098 ± 6.60 x 10-3 
260 1.16 0.214 0.00064 -1.74 x 10-5 9894 16266 1.93 0.004 ± 1.24 x 10-4 0.007 ± 2.57 x 10-4 
240 1.22 0.215 0.00057 -1.06 x 10-5 10529 14604 1.92 0.003 ± 2.62 x 10-4 0.006 ± 7.17 x 10-4 
* Not Applicable 
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Nonetheless, the effectiveness and tolerability of the drugs are essentially diminished by the 
development of activities such as photosensitive reactions [45-48], potentially causing severe 
impacts on the physical, psychological, and social well-being of patients. 
Thus, understanding the photoreactivity of these drugs aids the development of 
stabilization/protection techniques for improved drug delivery and bioavailability.  
The Φ-order kinetics, in this context, seem to be a good tool to harvest reliable data on drugs’ 
photostability.  
 
5.4. DEVELOPMENT OF ACTINOMETERS USING ANTI-CANCER DRUGS 
The Φ-order kinetic models can also be used in the development of new actinometers.  
In order to develop an actinometric method, solutions of DBZ, AXI and SUT were subjected to 
irradiation of varying radiant power at various wavelengths, spanning over regions mainly 
responsible for their photoreactivities. The experimental traces obtained were fitted with the 
Φ-order model and a good fitting was observed (Fig. 5.9), further confirming that the three 
drugs obey the Φ-order kinetics. 
In accordance to Eq. 2, the higher the 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  value, the faster the photodegration. 
Therefore, plots of 𝑘𝑘𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  against 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  for each set of experiments yielded linear correlations 
with r values over 0.95 and intercepts of practically zero value (Table 5.7). The factor 𝛽𝛽𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  is 
constant for a given irradiation wavelength and thus can be obtained from the equation of the 
line as the gradient. 
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Fig 5.9: Effect of increasing the radiant power of the monochromatic irradiation beam on the 
kinetic traces of SUT (8.94 x 10-6 M) when irradiated and observed at 480 nm. Circles 
represent experimental data and the solid lines are the fitting of the traces to the AB(2Φ) 
kinetic model. 
 
For all three drugs, the factor 𝛽𝛽𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  was plotted against irradiation wavelength and they were 
readily represented by a linear relationship (Fig. 5.10). The linear relationship easily enables 
the determination of the factor 𝛽𝛽𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  at any wavelength within their respective reactivity range 
(situated between 275-480 nm).  
More importantly, this 𝛽𝛽𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  factor enables the development of a new actinometric method. 
Rearrangement of Eq.2 will allow the determination of the radiant power of an unknown, 
monochromatic light source within 275-480 nm. 
The chemical actinometer recommended by the ICH (quinine hydrochloride) [49] presents 
various drawbacks that seriously hamper its application to photostability testing purposes [50-
53]. The reproducibility and reliability of results obtain using quinine varies depending on the 
spectral power distribution of the light source, its location in the chamber and the timing 
which the measurement of the absorbance is taken [50]. Supposedly, these can be overcome 
by calibrating the system for the type of light source used. However, the calibration of quinine 
depends on its concentration [51]. Yet, quinine has been found to be sensitive to dissolved 
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Table 5.7: Correlation equations for the variation of the three drug's photodegradation 
overall rate-constants (𝒌𝒌𝑨𝑨⇋𝑩𝑩
𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊 ) with radiant power (𝑷𝑷𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊), the corresponding 𝜷𝜷𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊 factor 
values, and the span of radiant power employed for various monochromatic irradiations. 
Irradiation 
wavelength 
 λ irr /nm 
Equation of the line 
𝒌𝒌𝑨𝑨⇋𝑩𝑩





/ einsteins-1 dm-3 
DBZ 
350 2120.6 x  𝑃𝑃350 + 0.0002 0.9969 1.01 – 2.51 
345 2589.8 x  𝑃𝑃345 - 0.0003 0.9830 0.95 – 2.20 
325 4013.2 x  𝑃𝑃300 - 0.0024 0.9499 0.93 – 1.90 
300 2499.3 x  𝑃𝑃300 - 0.0017 0.9987 1.05 – 1.31 
275 326.26 x  𝑃𝑃275 - 0.0001 0.9991 0.78 – 1.64 
AXI 
400 2193 x 𝑃𝑃400 - 0.0006 0.9599 1.59 – 3.51 
380 3126.2 x 𝑃𝑃380 + 0.0003 0.9875 1.36 – 3.04 
355 7691.6 x 𝑃𝑃355 - 0.0005 0.9894 1.25 – 2.62 
332 14552 x 𝑃𝑃332 - 0.0071 0.9583 1.17 – 1.77 
SUT 
480 3437.7 x 𝑃𝑃480 - 0.0013 0.9980 2.04 – 4.85 
460 4301.4 x 𝑃𝑃460 + 0.001 0.9887 1.80 – 4.30 
440 5521.9 x 𝑃𝑃440 + 0.0006 0.9882 1.77 – 4.07 
420 5846.6 x 𝑃𝑃420 + 0.006 0.9851 1.66 – 3.93 
400 5432.6 x 𝑃𝑃400 + 0.0023 0.9718 1.45 – 3.48 
380 3740.9 x 𝑃𝑃380 + 0.0019 0.9959 1.19 – 2.97 
360 5866.2 x 𝑃𝑃360 - 0.0064 0.9915 1.58 – 2.67 
345 1938.1 x 𝑃𝑃345 - 0.0004 0.9941 1.42 – 2.04 
340 1560.1 x 𝑃𝑃340 - 0.00007 0.9881 0.85 – 1.98 
320 1096.2 x 𝑃𝑃320 + 0.00001 0.9954 0.61 – 1.33 
 




Fig 5.10: Linear correlation of 𝜷𝜷𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊 with irradiation wavelength. 𝜷𝜷𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊 is expressed in 
einstein-1 dm3 
 
In order to measure the radiant power of an unknown light source, a monochromatic 
irradiation of DBZ, AXI or SUT needs to be carried out in ethanol at the specified 
concentrations and at an irradiation wavelength within the specified range. The experimental 
trace obtained is then to be fitted with the Φ-order model (Eq. 1) to determine the overall 
rate-constant of the reaction.  𝛽𝛽𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  at any irradiation wavelength situated between 275-480 
nm can readily be determined using Fig. 5.10. Subsequently, the radiant power can easily be 
worked out through the simple equations for 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  presented in Table 5.8. 
As long as the photochemical reaction obeys an AB mechanism, the present method will 
enable the development of reliable actinometers without prior knowledge of any of the 
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unknown reaction parameters. Thus, allowing more thermally-stable, simple AB(1Φ) and 
AB(2Φ) chemical actinometers to be developed. 
DBZ, AXI and SUT make ideal chemical actinometers, which covers a wide range of the 
absorption spectrum (270 – 480 nm), spanning from UVB to visible. They are commercially 
available and relatively cheap. In contrast to some existing chemical actinometers, the three 
presented here are simple to prepare, thermally-stable and have a known reaction 
mechanism. 
 
Table 5.8: Equations for calculation of the radiant power 𝑷𝑷𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊using the three drugs in 
ethanol 
Irradiation 
wavelength range  λ irr 
/ nm 
Equation for 𝜷𝜷𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊 
Correlation 
coefficient, r2 
Equation for 𝑷𝑷𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊 
DBZ (5.47 x 10-6 M) 
270-235 β270-325 = 73.739 x λ irr - 19842 0.989 
𝑘𝑘𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖
73.739 × λirr  − 19842
 
325-350 β325-350 = -72.834 x λ irr - 27690 0.999  
𝑘𝑘𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖
−72.834 × λirr  − 27690
 
AXI  (1.29 x 10-5 M) 
330-400 β300-400 = -183.39 x λ irr - 74149 0.961 
𝑘𝑘𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖
−183.39 × λirr +  74149
 
SUT (8.94 x 10-6 M) 
345-420 β345-420 = 52.312 x λ irr - 159256 0.978  
𝑘𝑘𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖
52.312 × λirr  − 159256
 
420-480 β420-480 = -42.234 x λ irr + 23782 0.960  
𝑘𝑘𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖
−42.234 × λirr + 23782
 
 
These alternative actinometers eliminates the post-irradiation analytical procedures required 
with the standard ferrioxalate actinometry [54] - which needs phenanthroline (a complexation 
reagent) for colour development to enable in-situ quantification of the light intensity. The 
reproducibility and reliability of the results obtain has been reported to be sensitive to 
procedural variations [55-57].  
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The method adopted here can easily be applied to many other photolabile drugs following the 
same AB mechanism, regardless of a unimolecular or photoreversible system, as prior 
knowledge of other reaction parameters are (ε and Φ) not required – unlike the current 
requirements for chemical actinometric systems [58].  
 
5.5. CONCLUSION 
The photokinetic data of drugs are often treated using thermal zero-, first- and/or second-
order thermal kinetic models, which gives poor fittings. This clearly shows that photokinetic 
data treatment is an area which requires crucial development to provide valid and reliable 
integration rate-law equations to describe and elucidate the kinetic behaviour of 
photodegradation reactions. 
This study further confirms the usefulness of the new Φ-order approach to elucidate the 
kinetics of unimolecular and photoreversible reactions obeying an AB mechanism - filling a gap 
in photokinetic studies of drug photodegradation.  
The photokinetic traces of DBZ, AXI and SUT were all well described by the newly proposed Φ-
order model. These and previous results presented by our team [14-18] strongly suggests that 
photodegradation of drugs are better described by Φ-order than the classic thermal reaction 
orders. 
The semi-empirical model elucidation method used is easy-to-implement, simple-to-achieve, 
reliable and effective. More importantly, it allows the determination of the quantum yield 
values - the only physical parameters capable of indicating the photoreactivity of a drug.  
For the first time, the quantum yields of DBZ, Z-AXI and Z-SUT were found and determined to 
increase with irradiation wavelength. Between 2.7 and 266-fold increase was recorded for 
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DBZ, Z-AXI and E-SUT 𝛷𝛷𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖
R  values. In contrast, the quantum yields of E-AXI and E-SUT were 
less affected by the variation of the irradiation wavelength of the same ranges. 
These findings strongly suggest that the quantum yield of drugs’ photodegradation should a 
priori be considered wavelength dependent, as also indicated by the results obtained for 
Nifedipine [14] and Montelukast [16]. Therefore, the average quantum yield values obtained 
using polychromatic irradiations, as reported on by many studies in the pharmaceutical 
literature [59-64], may be deemed unreliable and must be considered with caution.  
The actinometric techniques presented here cover a wide spectral range (270 – 480 nm), 
spanning from UVB to visible - in addition to that covered by Nifedipine [14], Montelukast [16] 
and Diarylethene derivatives [65], which are developed the same way using the Ф-order 
model. The spectral range covers most BNF drugs’ photodegradation causative ranges. 
It is important to note that the approach adopted here can easily be applied to many other 
photolabile drugs following the same AB mechanism, regardless of a unimolecular or 
photoreversible system.   
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6.1.  INTRODUCTION 
The presence of even the smallest of impurity can influence a drug’s efficacy and safety [1,2]. 
Thus, it is required by the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) that a report on all new 
drugs’ stability be prepared for submission in registration applications and photostability 
testing of all new drug substances and products was made an "integral part of stress testing" 
[3,4]. The ICH Q1b guideline [4] on photostability testing provides guidance on the basic 
information required to characterise the drug's light sensitivity and stability. If the Q1b 
document describes with some details test 1 and 2 it should also make provision for drugs’ 
photostability tests in solution. For solution tests there are however no stipulated (i) 
experimental details, (ii) methods for the treatments of photodegradation data, and/or (iii) 
standardized quantification/evaluation methods, in the Q1b document. This aspect does not 
follow the general pattern adopted in ICH documents were generally detailed procedures are 
provided. The choice of methods for testing, quantification and evaluation of photostability in 
solution was essentially left to the discretion of the experimentalist. 
The situation is even more acute when the photodegradation of drugs obeys complex 
(multistep) mechanisms that may involve both thermal and photochemical reactions yielding 
several products. Such complexity can be seen in the case of the ICH (Q1b) recommended 
actinometer, the quinine hydrochloride (QH) [4]. It has been clearly shown by many authors [5-
8] that the application of QH is not reliable and far from being standardised. One of the main 
problems of QH is its unknown mechanism that was evidenced to involve concurrent 
photochemical and thermal processes [7]. In a larger view, this is not a rare situation in drugs’ 
photodegradation. The lack of standardized methods is also related to the absence of kinetic 
methods able to handle photodegradation mechanisms. As it has been shown in chapter 3, 
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when integrated rate-laws are available, mostly for simple mechanisms, a considerable 
knowledge on the photodegradation reaction can be easily reached. Unfortunately for 
complex reactions, there is still no mathematical frameworks that would be useful. 
In the literature, a few attempts used computational techniques to overcome such a problem 
[9-17]. Such kinetic treatments enabled the spectra of each species, the concentration profiles, 
and equilibrium constant to be extracted from mixed spectral data. However, these methods 
presented two serious limitations: (i) they employed differential equations suitable for thermal 
reactions (which are inapplicable for photochemical reactions, as discussed in chapter 3); and 
(ii) they generally assumed a “minimum” mechanism to the drugs’ photodegradations studied. 
This state of the matter has prompted us to propose, in this chapter, a new alternative method 
aiming at circumventing the limitations of the published approaches and which is able to 
elucidate, quantify and evaluate complex photodegradation of drugs. It has been developed 
here for the photokinetic analyses of DBZ, AXI and SUT. 
 
6.2. ABSORPTION SPECTRA OF DRUGS IN WATER 
The electronic absorption spectra of the three drugs in water show similar transitions and 
spectral characteristics to those observed in ethanol, with only some maxima/intensity 
differences, Fig. 6.1. 
It is interesting to notice that, at low concentration, the hydrophobic AXI seem well solubilized 
in the predominantly aqueous mixture, water/ethanol (v/v, 97.5/2.5). This may provide 
evidence that small quantities of AXI may interact with water (especially in vivo) and hence 
may undergo degradation in this medium.  




Fig. 6.1: Native absorption spectra of the drugs in water and ethanol: (left) Dacarbazine 
(DBZ, 5.38 x 10-6 M and 5.47 x 10-6 M respectively), (right) Axitinib (AXI, 2.29 x 10-5 M and 
2.29 x 10-5 M respectively) (see SUT spectra in Annex A6.1).  
 
 
6.3. THERMAL STABILITY IN AQUEOUS MEDIA 
In Chapter 3, it had been established that all three drug (DBZ, AXI and SUT) were thermally 
stable in organic solutions. However, apart from DBZ which is known to be stable [18-23], AXI 
and SUT’s thermal stability in aqueous media has not been reported in the literature. Hence, 
we studied the thermal behaviour of the three drugs kept in the dark at 22°C, stirred and 
regularly monitored by DAD analysis. 
In water, AXI’s and SUT’s undergo a thermal degradation evidenced by a decrease of their 
respective absorption spectra. The more pronounced variation of absorbance recorded for AXI 
(Fig 6.2) was found to decrease at the same rate as a constant ratio of various peaks’ 
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Fig 6.2: Changes in the spectrum of (left) 1.97 x10-4 M AXI 2.5% v/v ethanol/water solution 
and (right) 1.92 x 10-5 M SUT in water kept in the dark, stirred and thermalstatically 
maintained at 22°C 
 
The kinetic traces of AXI and SUT (Fig. 6.3) mainly show two reaction regimes. In the case of 
AXI the first regime (~ 60 s) is slower than the second while the reverse situation is observed 
for SUT. For both drugs (labelled A2,3 in Fig. 6.3), the two reaction stages suggest the presence 
of at least two products (C2,3 and D2,3).  
The S1 section of SUT’s trace is similar to the one observed in ethanol which tends to a plateau 
in S2. This might indicate that Z-SUT (A3, in scheme 6.1) undergoes a thermal isomerisation to 
its E-isomer (in S1) as well as a degradation to another product (B3 in S1 and C3 in S2, 
respectively). The slow rate of formation of C3 allow to suggest that this reaction step (A3 → 
C3) is concurrent to the isomerisation but is only noticeable after the equilibrium is reached. 
Since, at this stage it wouldn’t be possible to rule out the preservation of the double bond, we 
can postulate that a similar degradation could take place from B3 (to D3). E-AXI (A2) however 
undergoes a priori a consecutive reaction involving C2 and D2. More evidence of this proposal 
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Fitting the traces (Fig. 6.3) on the bases of the mechanisms proposed in Scheme 1 (see 
corresponding differential equations of each drugs in annex A6.2), yielded the respective sets 
of kinetic parameters (Table 1).  
 
 
Fig 6.3: Thermaldegradation kinetic of 2.03 x 10-5 M AXI in 2.5 % (v/v) ethanol/water solution 
(right) and 1.12 x 10-5 M SUT (Left) when kept in the dark at 22°c, stirred, λobs = 330 nm, 
circles represent experimental data and the solid lines are the fitting of the trace based on 
scheme 6.1. Expected plateau indicated by the dotted lines and change in rate indicated by 
the solid line at 900 s, separating section 1 (S1) and section 2 (S2).    
 
The reaction rates for AXI’s thermal transformations indicate that the latter step of AXI’s 
reaction (C2 → D2) is more than two times faster than the former (A2 → C2). The results of 
SUT’s thermal degradation show that the formation of D3 from B3 is the slowest reaction, 
being 13 times slower than A3 → C3. The reversible isomers rate constants are much faster 
than their side reactions with the forward reaction (A3 → B3) is almost 4-fold slower than the 

















Time   /s 
Axitnib 



















Time    / s 
Sunintib 




S1       S2 
99 | P a g e  
 
Table 6.1: Overall rate-constants for AXI and SUT thermal degradation reactions in aqueous 
solution 
Drug 
(Concentration  /M) 
Epsilon of the Species at 
λobs 
Process 𝒌𝒌𝒙𝒙∆  / s 
AXI 
1.93 x 10-5 
A2 (330) 31162 
A2 → C2 1.55 x 10-3 
C2 (330) 27500 
D2 (330) 4028 C2 → D2 3.50 x 10-3 
SUT 
1.12 x 10-5 
A3 (430) 26750 A3 → B3 6.90 x 10-4 
B3 (430) 19400 B3 → A3 2.70 x 10-3 
C3 (430) 19580 A3 → C3 2.00 x 10-5 
D3 (430) 15010 B3 → D3 1.55 x 10-6 
 
6.4. KINETIC ANALYSIS OF THE DRUGS’ PHOTODEGRADATION REACTIONS. 
Monochromatic and continuous irradiation of the drugs in aqueous solution induces the 
decrease of the original peaks and the formation of new peaks (Fig. 6.4). One isosbestic point 
can be observed in the cases of SUT (at 266 nm) and AXI (at 360 nm), but no isosbestic points 
were recorded for DBZ. 
 
 
Fig 6.4: Evolution of the electronic absorption spectra under monochromatic irradiation of 
(Left) 5.38 x 10-6 M DBZ in water at λ irr = 254 nm (7.06 x 10-7 einstein s-1 dm-3, 22°C) and 
(Right) 2.03 x 10-5 M AXI in 2.5 % (v/v) ethanol/water solution, λ irr = 360 nm (1.15 x 10-6 
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In contrast to the behaviour observed for AXI’s thermal reaction, the successive spectra do not 
regularly decrease but are somewhat behaving similarly to what has been observed in ethanol. 
This would a priori suggest that the photochemical reaction (probably a photoisomerization) 
overtakes the thermal reactions which only becomes evident after the equilibrium (Fig. 6.5). At 
this stage a mechanism is proposed for AXI photodegradation (Scheme 6.2).   
 
 
Fig. 6.5: Photokinetic trace obtained when 2.03 x 10-5 M AXI in 2.5 % (v/v) ethanol/water 
solution (left, λ irr = 360 nm, 1.15 x 10-6 einstein s-1 dm-3, 22°C) was irradiated continuously 
with a monochromatic beam. Change in rate indicated by the solid line, separating section 1 
(S1) and section 2 (S2). Expected end of reaction (plateau) indicated by dotted line. (Right) 
1.92 x 10-5 M SUT in water (λ irr = 430 nm, 2.64 x 10-6 einstein s-1 dm-3, 22°C). Interruptions as 
shown by the dotted lines (D=Dark, L=Light). 
 
SUT’s kinetic traces show an interesting reversibility between irradiated and non-irradiated 
intervals (Fig. 6.5), with a good reproducibility. A behaviour that strongly suggest that a 
photoequilibrium (probably a Z/E photoisomerisation as the one observed in ethanol) is 
concurrent to a thermal one. The regular decrease of the maximum absorbance during the 
cycles attests to an extra degradation process which might well be the thermal degradations 
shown in Scheme 6.1. Accordingly, a minimum mechanism for SUT overall degradation was 
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Scheme 6.2: Proposed photodegradation reaction mechanism for AXI and SUT 
 
Most of DBZ’s traces showed a monotonical increase or decrease followed by a plateau (λobs 
>300 nm) suggesting a rather unimolecular reaction. However, the trace obtained at 276/276 
(Fig. 6.6) shows curves that successively decease, increase and decrease again; each 
characterised by a different length of time and slope. This indicates that there are at least 
three kinetic regimes (yielding three products: C1, D1 and E1) involved in the overall reaction.  
 
 
Fig 6.6: Changes in absorbance observed at 276nm when 5.38 x 10-6 M DBZ in water 
irradiated monochromatically at 276 nm (6.66 x 10-7 einstein s-1 dm-3, 22°C) 
 
The literature reports have proposed that the first step in the reaction is the breakage of the 
terminal N-N bond moiety separating the dimethylamine N(CH3)2 group from the rest of DBZ 
molecule [18-21]. However, this molecule is likely to absorb in the short wavelengths of the UV 
region and so might not be detected at 276 nm. Therefore, the proposed mechanism includes 
this species (E1), Scheme 6.3)  
B1 C1 D1E1 A1
 
























Our proposed mechanism (scheme 6.3) is found to be in agreement with that proposed by the 
literature (scheme 6.4)  [21,22]. It is worth noting that no colour change or absorbance band 
beyond 400 nm were observed in all our experiments regardless of the irradiation wavelength. 
This therefore means that the dimer reported as the last product by Saunders et al. [23] at λmax 
= 550 nm was not produced in the experimental conditions used for the present work. This 
may be due to the fact that the maroon precipitate only forms at relatively high initial 








































Scheme 6.4: Photodegradation pathways of dacarbazine  
proposed by Horton and Stevens [21,22] 
 
To shed more light on the reaction steps involved, solution of DBZ was subjected to irradiation 
for an interval of time then the irradiation was stopped and the solution monitored. 
As can be seen in Fig. 6.7, when the light is off, the reaction does not stop but carries on 
apparently at a much slower rate than when the sample was being irradiated. This clearly 
indicates that either or both B1 and C1 are thermally active where their cumulative rate of 




ℎ𝑣𝑣 . From these observations, it is possible to deduce that if B1 
and C1 were not photochemically active then the trace obtained under continuous irradiation 
would show a fast regime corresponding to the depletion of A1, where B1 and C1 mostly 
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accumulate, which would be followed by a slower regime where B1 and C1 should thermally 
transform into D1. This type of trace was not observed experimentally irrespective of the 
λ irr/λobs selected. Furthermore, when irradiation was resumed the rate of the reaction 
increased to a comparable level to that recorded at the light-off interval. Therefore, B1 and C1 













It is however difficult to obtain evidence to whether any reversible reactions steps are involved 
in the overall mechanism. Accordingly, the proposed mechanism Scheme 6.3 must be 
amended so that species B1 and C1 are photochemically and thermally active (scheme 6.5).  
The phototransformations of B1 and C1 has never been reported in the literature thus far. 
Generally, only DBZ (A1) has been assumed to be photoactive and the rest of the intermediate 
species postulated in the mechanism assumed to be undergoing exclusively thermal reactions 
[17-24].  
It is worth noting that photo and thermal mechanisms seem to produce the same species. 
There were no noticeable spectral features to indicate the occurrence of such differently 
absorbing products.  This is corroborated by the literature reports which indicated only a few 
 
Fig. 6.7: Photokinetic of 5.38 x 10-6 M DBZ reaction with 
interrupted reaction (●) and uninterrupted reaction 
data (○).  Interruption of irradiation as shown by the 
dotted lines (D=Dark, L=Light). (λirr = 254 nm, 7.06 x 10-7 
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Scheme 6.5: Proposed degradation 
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products without any variation being observed when different experimental conditions were 
used.  
The quick disappearance of all the products when the solution was subjected to irradiations at 
330 and 360 nm strongly indicated that besides DBZ some photoproducts also absorb at these 
wavelengths or that the sum of thermal and photochemical rate constants of some of these 
products is relatively high. Species D1 however is unlikely to absorb at this long wavelength 
range because the kinetic trace of the medium reaches a zero value at the end of the 
photoreaction. 
The study of the thermal reactions is realised by performing an irradiation for some time (S0) 
to produce the thermally instable photoproducts (B1 and C1), and then switch off this 
irradiation (similar to Fig. 6.7) and monitor the behaviour of the system for a sufficient time to 
be able to do kinetic measurements. 
In this situation we will assume that all the five reaction species are present in solution. Their 
respective reaction initial concentrations at the switch off time (t = 0 at the end of SO) will be 
labelled [𝑋𝑋]𝑆𝑆0. 
According to the above proposed mechanism (Scheme 6.5) species A1, E1 and D1 are thermally 
stable. Their cumulative absorbances will represent the background absorbance of the kinetic 
trace. The kinetics will involve the degradation of both species B1 ([𝐵𝐵1]𝑆𝑆0) via a consecutive 
reaction into C1 and D1, and species C1 ([[𝐶𝐶1]𝑆𝑆0) as a unimolecular transformation into D1 
(Scheme 6.6). 
D DB1 C1 D1           initial concentration [𝐵𝐵1]𝑆𝑆0 
 
DC1 D1                    initial concentration [𝐶𝐶1]𝑆𝑆0 
Scheme 6.6: consecutive reaction of B1 and unimolecular reaction of C1 
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Hence, the system of differential equations for these reactions is: 








∆ × 𝐶𝐶𝐶𝐶1 + 𝑘𝑘𝐵𝐵1→𝐶𝐶1
∆ × 𝐶𝐶𝐵𝐵1       Eqs.1,2 




∆ × 𝐶𝐶𝐶𝐶1            Eq.3 
 
These equations can be solved in a closed form [25]. For the consecutive reaction, the 
integrated rate-laws are: 
𝐶𝐶𝐵𝐵1 = [𝐵𝐵1]𝑆𝑆0 × 𝐶𝐶
−𝑘𝑘𝐵𝐵1→𝐶𝐶1
∆ ×�𝑡𝑡−𝑡𝑡𝑆𝑆0�         Eq.4.1 






∆ ×�𝑡𝑡−𝑡𝑡𝑆𝑆0� − 𝐶𝐶−𝑘𝑘𝐶𝐶1→𝐷𝐷1
∆ ×�𝑡𝑡−𝑡𝑡𝑆𝑆0��  Eq.4.2 












𝑡𝑡 ×�𝑡𝑡−𝑡𝑡𝑆𝑆0�� Eq.4.3 
 
and for the unimolecular reaction of C1, they are 
𝐶𝐶𝐶𝐶1 = [𝐶𝐶1]𝑆𝑆0 × 𝐶𝐶
−𝑘𝑘𝐶𝐶1→𝐷𝐷1
∆ ×�𝑡𝑡−𝑡𝑡𝑆𝑆0�       Eq.4.4 
𝐶𝐶𝐶𝐶1 = [𝐶𝐶1]𝑆𝑆0 × �1 − 𝐶𝐶
−𝑘𝑘𝐶𝐶1→𝐷𝐷1
∆ ×�𝑡𝑡−𝑡𝑡𝑆𝑆0��       Eq.4.5 
 
The total absorbances of the medium at the time of light switch off (tSO) is the sum of the 
species individual absorbances at that time. 
𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝐶𝐶𝐶𝐶𝐶𝐶/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜(𝑡𝑡𝑆𝑆𝑆𝑆) = 𝜀𝜀𝐴𝐴1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐴𝐴1]𝑆𝑆0 + 𝜀𝜀𝐵𝐵1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐶𝐶1]𝑆𝑆0 + 𝜀𝜀𝐶𝐶1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐶𝐶1]𝑆𝑆0 + 𝜀𝜀𝐶𝐶1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐶𝐶1]𝑆𝑆0 + 𝜀𝜀𝐸𝐸1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 ×
[𝐸𝐸1]𝑆𝑆0                     Eq.5 
The variation of the total absorbance after tSO is given by the following expression that takes 
into account Eqs.4. 
106 | P a g e  
 
𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜�𝑡𝑡 − 𝑡𝑡𝑆𝑆0� = �𝜀𝜀𝐴𝐴
𝜆𝜆 × [𝐴𝐴]𝑆𝑆𝑆𝑆 + 𝜀𝜀𝐶𝐶1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐶𝐶1]𝑆𝑆0 + 𝜀𝜀𝐸𝐸1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐸𝐸1]𝑆𝑆0� + 𝜀𝜀𝐵𝐵1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐵𝐵1]𝑆𝑆0 ×
𝐶𝐶−𝑘𝑘𝐵𝐵1→𝐶𝐶1









∆ ×�𝑡𝑡−𝑡𝑡𝑆𝑆0� − 𝐶𝐶−𝑘𝑘𝐶𝐶1→𝐶𝐶1


















∆ ×�𝑡𝑡−𝑡𝑡𝑆𝑆0�� + 𝜀𝜀𝐸𝐸𝜆𝜆 ×
[𝐶𝐶1]𝑆𝑆0 × �1− 𝐶𝐶
−𝑘𝑘𝐶𝐶1→𝐶𝐶1
∆ ×�𝑡𝑡−𝑡𝑡𝑆𝑆0���                     
  Eq.6 
 
Finally, the total absorbance of the medium can be expressed as a biexponential formula 
(Eqs.7): 
𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜�𝑡𝑡 − 𝑡𝑡𝑆𝑆0� = 𝛼𝛼 + 𝛽𝛽 × 𝐶𝐶
−𝑘𝑘𝐵𝐵1→𝐶𝐶1
∆ ×�𝑡𝑡−𝑡𝑡𝑆𝑆0� + 𝛾𝛾 × 𝐶𝐶−𝑘𝑘𝐶𝐶1→𝐶𝐶1
∆ ×�𝑡𝑡−𝑡𝑡𝑆𝑆0�  Eq.7.1 
 
𝛼𝛼 = �𝜀𝜀𝐴𝐴1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐴𝐴1]𝑆𝑆0 + 𝜀𝜀𝐵𝐵1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐵𝐵1]𝑆𝑆0 + 𝜀𝜀𝐶𝐶1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐶𝐶1]𝑆𝑆0 + 𝜀𝜀𝐶𝐶1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐶𝐶1]𝑆𝑆0 + 𝜀𝜀𝐸𝐸1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐸𝐸1]𝑆𝑆0� Eq.7.2 
𝛽𝛽 = 𝜀𝜀𝐵𝐵1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐵𝐵1]𝑆𝑆0 + 𝜀𝜀𝐶𝐶1











∆      Eq.7.3 
𝛾𝛾 = 𝜀𝜀𝐶𝐶1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐶𝐶1]𝑆𝑆0 − 𝜀𝜀𝐶𝐶1













𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × [𝐶𝐶1]𝑆𝑆0                  Eq.7.4 
 
Eq. 7.1 tends to α (as given in Eq.7.2) when t → ∞ and tends to 𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜(𝑡𝑡𝑆𝑆0) (as given in 
Eq.6) when t → 0. 
It is important to notice that the fitting of Eq.7.1 to experimental data makes it possible to 
determine the individual rate-constants of the reaction steps B1 → C1 (𝑘𝑘𝐵𝐵1→𝐶𝐶1
∆ ) and C1 → D1 
(𝑘𝑘𝐶𝐶1→𝐶𝐶1
∆ ) without the need to know, beforehand, the absolute values of the remaining 
reactions parameters. 
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As shown in Fig. 6.8, the data corresponding to two observation wavelengths (216 and 330 
nm) obey well the biexponential model given by Eq.7.1. This indicates that the thermal 
behaviour of the reaction involves at least two species, hence confirming the likelihood of the 
proposed thermal steps of the proposed mechanism in Scheme 5.    
The fitting of the thermal kinetic data to Eq.7.1 yields also the values of the equation 
parameters (Table 6.2). The reaction rates for the thermal transformations 𝑘𝑘𝐵𝐵1→𝐶𝐶1
∆  and 
𝑘𝑘𝐶𝐶1→𝐶𝐶1
∆ , are of the same order of magnitude and overall indicate that the reactions involved in 





6.5. RUNGE-KUTTA ANALYSIS OF THE PHOTODEGRADATION REACTION 
One way to solve this kind of complex kinetic situations, where the integrated rate-law is not 
known, is to apply numerical integration methods [25]. Current methods used in the literature 
are all based in the thermal differential equations which, as discussed, are unsuitable for 
characterising photokinetic data.  
For this purpose, we propose a new approach to solving such complex kinetics that has not 









0 5000 10000 15000
λobs = 216 nm 
λobs = 330 nm 







Fig. 6.8: Fitting of Eq. 7.1 to DBZ experiemental 
data for two wavelengths, 216nm and 330 nm. 
 
Table 6.2: Equation parameters yielded from 
the fitting of Eq.7.1 to the thermal kinetic 
data. 




∆ 𝒂𝒂  1.2 x 10-4 
𝜸𝜸 0.01311 
𝒌𝒌𝐶𝐶1→𝐶𝐶1
∆  7.3 x 10-5 
a: The rate-constants are expressed in s-1. 
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for the proposed mechanism of the considered overall photochemical reactions. Secondly, the 
unknown parameters of the reactive system (Φ𝑖𝑖→𝑗𝑗
λirr , ε𝑋𝑋
λirr , and 𝑘𝑘𝑖𝑖→𝑗𝑗∆  if not possible to determine 
it through experiments) are optimised until the data generated by the fifth-order Runge-Kutta 
(RK) fit well the experimental trace obtained at one λ irr/λ irr (e.g. λ254/λ254). Thirdly, the newly 
defined ε𝑋𝑋
λirr , and 𝑘𝑘𝑖𝑖→𝑗𝑗∆  parameters are then validated against a series of traces obtained for 
the same irradiation wavelength but at different observations (varying λ irr in: λ irr/λobs, e.g. λ254/ 
λobs) spanning the whole spectrum of the drug. Fourthly, the quantum yields as supposed to be 
wavelength-dependent i.e. for the new fittings of λ irr/λobs traces, the values of Φ𝑖𝑖→𝑗𝑗
λirr is 
changed and optimised until a good fit is obtained. The validation of the parameters 
and mechanism is performed on the experimental traces obtained at different 
irradiation conditions (varying λobs in: λ irr/λobs, e.g. λ irr/ λ330). 
If the newly defined parameter fails to fit any set of traces, the parameters are then 
considered incorrect and must be redefined until all sets of different traces can be fitted with 
just one set of parameter values that are unique to this drugs’ kinetic data. If it turns out that it 
is impossible to fit the experimental data with any single set of parameters, then the 
conclusion should be that mechanism is not correct and hence a new improved mechanism 
should be proposed and the whole procedure repeated. Such an inclusive approach, which has 
never been developed in earlier studies, allows to define a reliable set of parameters and 
validate the likelihood of the mechanism proposed. We applied this approach to AXI, DBZ and 
SUT kinetics in water. 
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6.6. RATE LAWS OF THE SYSTEMS 
The mathematical description of the photochemical/thermal mechanisms present for each 
drug is well provided by a system of differential equations (see Annex A6.4). For instance, and 









𝜆𝜆𝐶𝐶𝐶𝐶𝐶𝐶 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐴𝐴1 − 𝑘𝑘𝐵𝐵1→𝐶𝐶1
𝜆𝜆𝐶𝐶𝐶𝐶𝐶𝐶 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐵𝐵1 − 𝑘𝑘𝐵𝐵1→𝐶𝐶1




𝜆𝜆𝐶𝐶𝐶𝐶𝐶𝐶 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐶𝐶1 − 𝑘𝑘𝐶𝐶1→𝐶𝐶1
∆ × 𝐶𝐶𝐶𝐶1 + 𝑘𝑘𝐵𝐵1→𝐶𝐶1
𝜆𝜆𝐶𝐶𝐶𝐶𝐶𝐶 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐵𝐵1 + 𝑘𝑘𝐵𝐵1→𝐶𝐶1
∆ ×




𝜆𝜆𝐶𝐶𝐶𝐶𝐶𝐶 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐶𝐶1 + 𝑘𝑘𝐶𝐶1→𝐶𝐶1




𝜆𝜆𝐶𝐶𝐶𝐶𝐶𝐶 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐴𝐴1                                 Eq.12 
 
where t is the time, 𝐶𝐶𝑋𝑋 is the concentration of species X, 𝑘𝑘𝑖𝑖→𝑗𝑗
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖is the rate-constant of the 
photochemical reaction of species X, 𝑘𝑘𝑖𝑖→𝑗𝑗∆  is the rate-constant of the thermal reaction of 
species X and 𝐹𝐹λirr(𝑡𝑡) the photokinetic factor. 
The rate-constant of the photochemical reaction of species X (𝑘𝑘𝑖𝑖→𝑗𝑗





𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖                                  Eq.13 
 
Where Φ𝑖𝑖→𝑗𝑗
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 is the quantum yield of the photoreaction of species X at λ irr, 𝜀𝜀𝑋𝑋
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  is its 
absorption coeffient, lirr the optical path length of the irradiation beam in the sample and 
𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖the radiant power at λ irr. 
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The expression of 𝑘𝑘𝑖𝑖→𝑗𝑗
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 shows that the photochemical rate-constant directly depends on four 
quantities (Φ𝑖𝑖→𝑗𝑗
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 , 𝜀𝜀𝑋𝑋
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 , 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  and 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖) that all depend on the wavelength of the irradiation 
beam. This means that the comparison of photoreaction rate-constants must be considered 
with care since only experiments where only one quantity is varied can be readily compared. 
For instance, if the experimental results show that a given trace 1 is faster that a trace 2, this 
might not automatically mean that the efficiency of the photoreaction is higher for experiment 
1 (it can simply be explained by a higher quantity of the remaining three as expressed in 𝑘𝑘𝑖𝑖→𝑗𝑗
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 
formula). This is an important difference with rate-constants measured for thermal reactions 
(where the temperature is the main factor). 






                                                                                    Eq.14 
 
with 𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜  is the total absorbance of the reaction medium measured at λ irr. 
𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(𝑡𝑡) is time-dependent due to the variation of 𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜  with reaction time. Owing to that, 
the integration of photochemical reaction is made very difficult if at all possible. Only one 
example of closed-form integration of the unimolecular photoreaction has thus far been 
published [26].  
Accordingly, the closed-form integration of the system of differential equations, such as that 
describing DBZ (Eqs. 8-12), AXI (Eqs. 13-19, Annex A6.4) and SUT (Eqs. 20-23, Annex A6.4) 
phototransformation, has remained impossible until now - despite some intensive attempts in 
our team. 
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DBZ’s system of equations (Eqs. 8-12) involves nine unknown parameters, namely, three 𝑘𝑘𝑖𝑖→𝑗𝑗
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖, 
two 𝑘𝑘𝑖𝑖→𝑗𝑗∆ , and four absorption coefficients 𝜀𝜀𝑋𝑋
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖, to be optimised (there are eighteen 
unknowns for AXI and nine for SUT, see Annex A6.4). 
Due to the flexibility of a system depending on so many parameters, the optimisations were 
very difficult to achieve. Nonetheless, we have successfully proposed a mechanism for each 
drug of this study (Fig. 6.9, tables 6.3 and 6.4). It is important to mention that total solutions 
for the drugs kinetics not thus far been proposed in the literature.   Also, the present study 
represents the first of its kind in the field of drugs’ photodegradation based on a review of the 
main textbooks in photodegradation of drugs [7,8,24] and a wide number of papers and 
reviews in the field. 
 
 
Fig 6.9: Fitting of experimental kinetics traces (open circles) recorded at a number of 
observation wavelengths (λobs) with RK data (lines). (left) 5.37 x 10-6 M DBZ (λ irr = 254 nm, 
7.06 x 10-7 einstein s-1 dm-3, 22°C). (right) 1.12 x 10-5 M SUT (λ irr = 460 nm, 2.66 x 10-6 einstein 
s-1 dm-3, 22°C). See Annex A6.5 for AXI. 
 
The kinetic treatments of DBZ and SUT have shown that the proposed mechanisms (schemes 
6.5 and 6.2, respectively) were sufficient to fit the traces obtained at various irradiation and 
observation wavelengths. This in fact validates these mechanisms and confirms the 
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both isomers. There is also a confirmation of the involvement of thermal and photochemical 
reaction steps for the photodegradation of DBZ. This contrasts with the mechanisms proposed 
for these drugs in ethanol. It also stresses the need to acknowledge of SUT’s thermal 
degradation in water for any patient use.  
The case of AXI was special. The treatment based on the mechanism of scheme 6.2 was clearly 
unsatisfactory as it wasn’t possible to fit all the photodegradation traces of this molecule. A 
number of other mechanisms were applied with little success (Annex A6.6). This led us into a 
more thorough analysis that Z- (A2) and E- (B2) isomers undergo a photoisomerisation through 
the double bond and both hold another moiety in their chemical structures (different from the 
double bond) that degrades thermally to C2 and F2 but it is reversed to the original isomers (A2 
and B2) photochemically. This property could be attributed to the amide group that has been 
shown to react through this mechanism (Scheme 6.7, [27-30]).   
 
 
Scheme 6.7: Thermal and photo-induced tautomerisms 
 
This “square” mechanism (A2, B2, C2 and F2) was insufficient to render account of the full 
kinetics. Therefore, degradation steps were added successively to B2, C2 and F2 (as shown in 
Scheme 6.8) until a good correlation was finally find between the experimental traces and RK-5 
data. This mechanism explains well the significantly different kinetic behaviours of AXI in the 
dark and under irradiation, where the pure thermal degradation of AXI (Fig. 6.2, right) is largely 



























Scheme 6.8: Proposed degradation mechanism of AXI in aqueous solution 
 
6.7. QUANTITATIVE PROPERTIES OF THE PHOTODEGRADATION REACTIONS 
The RK treatment has also the advantage to provide a number of reaction parameters and 
species attributes without physical separation of the mixtures.  The time-variation of the 
individual concentrations of all the species involved in the reaction is one of the properties 
that can supply information on the composition of the medium at any reaction time (Fig. 6.10). 
At a relatively low concentration (0.5 - 2 x 10-5 M, ~0.05-0.4 % w/v) and a radiant power of ca. 
7 x 10-7 einstein s-1 dm-3 (~ 0.330 mW/cm2), more than 85 % of DBZ (A1) is depleted in less than 
1.5 Hours, only up to 74 % of AXI (A2) is missing in solution after 104 s (2.78 Hours), while just 
~46 % of SUT (1.12 x 10-5 M, 0.3 % w/v) depletes in 3 Hours (2.66 x 10-6 einstein s-1 dm-3, 0.692 
mW/cm2).  
The maximum concentration (Cmax) of species B1 is reached at a much earlier time (~2400s) 
compared to species C1 (~6000s) suggesting that the reactivity of C1 is significantly slower than 
B1. For DBZ, the ratio of the times corresponding to the maximum concentrations of C1 and B1 
(6000/2400 ~ 2.5) is higher than that the ratio recorded for the thermal rate-constants of 
species B1 and C1 (1.64). This strongly indicates that the reactivity of species B1 and C1 must 
involve photochemical routes. Therefore, the supposition that these species react exclusively 
through thermal reactions is not sustainable. These results further support our proposed 
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mechanism combining both thermal and photochemical reactions of species B1 and C1, 




Fig 6.10: Concentration profiles obtained for (left) 5.38 x 10-6 M DBZ and its products when 
monochromatic irradiation at 254 nm (7.06 x 10-7 einstein s-1 dm-3, 22°C).(right) 2.03 x 10-5 M 
AXI in 2.5 % (v/v) ethanol/water solution when monochromatically irradiated at 330 nm 
(6.99 x 10-7 einstein s-1 dm-3, 22°C). Annex A6.7 for SUT 
 
In both cases of AXI and SUT, almost all the photo/thermal products are present in solution 
after less than 2000 s (~35 min) which may raise the point to carefully consider, in future 
studies, the biological effects of these species.  
The RK treatments provide also the quantum yield values of all the photochemical reaction 
steps at any irradiation wavelength (Table 6.3). This represent a significant advantage since 
even if the physical separation was performed it would still be almost impossible to determine 
the quantum yields of most of the species, using the classical methods, due to their thermal 
instability.  
As it has been observed in ethanol, all species quantum yields were found to be wavelength 
dependent in water (table 6.3). This corroborates a number of results from our team [31-35], 
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be wavelength independent [8]. In addition, for AXI, DBZ and SUT the quantum yields generally 
increase with the increase of the irradiation wavelength, most of them in a sigmoid pattern 
(Figs. 6.11, annex A6.9 for AXI) – indicating that they are most photochemically active in the 
UVA-Visible regions.  
Table 6.3: Determined quantum yield values and estimated absorption coefficients of all 










λ irr  /nm 203 216 228 237 254 276 330 360 
𝛷𝛷𝐴𝐴1→𝐵𝐵1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  -
a - - 0.0386 0.0362 0.0811 0.104 0.114 
Φ𝐵𝐵1→𝐶𝐶1
λ𝑖𝑖𝑖𝑖𝑖𝑖  - - - 0.0762 0.0436 0.112 - - 
Φ𝐶𝐶1→𝐶𝐶1
λ𝑖𝑖𝑖𝑖𝑖𝑖  - - - 0.0223 0.0106 0.0136 - 0 
ε𝐴𝐴1
λirr  11560 9868 11706 - 7363 6435 19672 7744 
ε𝐵𝐵1
λirr  12490 4380 5050 - 5200 3970 6150 0 
ε𝐶𝐶1
λirr  7890 9150 5550 - 6860 10550 0 0 
ε𝐶𝐶1
λirr  4500 6960 4900 - 4190 7460 0 0 
ε𝐸𝐸1








λ irr  /nm 230 264 280 300 320 330 340 360 380 
Φ𝐴𝐴2→𝐵𝐵2
λ𝑖𝑖𝑖𝑖𝑖𝑖  - - - - 0.026 0.030 0.030 0.052 0.054 
Φ𝐵𝐵2→𝐴𝐴2
λ𝑖𝑖𝑖𝑖𝑖𝑖  - - - - 0.018 0.034 0.0235 0.0225 0.040 
Φ𝐶𝐶2→𝐹𝐹2
λ𝑖𝑖𝑖𝑖𝑖𝑖  - - - - 0.072 0.050 0.030 0.070 0.095 
Φ𝐹𝐹2→𝐶𝐶2
λ𝑖𝑖𝑖𝑖𝑖𝑖  - - - - 0.0015 0.120 0.030 0.020 0.200 
Φ𝐶𝐶2→𝐴𝐴2
λ𝑖𝑖𝑖𝑖𝑖𝑖  - - - - 0.210 0.250 0.140 0.005 0.550 
Φ𝐹𝐹2→𝐵𝐵2
λ𝑖𝑖𝑖𝑖𝑖𝑖  - - - - 0.088 0.330 0.230 0.530 0.480 
Φ𝐶𝐶2→𝐶𝐶2
λ𝑖𝑖𝑖𝑖𝑖𝑖  - - - - 0.049 0.150 0.155 0.650 0.135 
Φ𝐺𝐺2→𝐹𝐹2
λ𝑖𝑖𝑖𝑖𝑖𝑖  - - - - 0.125 0.150 0.350 0.100 0.450 
Φ𝐵𝐵2→𝐸𝐸2
λ𝑖𝑖𝑖𝑖𝑖𝑖  - - - - 0.00038 0.0019 0.0012 0.00063 0.0028 
ε𝐴𝐴2
λirr  27681 17503 17176 21607 28333 31162 28377 9008 2474 
ε𝐵𝐵2
λirr  - 20516 18269 21221 22921 22680 20174 12192 8500 
ε𝐶𝐶2
λirr  - 16243 17510 21576 24576 27500 26280 8523 2250 
ε𝐶𝐶2
λirr  2899 1976 1929 2296 2788 4028 2804 1297 796 
ε𝐸𝐸2
λirr  - 8207 6975 9153 8833 8500 7745 1850 650 
ε𝐹𝐹2
λirr  - 16434 17207 20514 19514 21500 19546 6263 1800 
ε𝐺𝐺2
λirr  - 14376 16070 6504 7204 8050 6215 1011 500 
n i   λ irr  /nm 215 250 273 360 400 430 460 480 
a  d i d 
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Φ𝐴𝐴3→𝐵𝐵3
λ𝑖𝑖𝑖𝑖𝑖𝑖  - - - 0.0134 0.019 - 0.019 0.0245 
Φ𝐵𝐵3→𝐴𝐴3
λ𝑖𝑖𝑖𝑖𝑖𝑖  - - - 0.028 0.029 - 0.040 0.060 
ε𝐴𝐴3
λirr  21380 7626 10259 8543 22120 26750 19281 9034 
ε𝐵𝐵3
λirr  18750 15322 5652 7655 19700 19400 8898 2511 
ε𝐶𝐶3
λirr  20100 8900 8500 5600 16550 19580 12550 6050 
ε𝐶𝐶3
λirr  17252 10252 5252 5252 5900 15010 10902 1500 
The photochemical reactions of species A1 and B1 are comparable in magnitude and they are 
always slightly higher than the efficiency of species C1 (Φ𝐶𝐶1→𝐶𝐶1
λ𝑖𝑖𝑖𝑖𝑖𝑖 ). These findings corroborate 
the difference recorded above on the times of maximum concentrations for B1 and C1 in the 
medium. It should be noted that this is the first time quantum yields have been determined 
and reported for DBZ and its degradation products (A1, B1 and C1). 
Changes in SUT’s Φ𝐴𝐴3→𝐵𝐵3
λ𝑖𝑖𝑖𝑖𝑖𝑖
R and Φ𝐵𝐵3→𝐴𝐴3
λ𝑖𝑖𝑖𝑖𝑖𝑖  values between the irradiation range (360-480 nm) in 
aqueous solution are comparable to that in ethanol of the same range (2-fold and 1.8-fold 




λ𝑖𝑖𝑖𝑖𝑖𝑖  respectively.  
While AXI’s Ф values for the similar λ irr (320 – 380 nm) in water were found rather different to 
those in ethanol. Φ𝐴𝐴2→𝐵𝐵2
λ𝑖𝑖𝑖𝑖𝑖𝑖  in water was found to be 5-times smaller than that in ethanol and 
Φ𝐵𝐵2→𝐴𝐴2
λ𝑖𝑖𝑖𝑖𝑖𝑖  was 4.5-times greater in water.  
Although, species B2 is also photochemically produced from A2 in water, the quantum yield 
values (Table 6.3) shows that B2 is mainly formed from F2, which is formed from C2. This 
suggests that thermal degradation of A2 to C2 actually has a greater role to play in AXI’s 
photochemical reaction in aqueous solution as well.  Thus, a greater Φ𝐵𝐵2→𝐴𝐴2
λ𝑖𝑖𝑖𝑖𝑖𝑖  value, than in 
ethanol, to compensate for A1 lost thermally. 
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Yet, for both AXI and SUT, the Z- to E- conversion was found to be more efficient - possibly due 
to steric effect in the E-isomers. While DBZ’s Ф values were respectively almost 2 times higher 
than those recorded in ethanol. 
Since carrying out a systematic study on the effect of the whole spectral range of the species 
absorption will be time consuming, it is better to find a mathematical model that can give the 
trend of the variation observed and estimate Φ𝑖𝑖→𝑗𝑗
λirr  value. 
 
 
Fig 6.11: Sigmoid relationship obtained for the photochemical quantum yield of DBZ and 
SUT. 
 
A sigmoid relationship fits the data obtained on Φ𝑖𝑖→𝑗𝑗
λirr . The following expressions are proposed 




  and  Φ𝐵𝐵3→𝐴𝐴3
λ𝑖𝑖𝑖𝑖𝑖𝑖 = 0.2
1+42550×𝑠𝑠−0.05×(λ𝑖𝑖𝑖𝑖𝑖𝑖−300)
+ 0.028      Eq.16,17 
 
It should be noted that this is the first time quantum yields and concentration profiles have 
been determined and reported for DBZ, AXI, SUT and their degradation products. 
Although many drugs are reported to be photolabile, quantum yields are less frequently 
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report quantum yields for a given drug are variable, predominantly due to the way the 
property is determined [36].  
As discussed above, some of the system parameters optimised by the RK analysis are the 
absorption coefficients (𝜀𝜀𝑋𝑋𝜆𝜆) of the reactive species (Fig. 6.12).  
The spectrum of DBZ’s species E1 seems to mainly occur below the 200 nm limit with its cut off 
absorption limit situated at around 220 nm. This fits well with the structure of compound E 
(HNMe2) as indicated in Scheme 6.4. 
Remarkably enough, species C1 and D1 share very similar spectral shapes throughout the UV 
region 200 – 320 nm suggesting that they should have close chemical structures.  
 
Fig 6.12: Estimated electronic absorption spectra of (left) DBZ, (right) AXI and their products 
 
Beside DBZ (A1), only species B1 shows absorption in the visible region. Its maximum is found 
at approximately at 330 nm though its absorption coefficient is about the third of that of A1. 
Here as well, we can postulate some similarity between the electronic distributions in the 
chemical structures for these two species.   
The shapes of species B1 and D1 spectra are very similar to those recorded by Kawahara et al. 
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obtained by our RK treatment of DBZ kinetics show a good overall agreement with the 
literature. 
The spectrum of all of SUT’s species (Annex A6.8) are all very similar in shape, which suggests 
that they have close chemical structures. This correlates well with the small change in 
absorbance recorded across the absorption spectrum (200 – 450 nm). 
Their maxima were all found to be situated around 430 nm (i.e. absorbing in the visible range). 
This agrees with the fact that the solution remained coloured after degradation. Although, the 
absorption coefficient of species D3 is about half of A3’s (SUT), this is not as visible in the 
evolution spectra (Fig. 6.2 and 6.4), due to the slow thermal reactivity of the species (Table 
6.1).  
AXI and its products (except species G2) all have their main absorbance coefficient maxima 
situated within 300-360 nm, as shown in Fig. 6.12, suggesting a rather similar chemical 
structure. Species C2 and F2 share very similar spectral shapes from 200 nm to 400 nm. These 
features would suggest that C2 and F2 should have close chemical structures, as is A2 and B2. 
Here, only species B2 have high absorbance beyond 360 nm – the same as in ethanol. Also, the 
electronic spectra of B2 obtained here in water is extremely similar to that obtained in ethanol, 
strongly suggests that species B2 is Z-AXI. 
Species D2’s low absorbance coefficient throughout the spectrum corroborates well with the 
significant decrease seen in AXI’s thermal evolution spectra (Fig. 6.2). Likewise, the high 
absorption coefficient of species E2 explains well why AXI’s photochemical spectral evolution 
does not decrease as it does under thermal conditions. 
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There are however no available data in the literature to compare our results with for AXI and 
SUT. 
 
6.8. POTENTIAL DEVELOPMENT OF ACTINOMETERS  
Solutions of DBZ in water were subjected to irradiation of varying radiant power at various 
wavelengths, spanning over its photoactive regions. The initial velocities (ν0) were then 
determined from a theoretical initial velocity equation (𝜈𝜈0(𝑐𝑐𝑠𝑠𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 ), Eq.18) [32] and values 




𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜�× 𝐹𝐹𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 × 𝛷𝛷𝐴𝐴1→𝐵𝐵1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝜀𝜀𝐴𝐴1
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(0) × 𝐶𝐶0  Eq.18 
Where 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(0) is calculated using the initial absorbance, 𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜  (0).   
Alternatively, the initial velocity (𝜈𝜈0(𝑚𝑚𝑡𝑡𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜⁄ ) can also be determined by differential equation of 
the model equation describing unimolecular Φ-order kinetics at t=0 (eq. 12, Annex A6.3). 
Where 𝑘𝑘𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  can be determined through fitting with Φ-order kinetics’ model. 
The results showed good correlation when ν0 values obtained via the different methods were 
validate against each other (Table 6.4). 
 
Table 6.4: correlation equation and r2 values obtained when v0 values for a range of 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  
were plotted against each other for each irradiation wavelength 
λ irr  /nm 255 276 300 330 360 
𝑷𝑷𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊  (x 10
-6) 0.4 - 1.28 0.13 – 0.94 0.14 – 0.53 0.32 – 1.05 0.53 - 1.86 
𝝂𝝂𝟎𝟎(𝒎𝒎𝒕𝒕𝒎𝒎.)




𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 =  
-7021.7 x 
𝜈𝜈0(𝑚𝑚𝑡𝑡𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜⁄ – 
0.1727 
𝜈𝜈0(𝑐𝑐𝑠𝑠𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  =  
-0.5213 x 
 𝜈𝜈0(𝑚𝑚𝑡𝑡𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜⁄  –  
7 x 10-6 
𝜈𝜈0(𝑐𝑐𝑠𝑠𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  =  
0.6656 x 
𝜈𝜈0(𝑚𝑚𝑡𝑡𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜⁄  + 
5 x 10-6 
𝜈𝜈0(𝑐𝑐𝑠𝑠𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  =  
0.7481 x 
𝜈𝜈0(𝑚𝑚𝑡𝑡𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜⁄  –  
3 x 10-6 
𝜈𝜈0(𝑐𝑐𝑠𝑠𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  =  
0.7216 x 
𝜈𝜈0(𝑚𝑚𝑡𝑡𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜⁄  + 
6 x 10-6 
r2 0.89 0.99 0.98 0.99 0.97 
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Not only do these results show DBZ’s potential as an actinometer in water solution, but it also 
validates the quantitative values determined via RK treatment of DBZ photokinetic data – 
further supporting the usefulness of RK to solve complex photokinetic data.  
The excellent linear correlations (Fig. 6.13) obtained when measured experimental Pirr values 
were plotted against recalculated P values using the P equations (Annex A6.9) from the two 
methods.  
In this study, DBZ has been successfully shown to be a potential drug actinometer for 
irradiation wavelengths above 300 nm in both water and ethanol (section 5.4).  
 
Fig. 6.13: Linear correlation obtained when experimental PExp values were plotted against 
calculated values (Pcal) 
 
More importantly, this study has shown viability of Φ-order kinetics’ potential for the 
development of reliable actinometers without prior knowledge of any of the unknown reaction 
parameters – even for drugs’ with a complex mechanism. This opens up the possibly for other 
drug actinometers. 
 
PCal = 0.9991 x PExp - 2E-08 
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122 | P a g e  
 
6.9. THE EFFECT OF POLYCHROMATIC LIGHT 
Solutions of DBZ, AXI and SUT were exposed for a period of time to ambient diffuse light 
(natural and artificial) at ambient room temperature in our laboratory (Fig. 6.14 and 6.15). 
Photodegradation of DBZ and SUT recorded matches well that reported in the literature [17-
23] and that observed under monochromatic irradiation in aqueous solution. While, AXI’s was 
found to be predominantly thermal reaction, rather than photochemical. 
 
Fig 6.14: Evolution of the electronic absorption spectra of (Left) 1.02 x 10-5 M AXI in 2.5 % 
(v/v) ethanol/water solution and (right) 3.76 x 10-5 M SUT in water, when subjected to 
ambient polychromatic irradiation and ambient room temperature. (Annex A6.10 for DBZ) 
 
The data for all three drugs were shown to obey AB(1Φ) or AB(2Φ)  Φ-order kinetics (Fig. 
6.15). This result has a dual importance. Firstly, it confirms that the DBZ’s data could be 
modelled on a AB(1Φ) unimolecular reaction and AXI and SUT by an AB(2Φ) photoreversible 
reaction. Secondly, it represents the first example of modelling data obtained with 
polychromatic light. This also indicates that the kinetic data relative to the degradation of 
drugs using polychromatic irradiation is most likely to obey Φ-order kinetics. This may in fact 
help investigations of drugs’ photodegradation as an alternative to first-order kinetic usually 














Wavelength  / nm 
Axitinib 
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Fig 6.15: Kinetic traces obtained for (top left) DBZ in water, (right) 3.76 x 10-5 M SUT in water, 
when subjected to ambient polychromatic irradiation. Open shapes are experimental data 
and solid lines are fittings. 
 
6.10. CONCLUSION 
To the best of our knowledge, this study is the first to demonstrate the potential application of 
a new method to drug photokinetic data. It helped elucidate complex drug mechanisms 
(number of species and occurrence of thermal and photochemical steps). It enabled the 
determination of the quantum yields and absorption coefficients, not only of the mother 
compound but of all photoactive degradation products, in addition to showing the evolution of 
the species respective concentrations during reaction time - all with a better performance than 
separation techniques commonly employed. 
The degradation of DBZ was found to involve at least four products – thermally stable: A1, D1 
and E1; and photochemically active: A1, B1 and C1. In the literature, only the first step of DBZ’s 
degradation was reported to be photochemically induced. Thus, the present study has proven 
for the first time that two of the products are both photochemically and thermally active. 
For the first time, AXI and SUT have been shown to be thermally and photochemically active in 
aqueous solution. Both involving reversible reactions. While SUT’s mechanism was determined 



























































kABA = 0.00106 s-
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Analysis of AXI’s photoreaction revealed that the thermal reaction has a greater role in AXI’s 
degradation in aqueous solution. Although for SUT, the quantum yield of B3 was found to be 
two times higher than A3, its thermal reaction in aqueous solution may be problematic. 
The relatively high quantum yield values of SUT and DBZ in the UVA-Visible region was shown 
to be problematic by their high sensitivity to ambient (natural and fluorescent) light. This 
presents a big problem in hospital applications. 
For the first time, a method which enables complex drug photokinetic data to be resolved, 
based on photokinetic equations (not thermal), has been shown successfully. Not only will this 
allow the quantum yields of other photolabile pharmaceutics to be determined, but for them 
to be determined in a more reliable manner. 
The Φ-order kinetics model applied here showed great potential as a new simple approach to 
developing actinometers with complex mechanisms. It was also shown to be applicable to data 
obtained by polychromatic irradiation. Further suggesting that that photodegradation of drugs 
are better described by Φ-order than the classic thermal reaction orders. 
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7.1. INTRODUCTION 
Due to their unique property to form water-soluble inclusion complexes with a variety of 
molecules [1], the use of cyclodextrins (CDs) as pharmaceutical excipients has grown rapidly 
over the last two decades and has been the subject in a number of stability studies [2].  
Recent advances in nanotechnology have increased attention paid to cyclodextrin polymers 
(CDP, chains of more than one α-, β- or γ-CD monomers) for applications in the field of 
nanomedicines. Nanosponges (3D cross-linked CDPs) have been successfully used to improve 
the water solubility of hydrophobic drugs. Compared to the monomers, nanosponges have the 
advantage of being much more soluble in water.  
Besides increasing aqueous solubility of poorly water-soluble drugs, these systems are used for 
sustaining delivery of drugs and modifying pharmacokinetics, biodistribution and cellular 
trafficking of the active substances included within the nanostructure [3]. 
When preparing inclusion complexes, it is not enough to control these effects, it is important 
to know exactly what complex has been formed, by evaluating its stoichiometry, stability 
constant and unravel its structure. Knowledge of the complexation efficiency is useful in drug 
development. 
The identification of the stoichiometry of the complex formed between on one hand a water 
soluble nanosponge, bearing “p” cyclodextrin units (CDp), and on the other hand, “n” 
individual drug molecules (Gn), has represented a tedious task. The literature is well 
documented for monomer stiochiometry and methods to define it, but lacks any 
comprehensive reports in relation to polymer cyclodextrins. Spectroscopic characterisations 
and phase solubility studies employed thus far [4-8], provide good evidence for the 
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nanosponge:drug complexation but generally fall short in giving details on the stoichiometry of 
the complex.  
 
As far as we are aware, the model equation of the isotherm for the general case, Gn:(CDp)m 
has not been yet proposed in the literature. 
Despite fluorimetry being one of the methods of choice for the characterization of drugs 
involved in cyclodextrin monomer complexes, it is not much employed for cyclodextrin 
polymers.  Therefore, in this paper the fluoimetric monitoring of the nonosponge:drug 
interaction is quantified and analysed with the purpose to determining the stoichiometry of 
the complex. This will be achieved by proposing mathematical expressions linking the variable 
fluorescence intensity of the medium to the concentration of the nanosponge and presented 
using two fluorescent molecules, Axitinib (AXI) and 8-Anilino-1-naphthalenesulfonic acid 
ammonium salt (ANS), as models. Each of these molecules was been studied in the presence of 
either a β-cyclodextrin monomer (hydroxypropyl-β-cyclodextrin, HP-β-CD) or nanosponge (β-

















Scheme 7.1: Chemical structures of ANS and AXI. 
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7.2. MATHEMATICAL MODEL FOR A Gn:(CDp)m COMPLEX   
The association of “n” (one or more) guest species with a polymer “m” (one or more) 
cyclodextrin chain-molecules that may encompass each up to “p” cyclodextrin monomer–
units, form a type of complex that will be labelled here as 𝐺𝐺𝑛𝑛: �𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚 (Scheme 7.1). Hence, 
for monomer cyclodextrins, p = 1. Such a complex is supposed to instantaneously occur in the 
solution medium with a unique stoichiometry for the guest/nanosponge complex (irrespective 
of the specific type of binding that may include an inclusion, non-inclusion, clustering or 
aggregation).  
The overall association reaction is given by 
 
n G  + m CDp   ⇌ Gn:(CDp)m 
Scheme 7.2: Association reaction of n guest molecules with m 
cyclodextrin nanosponge units (CDp). 
 
A general equation for the variation of the medium total fluorescence intensity (𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 ) with 
nanosponge “j” concentration (�𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑖𝑖,𝑗𝑗) for a  𝐺𝐺𝑛𝑛: �𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚 complex can be describe by Eq. 1 



















𝑚𝑚                        Eq. 1 
 
Where 𝐹𝐹𝐹𝐹0,(𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚)
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜  is the fluorescence intensity of the medium when every guest molecule 
is complexed,  𝐹𝐹𝐹𝐹0,𝐺𝐺,𝑖𝑖
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜  is the native fluorescence of the guest at “i” concentration ([𝐺𝐺]0,𝑖𝑖𝑛𝑛−1) and 
𝐾𝐾𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
 the association constant of the complex. 
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Transformation of Eq. 1 into a linear relationship (Eq. 2) allows the true stoichiometry of the 



















× [𝐺𝐺]0,𝑖𝑖� + 𝐿𝐿𝐶𝐶 �𝐶𝐶 ×
𝐾𝐾𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
× �𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑖𝑖,𝑗𝑗
𝑚𝑚 �                 Eq. 2 
 
where the gradient of this linear relationship, Eq. 2, is the parameter n. The latter parameter 
can readily be determined from Eq. 2 if the total fluorescence intensity of the medium 
�𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 �, is measured for each of the individual “i” experiments at a unique CD concentration 
��𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑥𝑥� value. Practically, this can amount to drawing a vertical line on the isotherms and 
reading the fluorescence intensity values corresponding to the point of intersection of the 
vertical line with each isotherm. It is worth noting that because of such a particular �𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑥𝑥 
value, the term representing the intercept �𝐿𝐿𝐶𝐶 �𝐶𝐶 × 𝐾𝐾𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
× �𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑥𝑥
𝑚𝑚 �� in Eq. 2, is a 
constant (only involving constant quantities).  
Once the parameter n is known, the treatment of the data corresponding to one of the “i” 
isotherms (i.e. where [𝐺𝐺]0,𝑖𝑖 is constant and �𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑖𝑖,𝑗𝑗  is variable), by the following equation 
that has been derived from Eq. 1,  
 















𝑛𝑛−1 �          Eq. 3 
 
will allow, in a second step, the determination of parameter m (from the gradient of Eq. 3). 
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Having determined the parameters n and m, the third and final step of the present method 
focuses on the determination of the association constant value from the intercept formula and 









𝑛𝑛−1                          Eq. 4 
 
If the relative molar mass of the CD polymer (𝑅𝑅𝑀𝑀𝑀𝑀(𝐶𝐶𝐶𝐶𝑝𝑝)) is not known with accuracy (which 
is indeed the case for a majority of nanosponges), then it is possible to employ a g/L unit for 
concentrations (instead of the molarity unit). An alternative “pseudo–association” constant, 
𝐾𝐾𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
ʹ  (Eq. 5), which will be expressed in (g/L)1-m-n or equivalent.  
 
𝐾𝐾𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
′ =  𝐾𝐾𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
× [𝑅𝑅𝑀𝑀𝑀𝑀(𝐺𝐺)]0,𝑖𝑖1−𝑛𝑛 × �𝑅𝑅𝑀𝑀𝑀𝑀�𝐶𝐶𝐶𝐶𝑝𝑝��0,𝑖𝑖
−𝑚𝑚                 Eq. 5 
 
According to a great number of simulations performed on Eq. 1, the isotherms can have one of 
two general shapes. Either they are exponential-like (as for the usual isotherms observed for 
1:1 complexes) when m = 1 and any n values, or S-shaped curves if m > 1 for any n (even for a 
1:2 complex). Therefore, the shape of the isotherm can inform on whether m is equal to unity.       
It is worth noting that the method presented here considers the treatment of the data 
collected for a series of isotherms corresponding to selected “i” concentrations of the guest 
molecule in the presence of increasing host concentrations “j” to overcome the 
distinguishability problems associated with a single isotherm involving a constant host 
concentration while that of the guest gradually increases. In this sense our approach is 
somewhat similar to Job’s method of continuous variation as the data corresponding to the 
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variation of CD are also taken into account in the fluorescence intensity recorded at the 
plateau region [9].  
Contrary to our approach, Job’s method requires the total concentration of [CD] and [G] to be 
constant and the molar fraction of [G] to vary within the range 0-1 [9]. However, it has been 
found that while Job’s method works well for NMR data, it is not practical for fluorescence 
data, due to the low guest concertation that must be used [10]. In addition, at high 
concentrations, analysis by fluorescence becomes difficult due to self-quenching.   
This also means that Job’s method is dependent on precise knowledge of the species’ relative 
molar masses. This is problematic, if the RMM of one or both of the species is not available - as 
with a majority of nanosponges. Thus, our approach has the advantage of allowing the 
stoichiometry of the complex to be determined using g/L units for concentrations instead of 
molarity units.   
Another advantage of our approach over Job’s method is that it offers a reliable determination 
of the true stoichiometry without imposing preselected n:m complex stoichiometries (1:1, 1:2, 
1:3, etc) on isotherm data treatment. Job’s method makes assumptions on the composition 
and the number of complexes formed. But even so, higher-order stoichiometries (e.g. 2:1) are 
not considered [11]. Thus, if a sigmoidal curve is obtained, the higher-order stoichiometry 
must be determined by alternative approach [12]. 
Finally, our approach provides information on both stoichiometry and association constant of 
the complex – while Job’s method does not provide any information on the binding constant. 
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7.3. FLUORESCENCE PROPERTIES OF THE SPECIES IN DIFFERENT MEDIA 
Fluorescence excitation and emission spectra of ANS and AXI have been recorded in water and 
water/ethanol (v/v, 98/2) (respectively) in the presence and absence of HP-β-CD or β-CDP (Fig. 
7.1).   
Fig 7.1: Excitation and Emission spectra of (left) 3.36 x 10-5 M ANS in water (plain lines), 5.41 
x 10-6 M in 0.015 g/mL HP-β-CD (dashed lines), and 3.61 x 10-6 M in 0.002 mg/mL β-CDP 
(dotted lines) (Right) 1.53 x 10-5 M AXI in water/ethanol (v/v, 98/2) (plain lines), 1.02 x 10-5 M 
in 0.1 mg/mL HP-β-CD (dashed lines), and 9.6 x 10-7 M in 5 x 10-3 mg/mL β-CDP (dotted lines), 
at room temperature. 
 
A red-shift (~10 nm) can be observed for the excitation spectra of ANS and AXI in the presence 
of cyclodextrin monomer and polymer compared to their homologues obtained in their 
absences. Whereas, the emission spectra undergo significant blue-shifts (30 nm for AXI and 50 
nm for ANS) in the presence of the cyclodextrin molecules (Fig. 7.1 and Table 7.1).  
As a consequence, the Stokes’ shift considerably reduces from 86 nm to 52 nm for AXI and 
from 142 nm to 89 nm for ANS, in the absence and the presence of nanosponge, respectively.  
A significant increase of the fluorescence intensity is also recorded, reaching over 90- and 670-
folds (AXI and ANS, respectively) in the presence of the nanosponge compared to that 
measured in its absence (Fig. 7.2). 
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An increase in fluorescence intensity of polarity-sensitive molecules in the presence of CD 
monomers is well-documented [6,10]. Such an enhancement might be due to either lesser 
specific interactions of the polarity-sensitive guest with water or a reduction of fluorescence 
quenching by oxygen molecules when the guest species is shielded by the cyclodextrin from 
the bulk of the solution. Also, the sterical restriction of the guest intramolecular rotational 
freedom within the cavity might contribute to the observed increase of fluorescence quantum 
yield [6,10]. 
 
Table 7.1: Fluorescence features of AXI and ANS in the presence and absence of HP-β-CD and 



















418 86 1 





393 57 2.51 




393 52 93.1 




510 142 1 





468 97 2.14 




463 89 671 
a the spectral highest maximum is underlined and the shoulders are presented in brackets 
b the stocks’ shift was calculated as the difference between the emission maximum and the lowest 
energy excitation peak 
c the fluorescence intensity in the numerator corresponds to that of the nanosponge/guest complex, 
whereas the denominator represents the fluorescence intensity in one of the media used (𝐹𝐹𝐹𝐹𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 is 
equal to either 𝐹𝐹𝐹𝐹0,𝐺𝐺,𝑖𝑖
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜, 𝐹𝐹𝐹𝐹0,(𝐺𝐺1:𝐶𝐶𝐶𝐶1)
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜  or 𝐹𝐹𝐹𝐹0,(𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚)
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 ).  
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The reduced polarity of the cyclodextrin interior has another effect relating to the shift of the 
emission maximum to shorter wavelengths, and as a result to a smaller Stokes’ shifts, shown 
by guest molecules within cyclodextrin monomers compared to the free molecules. These 
effects can be attributed to a greater destabilization of the excited singlet–state (S1) of the 
guest by the non-polar micro-environment offered by the cyclodextrin cavity, as in general, S1 
is more polar than the ground singlet-state (S0) for many organic drug molecules [10, 13-15]. 
The above effects proven to take place for cyclodextrin monomer/guest complexes, would also 
be attributable to similar spectral changes caused by nanosponges. Accordingly, the data 
recorded for AXI and ANS (Table 7.1, Figs. 7.1 and 7.2) clearly indicate that both molecules 
form complexes with the nanosponge. 
 
 
Fig 7.2: Comparative fluorescence emission spectra of (Left) 1.1 x 10-5 M ANS in water and 
(right) 1.02 x 10-5 M AXI in water/ethanol (v/v, 98/2) (plain line) in the presence of 0.02 g/mL 
of either HP-β-CD (dashed line) or β-CDP (dotted line) 
 
When both AXI and ANS were in the presence of β-CDP, a greater fluorescence emission 
intensity enhancement was exhibited (313- and 37-fold, respectively), compared to their 
fluorescence intensities in the presence of HP-β-CD. Our findings for ANS agree with reported 
data which attributed an equatorial inclusion of the naphthalene moiety for the complex 
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AXI. The difference in the induced fluorescence enhancement may indicate that there is a 
considerable sensitivity to polarity difference in the medium between the two molecules. This 
correlates with the fact that ANS is one of the most widely employed polarity-sensitive 
fluorescent probes [17-19]. 
When similar amounts of nanosponge (as HP-β-CD) are used, this enhancement in 
fluorescence intensity is further emphasized. A more significant increase of the fluorescence 
intensity were found for the complexes formed with both AXI and ANS molecules with 
nanosponges compared to the effects recorded when cyclodextrin monomers were used (Fig. 
7.2). Such an increase further supports the hypothesis of a major role played by the sensitivity 
of the species to the medium polarity, which is probably more extended within the 
nanosponge structure [10].  
 
7.4. EFFECT OF GUEST CONCENTRATION 
A smooth increase of fluorescence intensity of the medium was observed with increasing 
concentration of both HP-β-CD monomer and β-CDP nanosponge. No other spectral features 
were observed on the spectra (Fig. 7.3).   
 
Fig 7.3: Evolution of the fluorescence emission spectrum of (left) 1.07 x 10-5 M ANS in water 
with increasing concentrations of HP-β-CD monomer at room temperature; (right) 5.15 x 10-6 
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The isotherms recorded, at the maximum fluorescence emission maxima, for both molecules 
with either HP-β-CD or β-CDP showed a steep increase in fluorescence intensity followed by a 
plateau (Fig. 7.4). However, the overall shape of the isotherms is found to be insensitive to the 
concentration of the guest. The latter observation together with the occurrence of a recurrent 
plateau region might suggest that the stoichiometry of the complexes is not concentration-
dependent.  
Also, the absence of S-shaped isotherms may qualitatively indicate that a single (monomer or 
polymer) cyclodextrin unit is involved in the complexation process, as has been discussed for 
the possible outcomes of Eq. 1 (Section 7.2). Therefore, the value of parameter “m” is 
expected to be close to unity for both complexes formed by ANS and AXI with either HP-β-CD 
monomer or β-CDP nanosponge. 
 
Fig 7.4: Isotherms of varying ANS and AXI concentrations (1.07 – 7.2 x 10-6 M and 5.15 x 10-6 – 
2.03 x 10-5 M, respectively) in water or water/ethanol (v/v/, 98/2) with increasing 
concentrations of β-CDP or HP-β-CD at room temperature. 
 
7.5. DETERMINATION OF THE STOICHIOMETRIES OF THE COMPLEXES 
A set of isotherms corresponding to selected “i” concentrations of ANS and AXI in the presence 
of varying “j” concentrations of either HP-β-CD or β-CDP were treated using Eq.2. For each 
isotherm, the fluorescence data were collected in the absence of the host (𝐹𝐹𝐹𝐹0,𝐺𝐺,𝑖𝑖
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given concentration of either (monomer or polymer) host, 𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜  (e.g. at [HP-β-CD] = 20 
mg/mL for AXI and [β-CDP] = 20 mg/mL for ANS) and at the plateau region, 𝐹𝐹𝐹𝐹0,(𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚)
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 . The 
plots corresponding to 𝑌𝑌𝑛𝑛 against 𝑋𝑋𝑛𝑛 (Eqs. 6), should yield straight lines. 
 
𝑌𝑌𝑛𝑛 = 𝐿𝐿𝐶𝐶 ��𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 − 𝐹𝐹𝐹𝐹0,𝐺𝐺,𝑖𝑖
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜� × [𝐺𝐺]0,𝑖𝑖 �𝐹𝐹𝐹𝐹0,�𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚�
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 − 𝐹𝐹𝐹𝐹0,𝐺𝐺,𝑖𝑖
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜�� �     Eq. 6a 
 
𝑋𝑋𝑛𝑛 = 𝐿𝐿𝐶𝐶 ��𝐹𝐹𝐹𝐹0,�𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚�
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 − 𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 � × [𝐺𝐺]0,𝑖𝑖 �𝐹𝐹𝐹𝐹0,�𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚�
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 − 𝐹𝐹𝐹𝐹0,𝐺𝐺,𝑖𝑖
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜�� �    Eq. 6b 
 
The gradient of the linear relationship (𝑌𝑌𝑛𝑛 = 𝑓𝑓(𝑋𝑋𝑛𝑛)) corresponds to the number of guest 
molecules involved in the complex “n” (Eq. 2). Whereas, the number of the host molecules “m” 
can be worked out from the intercept of the line plotted as 𝑌𝑌𝑚𝑚 against 𝑋𝑋𝑚𝑚 (Eqs. 7) as given in 
Eq. 3, using the data corresponding to any of the isotherm series.   
 






𝜆𝜆𝐶𝐶𝑜𝑜𝑝𝑝 �� �      Eq. 7a 
 
𝑋𝑋𝑚𝑚 = 𝐿𝐿𝐶𝐶�𝐶𝐶𝐶𝐶𝑝𝑝�0,𝐶𝐶,𝑗𝑗           Eq. 7b 
 
The association constant can then be determined, for each guest molecule, from the value and 
the formula of the intercept as given by Eq. 4.  
For ANS, 1.06:1 stoichiometry was found when in the presence of HP-β-CD (Fig 7.5 and Table 
7.2). This agrees well with the generally proposed 1:1 complexes for the widely studied ANS 
dyes [10,20]. The association constant (𝐾𝐾𝐺𝐺1:𝐶𝐶𝐶𝐶1
𝐴𝐴𝐴𝐴𝑆𝑆 = 456 M-1) determined here for ANS is also 
very close to those obtained through fluorimetric determination by other authors (c.a. 480 M-
1, [10]); However, it has been reported in the literature that the values of an association 
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constant for a given species and monomer cyclodextrin varied considerably with the analytical 
method used [21].  
 
 
Fig 7.5: Determination of coefficients n and m for ANS/HP-β-CD (left) and AXI/β-CDP (right) 
complexes 
 
Table 7.2: Correlation coefficients, stoichiometries and association constants determined 
obtained for AXI and ANS complexes with HP-β-CD and β-CDP. 
 
n a int b r c m d int r K' e K 
β-CDP 
ANS/β-CDP 1.32 3.22 0.96 1.09 1.75 0.98 6.44 -f 
AXI/β-CDP 0.98 0.86 0.98 0.79 -1.54 0.97 3.33 - 
HP-β-CD 
ANS/HP-β-CD 1.06 1.16 0.98 1.00 1.86 0.99 0.31 456 
AXI/HP-β-CD 1.09 2.42 0.95 0.82 -0.89 0.99 6.84 2041 
a n is the number of guest molecules 
b int is the intercept of the linear relationship. 
c r is the correlation coefficient of the linear relationship.  
d m is the  number of cyclodextrin molecules 
e calculated using Eq. 5 for HP-β-CD 
f not applicable 
 
On the other hand, a 1.09:0.82 stoichiometry was found for AXI. Although, the fractional 
number found cannot be attributed with certainty, it might suggest the presence of partial 
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Due to β-CD’s cavity diameter of 0.60 – 0.65 nm [1] and AXI’s size, an inclusion of the benzene 
ring near the sulphur bond or the pyridine ring might be possible (Fig. 7.6 A1 and A2). Its 
association constant (K) is however almost 6-fold higher than that of ANS. The stronger binding 
of AXI to HP-β-CD might be due to the more suitable size of the pyridine ring to fit the 
cyclodextrin cavity compared the loose association of ANS which involves an equatorial 
inclusion (Fig 7.6 A3) of the much bigger naphthalenic structure [10]. The charge on ANS might 
also contribute to decreasing the value of 𝐾𝐾𝐺𝐺1:𝐶𝐶𝐶𝐶1
𝐴𝐴𝐴𝐴𝑆𝑆 , i.e. disfavouring ANS:HP-β-CD association, 
due to partition of the solute between hydrophobic inclusion in HP-β-CD and hydrophobic 
dissolution in the bulk aqueous solution.     
 
 
Fig 7.6: Possible complex formations between β-cyclodextrin unit and AXI (A1, A2) or ANS 
(A3). 
 
A similar result to ours has been reported for complex formed between pentamidine 
isethionate and β-CD, where a stoichiometry ratio of 0.84 was found from a curve fitting using 
the non-linear adjustment based on Wiseman isotherm [22]. The latter value was attributed to 
the possible occurrence of different equilibria of the supramolecular system in solution, in 
agreement with other results previously reported in the literature [23,24]. 
The same set of equations employed for the monomers were applied to isotherms obtained 
with nanosponge, except Eq. 4 which is only applicable to monomers and polymers with 
known RMM. For the polymers whose RMM is not known with accuracy (as it is the case for 
the nanosponge used in this study), only the pseudo-association constant can be derived:      












 expressed in mg/ml. 
The results for the nanosponges indicate that AXI and ANS form a 0.98:0.79 and 1.32:1.09 
complexes (respectively, Fig 7.5 and Table 7.2).  These values further points to the possibility of 
multiple association sites and/or different types of binding offered by the nanosponges.  
The K’ determined for ANS in the presence of nanosponges is twice that of AXI. This might 
suggest a steric hindrance in the polymer, which led to the less efficient complexation in the 
nanosponge. 
Nonetheless, the stoichiometries found for AXI and ANS strongly suggest simple associations 
between only very few guest molecules and the three-dimensional structure of the 
nanosponge. Overall, this finding is consistent with the considerable differences of 
concentrations between host and guest in solutions (i.e. w/w ratios of over 2000 at the plateau 
regions).  
The hint of more than one complex structures in solution provided by our method is an 
advantage over Job’s method, whereby further analysis by other techniques (such as 
isothermal calorimetric titration or electrospray mass spectrometry) is required [23]. In this 
respect, the stoichiometry obtained by Job’s method can be viewed as an average rather than 
an absolute value in the case of cyclodextrin complexes.          
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7.6. CONCLUSION 
In drug development, knowledge of the complexation efficiency is useful. However, even with 
increased interest in CDP due to advances in nanotechnology, only few studies have reported 
on the fluorimeteric characterisation of nanosponge-drug complexes. 
The new mathematical framework proposed in this study for characterisation of such systems 
enabled a reliable determination of the true complex stoichiometry without imposing any 
preconception on the stoichiometry, as current methods do.  
This flexibility in the system allows the method presented here to provide hints on the possible 
existence of multi-equilibria in solution.  
In addition to not requiring the precise knowledge of the relative molar mass, the method 
gives information on both stoichiometry and association constant of the complex – while Job’s 
method does not provide any information on the association constant.  
Equations and method developed here for the purpose of fluorimetry can easily be adapted to 
other spectroscopic methods for the characterisation of other systems, not just cyclodextrin 
and nanosponge.  
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STABILITY OF THE DRUGS IN 
CYCLODEXTRINS  
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8.1. INTRODUCTION 
As evident from this study, these drugs (DBZ, AXI and SUT) are very photochemically and 
thermally unstable in solution and require photoprotection.  
Cyclodextrins (CDs) are cyclic oligomers of glucose known to form water-soluble inclusion 
complexes with a variety of molecules [1]. Due to their unique property, the use of 
cyclodextrins as pharmaceutical excipients has grown rapidly over the last two decades and 
has been the subject in a number of stability studies [2]. 
In the pharmaceutical industry, cyclodextrins are mainly used to aid the dissolution of poorly 
soluble drugs [3-9].  However, they have also been used to improve stability of drugs. When 
unstable molecules are entrapped within the cavity of cyclodextrins monomers, their thermal- 
and photostability could be enhanced [10-14], but no reports have ever been published on the 
effect of cyclodextrins on DBZ, AXI or SUT’s stability or on CDP in general, in this respect. Here, 
a comprehensive study of the effect of both cyclodextrin monomers and polymers on these 
three drug samples when degraded thermally and photochemically is presented. 
 
8.2. EFFECT OF CYCLODEXTRIN ON THE THERMALSTABILITY OF THE DRUGS 
8.2.1 Absorption Spectrum Features of AXI and SUT with Cyclodextrins 
AXI and SUT were shown to be thermally degradable in aqueous solution and DBZ was not 
(Chapter 6). Thus, solutions containing 2 mL of water or cyclodextrins were spiked with AXI or 
SUT. The effects of the addition of CD on the electromagnetic spectrum are shown in Fig 8.1. 




Fig 8.1: Electronic absorption spectra of SUT (0.020 mg/mL) and AXI (0.0095 mg/mL) in the 
presence and absence of α-, β- and γ-cyclodextrin monomers (24.94 mg/mL, 149.88 mg/mL 
and 0.23 mg/mL, respectively) and polymers (11.95 mg/mL, 20.55 mg/mL and 8 mg/mL, 
respectively). Bathochromic shift indicated by vertical lines.  
 
The bathochromic shift of the maxima and change in absorbance values observed in all 
solutions containing cyclodextrins are good indicators of the inclusion within the cyclodextrins 
[15].  In α-CDP and β-CDP solutions, the change in absorbance of both drugs is greater than 
that seen for γ-CDP. This may be due better inclusion of the drug molecule within α-CDP and β-
CDP.  
While it is usual that changes in absorbance observed for free drugs and complexes are small 
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The more significant bathochromic and hyperchromic shift in SUT’s spectrum in all CDs may 
reflect a greater interaction or effect of CD inclusion on SUT’s polarity [15]. 
 
8.3. THERMALSTABILITY OF AXI AND SUT WITH CYCLODEXTRINS 
Solutions of the two drugs in the presence and absence of α-, β- and γ-cyclodextrin monomers 
and polymers were thermally degraded at 22°C.   
 
 
Fig 8.2: Effect of α- , β- and γ-cyclodextrin monomers and polymers on the thermal 
degradation of AXI observed at 332 nm, stirred and thermalstatically maintained at 22°C for 
an hour. 
 
Addition of Cyclodextrin monomers and polymers were shown to reduce AXI’s rate of 
degradation. In the absence of any cyclodextrins AXI degrades rapidly (Fig. 8.2, Table 8.1), 
completing its reaction within an hour. When cyclodextrins were added, AXI’s stability was 
found to be enhanced greatly, if not completely, under the same conditions.  
Of the CD monomers studied, 20 mg/mL β-CD provided more stability than 25 mg/mL α-CD 
(2.76 % and 27.04 % degradation, respectively). However, in their polymeric forms (where 
solubility is not an issue), 48.82 mg/mL α-CDP offered much better stability (2.03 % 
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This may be due to the smaller cavity size of α-CDs, offering a better encapsulation than the 
two larger ones. 
In the literature, CDPs have been reported to afford drugs better stabilizing effect than 
monomers, due to improved encapsulation [16-19].  
 
Fig 8.3: Effect of α- , β- and γ-cyclodextrin monomers and polymers on the thermal 
degradation of SUT observed at 430 nm, stirred and thermalstatically maintained at 22°C for 
an hour. 
 
Table 8.1: Percentage of degradation recorded for AXI and SUT in the presence and absence 
of cyclodextrin monomer and polymers and their effects on the initial velocity of the thermal 
reaction. 
 
Water α-CD HP-β-CD α-CDP β-CDP γ-CDP 
AXI 
Concentration (mg/mL) 0.008 25 19 48.82 20.49 8.00 
Initial Velocity (s-1, x 10-4) 1.76 2.62 0.82 0.04 0.63 0.21 
Percentage of Degradation (%) 88.95 27.04 2.76 2.03 2.63 7.72 
SUT 
Concentration (mg/mL) 0.006 25 19 12 20 -a 
Initial Velocity (s-1, x 10-5) 6.01 7.17 6.44 7.80 6.45 - 
Percentage of Degradation (%) 4.21 3.72 5.52 8.78 13.90 - 
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On the other hand, presence of α-CDP and β-CDP were found to slightly increase the thermal 
degradation of SUT (Table 8.1, Fig. 8.3). As a result, it could be concluded that the addition of 
cyclodextrins (monomers or polymers) has no effect on SUT’s stability – this is not an unknown 
phenomena [20]. As SUT has a number of potential inclusion sites, the drug might be included 
but the complex has no effect on its thermal reactions.  If the E/Z reaction is accepted as 
postulated in Chapter 6 (scheme 6.2), then the inclusion does not involve the double bond. 
This might be explained by the large size of SUT. 
 
8.4. EFFECT OF CYCLODEXTRIN ON THE PHOTOSTABILITY OF THE DRUGS 
8.4.1. Photostability of AXI with Cyclodextrins 
Samples of AXI in the presence and absence of α-, HPβ- and γ-cyclodextrin were exposed to 
ambient polychromatic light (laboratory light, Fig 8.4) and monochromatic irradiation (Fig 8.5).  
 
Fig. 8.4: Effect of cyclodextrin monomers (Left) and polymers (right) on 0.0095 mg/mL AXI’s 
degradation under ambient room lighting and temperature conditions. 
 
Under ambient lighting, both γ-CD and α-CD were found to reduce AXI’s rate of degradation. 
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significantly extended to 7 and 30 minutes when γ-CD and α-CD were added, respectively 
(Table 8.2). 
However, when HP-β-CD was added, a rapid increase in absorbance was seen within the first 
10 minutes, suggesting a different reaction is taking place or the product is included with a 
higher ε than that of AXI. 
 
Table 8.2: Axitinib’s half-life times in the presence and absence of cyclodextrins monomers 
Sample Half-Life Time (t1/2, min) 
AXI Alone 1.5 
AXI with α-CD 30 
AXI with HP-β-CD N/A 
AXI with γ-CD 7 
 
Although an improved rate of degradation was achieved, the stabilizing effects of these 
cyclodextrins are limited by their solubility. 
α- and γ-CDP were found to completely stabilise AXI under the given conditions (Fig. 8.4). 
 
 
Fig. 8.5: Effect of α- , β- and γ-cyclodextrin monomers (Left) and polymers (Right) on the 
degradation of AXI (0.0095 mg/mL) observed at 332 nm, when monochromatically irradiated 
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The presence of β-CDP appears to bring about the same reaction as that observed for HP-β-CD. 
However, in this case, the reaction is more defined and slower than that observed earlier - 
reaching maximum absorbance around 20 minutes rather than 10 minutes. 
Contrary to the results observed under ambient conditions, monochromatic irradiation of γ-
CD, γ-CDP and α-CDP was found to accelerate the photodegradation of AXI in aqueous media 
(Fig. 8.5). The fact that the concentrations in samples used were not significantly different, it 
suggests that under ambient conditions AXI mainly undergoes thermal degradation. So, the 
presence of α-CDP, γ-CD and γ-CDP appears to only thermally protect AXI under ambient 
conditions. 
This idea seems evident in the trace obtained here for α-CD, where the photodegradation 
reaction of AXI ends with a plateau – as observed in organic media where no thermal reaction 
takes place; further confirming that α-CD, α-CDP, γ-CD and γ-CDP thermally protects AXI. 
α-CD has a cavity diameter of just 0.47 – 0.53 nm [21], whereas the diameter of a benzene ring 
is ca. 0.6 nm [22] and so the inclusion of AXI is most likely to form around the amide group (Fig. 
8.6 A1). In this formation, reaction of the amide group is hinder by the presence of α-CD and 
so preventing thermal degradation of AXI in aqueous media. 
This corroborates our hypothesis postulated earlier for AXI’s mechanism (Chapter 6, scheme 
6.8). 
γ-CD, on the hand, has a much larger cavity size of 0.75-0.83 nm [21], enabling much more of 
AXI to be included. Due to this and that γ-CD only thermally protect AXI, it can be supposed 
that it is most likely to be the amide end of AXI that is included within γ-CD (Fig. 8.6 A2) rather 
than the pyridine ring - which is of a similar size to benzenes [23] (Fig. 8.6 A3). 
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For both α-CD and γ-CD, the unlikely inclusion of the pyridine ring and double bond (Fig. 8.6 
A3), agrees well with the lack of photoprotection provided – as isomerisation of the double 
bond occurs when AXI is irradiated. These findings suggest that the stability studies in the 
presence of various CDs gives valuable information on the structure of the complex. 
 
Fig 8.6: Possible complex formations between AXI and α-CD (A1), γ-CD (A2) and β-CD (A3 and 
A4). 
 
Under monochromatic conditions, HP-β-CD and β-CDP was found to induce the same reaction 
observed under ambient conditions. It appears that neither thermal- nor photo-protection is 
provided. However, it is clear that there is some kind of interaction between AXI and the CD 
due to the presence of a different reaction. 
β-CD has a cavity diameter of 0.60 – 0.65 nm [21], bigger than α-CD but smaller than γ-CD. 
Thus, it is possible for the amide group to be included like with α-CD. However, due to its 
slightly larger cavity, the fit is looser and so the inclusion of benzene or pyridine ring is much 
preferred (Fig. 8.6 A4 or A3). The fact that AXI’s reaction in the presence of β-CD does not 
appear to be the E-Z isomerisation observed in the free AXI, it is plausible to propose that the 
complex involves the inclusion of the pyridine and double bond (Fig. 8.6 A3). 
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However, it could also be possible that benzene ring near the sulphur bond is included (Fig. 8.6 
A4). Inclusion here, might hinder the reaction of amide group and so preventing the thermal 
degradation seen for free AXI in aqueous solution. 
 
8.4.2. Photostability of DBZ and SUT with Cyclodextrin 
The presence of cyclodextrins (HP-α-CD, α-CDP, HP-β-CD, β-CD Polymer, γ-CD and γ-CD 
polymer) were found to have little effect on the photodegradation of DBZ and SUT when 
monochromatically irradiated (Fig 8.7). 
 
 
Fig 8.7: Effect of α- , β- and γ-cyclodextrin monomers and polymers on the degradation of 
0.02 mg/mL SUT observed at 430 nm, when monochromatically irradiated at 430 nm (5.50 x 
10-6 einstein s-1 dm-3, 22°C, stirred) and 0.001 mg/mL DBZ observed at 330 nm, when 
irradiated monochromatically at 330nm (1.06 x 10-6 einstien-1 s-1 dm-3, 22°C) (Bottom Left) 
Electronic absorption spectra of DBZ (0.001 mg/mL) in the presence and absence of α-, β- 
and γ-cyclodextrin monomers (12.5 mg/mL, 145 mg/mL and 121 mg/mL, respectively) and α-
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The lack of improvement in photostability of DBZ may be due to the fact that the primary 
photochemical step in its photodegradation involves a scission of the N – N bond, which does 
not seem to be hindered by the cyclodextrin if we assume a total inclusion. Otherwise, these 
results (Fig. 8.7) may indicate that DBZ is only partially included within the cavity. Thus, 
inclusion within cyclodextrin did not provide photoprotection. 
~5% degradation was observed for SUT in aqueous solution and similar percentage of 
degradation were observed when α-CD, HP-β-CD, α-CD-P and β-CD-P were present in solution. 
However, when γ-CD and γ-CDP were used, a greater degree of degradation was observed. 
The initial velocity calculated for the reactions (Table 8.3) showed little/no change in rate, 
under both monochromatic and polychromatic conditions. As a result, it could be concluded 
that the addition of cyclodextrins (monomers or polymers) does not provide SUT with any 
protection from light. 
Although the addition of cyclodextrins did not provide any stabilising effect on DBZ or SUT, this 
study is the first to carry out such investigation on the effect of both cyclodextrin monomers 
and polymers on the thermal- and photodegradation of DBZ and SUT, in both monochromatic 
and polychromatic light conditions. The acceleration of the guest compound’s degradation by 
cyclodextrins seen here is not an unknown phenomenon [24-25].  
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Table 8.3: Percentage of Photodegradation for SUT in the presence and absence of 
cyclodextrins and their effects on the initial velocity of the reaction when exposed to 
monochromatic and polychromatic irradiation. 
 
SUT α-CD HP-β-CD γ-CD α-CDP β-CDP γ-CDP 
Monochromatic irradiation at 430 nma 
Concentration (mg/mL) 0.019 24.94 149.88 0.23 11.95 20.55 8 
Initial Velocity (s-1, x 10-4) 2.29 1.97 3.82 1.33 3.00 2.48 1.20 
Percentage of Degradation (%) 5.54 4.76 7.62 20.75 9.87 8.43 23.53 
Ambient laboratory light and temperature 
Concentration (mg/mL) 0.019 24.9 149.9 -b 11.9 20.5 - 
Initial Velocity (min-1, x 10-3) 2.18 2.75 4.39 - 3.78 2.82 - 
Percentage of Degradation (%) 4.55 6.83 7.19 - 6.00 5.56 - 
a 5.51 x 10-6 einstien-1 s-1 dm-3, 22°C, stirred 




For the first time, a systematic study of the effects of cyclodextrin monomers and polymers on 
Dacarbazine, Axitinib and Sunitinib’s thermal and photoactivities has been conducted in the 
present work.  
Our results have proven that only minor effects on the stability of DBZ and SUT are expected to 
be observed from the involvement of such supramolecular systems. Therefore, DBZ and SUT’s 
stability cannot be improved by this strategy.    
Addition of Cyclodextrin monomers and polymers were shown to reduce AXI’s rate of thermal 
degradation significantly. Of all the CDs, α-CDP offered the best thermal stability improvement.  
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Under monochromatic irradiation, a reduction in AXI’s photosatbility was not seen. However, 
the photokinetic trace for AXI samples in the presence of α-CDP ends with a plateau – as 
observed in organic media where no thermal reaction takes place. Further confirming that 
complexation of AXI with α-CDP can provide thermal stability to the drug.  
This was further proven by the complete stability observed when AXI was exposed to ambient 
light and temperature conditions. Under these conditions little/no photodegradation was 
observed, suggesting that thermal degradation is the main issue under ambient settings. Thus, 
here in this study, it has been shown that a thermally stable AXI could be made through 
inclusion complexation with α-CDP. 
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PHOTOSTABILITY BY SELECTED 
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9.1. INTRODUCTION 
The addition of inactive substances (pharmaceutical excipients) with similar absorption spectra 
to the drug formulation, film coating and capsule shell is a well-established method of 
photoprotection [1-14]. For this the excipient must have an absorption spectrum that overlays 
the absorption spectrum of the drug requiring protection [1-7]. The idea is that the excipient 
will compete with the drug for the energies from the light source and as a result, reducing the 
amount of damage done to the drug by reducing the amount of light absorbed [1-7]. 
Obviously, not only does the excipient requires the appropriate absorption spectrum for 
overlay, but it must also be pharmaceutically inactive, non-toxic and be photostable itself. 
Hence, the potentially useful materials is limited [5]. 
This application was shown very effective when applied to many drugs [6-14]: nifedipine [6,7], 
sorivudine [7], molsidomine [8], Axitinib [9], furosemide [6], daunorubicin [6], nitrofurazone 
[6], dihydroergotamine [6] and haloperidol [6]; and in solution for colchicine [10], tetracycline 
[11], reserpine [12], doxorubicin [13] and dacarbazine [14]. 
Yet, in the literature there is a lack of method to quantify this effect. Most commonly HPLC [6-
9] and spectrophotometers [10-14] are employed for analysis. The percentage of 
decomposition [6-9] or rate-constants are calculated using thermal kinetic plots [10-14] as 
measures of photostabilization.  
Even though the method was found to be effective in photostabilizing DBZ solutions [14] and 
AXI tablets [9], glutathione is not employed in commercial formulations because inhibits DBZ-
induced cell apoptosis [15] and AXI is still only available in solid dosage form. No studies on the 
application of this method have been reported for SUT yet and thus, a suitable 
photoprotective excipient for liquid formulation is still yet to be discovered for these drugs.   
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Excipients selected for this study are four pharmaceutical excipients (Sunset Yellow, Tartrazine, 
Vanillin and β-Carotene) and an anti-emetic drug often co-administered with DBZ 
(Ondansetron) [16]. They are mainly selected based on their absorption spectra, safety for 

























Scheme 9.1: Molecular structures of Dacarbazine (DBZ), Axitinib (E-AXI) and Sunitinb (Z-SUT) 
 
9.2. EFFECT OF AZO DYES: SUNSET YELLOW AND TARTRAZINE 
Sunset Yellow (E110, SSY) and Tartrazine (E102, TRZ) are two of the most widely used artificial 













































Scheme 9.2: Molecular structures of Sunset Yellow and Tartrazine 
 
They can be found in various pharmaceutical products such as Beechams [17], a drug for the 
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antimicrobial drug Metronidazole [20]; the cough syrup, Buttercup [21]; Lemsip’s Cold and Flu 
Relief Capsules [22]; cough medicine, Acetaminophen and Codeine Phosphate Oral Solution 
[23] and the antibiotic drug Oxytetracycline tablets [24].  
SSY and TRZ absorbs within the range 200 nm – 550 nm, which fully cover the absorption 
spectrum of DBZ, AXI and SUT (Fig. 9.1). Thus, absorbing light of the same wavelength and 
could potentially act as competitive light absorbers for all three drugs. 
 
 
Fig 9.1: Absorption spectra of Dacarbazine (DBZ), Axitinib (AXI), Sunitinib (SUT), Sunset 
Yellow (SSY, Left) and Tartrazine (TRZ, Right) in water or 2.5% v/v ethanol/water for AXI. 
 
Irradiation of the drugs in the presence of SSY and TRZ were found to reduce the rate of 
degradation (Fig. 9.1 and 9.2). For DBZ and AXI, SSY appears to be more effective than TRZ due 
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On the other hand, TRZ was shown to almost completely stabilise SUT, while SSY induced a 
reaction which produced orange precipitates to form in solution. This may be an interaction 
between the SSY and fluoro end of SUT, as SSY has been reported to form non-covalent 
aggregates with fluorophenols and form liquid crystals at high concentrations [25]. 
This may present a huge problem for patients on SUT treatment, as mentioned, SSY can be 
found in a large number of confectionery, soft drinks, drugs and cosmetics. 
 
 
Fig 9.2: Effect of tartrazine (TRZ) and sunset yellow (SSY) on the photodegradation of 0.001 
mg/mL DBZ observed at 330 nm, when irradiated monochromatically at 330nm (1.96 x 10-6 
einstien-1 s-1 dm-3, 22°C) and 0.008 mg/mL AXI in 2.5% (v/v) ethanol/water solution observed 
at 430 nm, when monochromatically irradiated at 330 nm (3.05 x 10-6 einstein s-1 dm-3, 22°C, 
stirred) 
 
To quantify the effects, the initial velocity (𝜈𝜈0(𝑚𝑚𝑡𝑡𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜⁄ ) was determined by differential equation 
of the model equation describing Φ-order kinetics at t=0 (eq. 12, Annex A5.3), AB(1Φ) for DBZ 
and AB(2Φ) for AXI and SUT.  
The presence of TRZ, both AXI and SUT showed a significant increase of 10 and 18.1-fold in 
stability in aqueous solution (respectively, Table 9.1). Their 𝜈𝜈0(𝑚𝑚𝑡𝑡𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜⁄  were reduced from 7.23 
x 10-4 s-1 and 2.40 x 10-4 s-1 (AXI and SUT, respectively) to 7.26 x 10-5 s-1 and 1.33 x 10-5 s-1. While 
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Due to SSY’s higher absorption around DBZ and AXI’s peak maxima (320 nm and 330 nm, 
respectively) than TRZ, an even greater increase in stability were observed (4.5 and 13-fold, 
respectively). 
The low photostability effect of SSY and TRZ on DBZ, in comparison to that on AXI and SUT, 
may be due to the dyes low absorptivity at the irradiation wavelength – even at increased 
concentrations. 
 
Table 9.1: Initial velocities of DBZ, AXI and SUT degradation in water, tartrazine (TRZ) and 
sunset yellow (SSY) and the percentage of degradation observed 
Dye Added 
𝑷𝑷𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊 
x 10-6 einstien-1 s-1 dm-3 𝜈𝜈0(𝑚𝑚𝑡𝑡𝑑𝑑.)




1.05 x 10-3 mg/mL Dacarbazine (λ irr = 330 nm) 
None  1.96 6.55 x 10-4 1 100.00 
0.18 mg/mL TRZ 2.03 2.90 x 10-4 2.3 100.00 
0.078 mg/mL SSY 2.03 1.45 x 10-4 4.5 92.88 
0.008 mg/mL Axitinb (λ irr = 360 nm) 
None  3.05 7.23 x 10-4 1 34.18 
0.27 mg/mL TRZ 3.06 7.26 x 10-5 10 27.54 
0.116 mg/mL SSY 3.06 5.55 x 10-5 13 22.50 
0.01 mg/mL Sunitinib (λ irr = 430 nm) 
None 5.67 2.40 x 10-4 1 3.68 
0.02 mg/mL TRZ 5.67 1.33 x 10-5 18.1 0.88 
0.19 mg/mL SSY 5.85 -b - 100.00 
a Ratio = ratios of the initial velocities to that of the drug’s photodegradation in water alone 
b solution precipitated 
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In the literature the percentage degradation is often used as a measure of photostabilization 
[6-9]. However, the percentage of degradation alone is not sufficient enough to express the 
effect of the excipient – as shown here in the case of DBZ with SSY and TRZ (Table 9.1). While 
the percentage of degradation indicates little difference between the effect of SSY and TRZ to 
DBZ’s photodegradation, calculation of 𝜈𝜈0(𝑚𝑚𝑡𝑡𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜⁄  demonstrates that SSY is in fact almost two 
times more effective at half the concentration. 
Increasing concentrations of SSY (0 mg/mL to 0.025 mg/mL) in DBZ solution were investigated 
to see if increasing SSY concentration had an effect; as well as whether it will be possible to 
quantify such an effect using RK treatment. 
A good fit between the experimental and RK data was found. The fact that the RK data was 
obtained on basis of Scheme 6.5 reinforces the validity of the proposed reaction mechanism. It 
was found to gradually reduce the drug’s photodegradation reaction (Fig 9.3). Suggesting that 
at higher SSY concentrations, it may be possible to reduce DBZ’s photodegradation even more.   
 
 
Fig 9.3: Changes in 1.05 x 10-3 DBZ photodegradation rate observed at 330 nm when 
increasing amount of SSY was added, when monochromatically irradiated at 330 nm (1.10 x 
10-6 einstien-1 s-1 dm-3, 22°C). Open circles are experimental data points and lines are RK 
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9.3. EFFECT OF VANILLIN 
Vanillin (4-hydroxy-3-methoxybenzaldehyde, VAN) is a flavouring additive obtained from 
vanilla beans used to produce natural vanilla and from by-products from the production of the 
paper for artificial vanilla. Because of its characteristic taste and odour of natural vanilla, it is 
widely used in pharmaceuticals, foods, beverages and as an aromatic ingredient in candles, air 









Scheme 9.3: Molecular structure of Vanillin 
 
As a pharmaceutical excipient, vanillin is used in tablets, solutions (0.01-0.02 % w/v), syrups 
and powder to mask the unpleasant taste and odour of various formulations [27]. Vanillin has 
also been investigated as a photostabilizer in furosemide 1 % (w/v) injection, haloperidol 0.5 % 
(w/v) injection and thiothixene 0.2 % (w/v) injections [26]. Therefore, it would be interesting to 
investigate the effect of vanillin on the photostability of DBZ and AXI as their spectra overlaps 
(Fig. 9.3). 
169 | P a g e  
 
 
Fig 9.4: Absorption spectra of Dacarbazine (DBZ), Axitinib (AXI), Sunitinib (SUT) and 0.012 
mg/mL Vanillin (VAN, Left) and the higher concentration used (0.1 mg/mL, Right) 
 
Irradiation of DBZ (Fig. 9.5) and AXI in the presence of VAN showed significant improvement in 
the photostability of both drugs, DBZ in particular. 
In the presence of VAN, the initial velocity of DBZ’s photodegradation in water was reduced 
from 6.55 x 10-4 s-1 to 1.29 x 10-5 s-1. That gives an impressive 50.7-fold increase in 
photostability (Table 9.2). 
 
 
Fig 9.5: Change in absorbance observed at 330 nm when 0.001 mg/mL DBZ was irradiated 
monochromatically at 330 nm (1.97 x 10-6 einstien-1 s-1 dm-3, 22°C) with 0.1 mg/mL Vanillin 
and when 0.004 mg/mL AXI was monochromatically irradiated at 430 nm (1.18 x 10-6 
einstien-1 s-1 dm-3, 22°C). Open shapes represents experimental data and solid lines 
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However, VAN had less of a stabilizing effect on AXI, with just 6.9-fold increase in 
photostability. This is due to the fact that VAN’s absorption at 360 nm is not much more than 
AXI’s. Therefore, is less efficient as a competitive light absorber for AXI than SSY. 
 
Table 9.2: Initial velocities of DBZ and AXI degradation in water in the presence and absence 
of vanillin and the percentage of degradation observed 
Vanillin Added   
mg/mL 
𝑷𝑷𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊 
x 10-6 einstien-1 s-1 dm-3 
𝜈𝜈0(𝑚𝑚𝑡𝑡𝑑𝑑.)




1.05 x 10-3 mg/mL Dacarbazine (λ irr = 330 nm) 
None  1.87 6.55 x 10-4 1 100.00 
0.1 1.97 1.29 x 10-5 50.7 18.83 
3.96 x 10-3 mg/mL Axitinb (λ irr = 360 nm) 
None  1.18 1.14 x 10-5 1 100.00 
0.1 1.18 1.66 x 10-6 6.9 39.34 
a Ratio = ratios of the initial velocities to that of the drug’s photodegradation in water alone 
 
9.4. EFFECT OF ODANSETRON HYDROCHLORIDE 
Ondansetron Hydrochloride (OHCl) is used to prevent nausea and vomiting caused by cancer 
chemotherapy, radiation therapy and surgery. It works by blocking the action of serotonin (5-













Scheme 9.4: Molecular structure of Ondansetron Hydrochloride 
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Stewart et al. [29] investigated the photostability of solutions containing 0.3 mg/L OHCl and 1 
mg/L DBZ and reported that when stored in polyvinyl chloride (PVC) bags under ambient room 
temperature and fluorescence light intensity, DBZ injections were slightly more stable by a 
modest (5.7 %) when combined with OHCl than when alone in solution. 
However, as stated by the authors, the instability of DBZ found in their study (48 hours) was 
inconsistent with that found by Benvenuto et al. [30] and that stated by the manufacturer (24 
and 8 hours, respectively). 
Thus, in this study the photostabilizing effect of ondansetron on DBZ was investigated as OHCl 
can act as a competitor for light absorption as its absorption spectrum overlays that of DBZ (Fig 
9.6). It is also interesting to see whether a higher photoprotection rate than that previously 
obtained (5.7 %) can be achieved. 
 
 
Fig 9.6: Absorption spectra of Dacarbazine (DBZ), Axitinib (AXI), Sunitinib (SUT) and 0.014 
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Fig 9.7: Changes in 0.001 mg/mL DBZ photodegradation rate observed when increasing 
amount of Odansetron was added, when monochromatically irradiated at 330 nm (1.05 x 10-
6 einstien-1 s-1 dm-3, 22°C). Data points are experimental data and lines are RK fitting on the 
basis of Scheme 6.5.  
 
OHCl is photostable in the irradiation conditions used for DBZ photodegradation (Fig. 9.7). 
With increasing amount of OHCl, the photostability of DBZ increased.  
RK treatment of the experimental data gave a good fit (Fig. 9.7). The fact that the RK data was 
obtained on basis of Scheme 6.5 further reinforces the validity of the proposed reaction 
mechanism. It can be clearly seen, that with increasing concentrations of OHCl, the rate (kA) of 
DBZ is reduced, hence extending its life-time. 
The recommended daily dose of OHCl is 32 mg or 2 mg/mL solutions for injection [31]. In this 
study, the highest amount of OHCl used to photostabilize 0.00098 mg/mL DBZ was 0.18 
mg/mL. This means that for 1 mg/mL of DBZ, 181 mg/mL of ondansetron is required. This is 
much higher than the recommended dose.   
However, it has been reported that individual intravenous doses as large as 150 mg and total 
daily intravenous doses as large as 252 mg have been inadvertently administered without 
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In any case, the limitation due to the maximum recommended intake amount makes it clear 
that OHCl cannot represent a practical solution to improving DBZ photostability. 
 
9.5. EFFECT OF β-CAROTENE 
Carotenoids such as β-carotene (provitamin A) and lycopene that are found in many yellow 
and red vegetables are powerful antioxidants that protect cells from free radicals that can 
damage DNA and lead to cancer. Nutrients like vitamin A and β-carotene are found to be anti-
carcinogenic and are often used in chemoprevention and treatment [32]. 
In 1994, Prasad et al. [33] investigated the effect of a mixture of vitamins (vitamin C, β-
Carotene, d-alpha-tocopheryl succinate and 13-cis-retinoic acid) in modifying the efficacy of 
commonly used drugs in the treatment of human melanoma. It was found that the mixture of 
vitamins can enhance the growth-inhibitory effect of currently used chemotherapeutic agents 
on human melanoma cells, one of which was DBZ. 
β-carotene (β-Ca)
C H 3
C H 3C H 3
C H 3C H 3C H 3
C H 3
C H 3 C H 3
C H 3
Scheme 9.5: Molecular structure of β-carotene 
 
A later study [34] showed that mice with metastasis melanoma, fed a diet supplemented with 
beta-carotene, had 71% fewer tumours than mice not fed β-carotene.  
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Photochemically, β-Carotene was found to enhance the photostability of nisoldipine (a 
calcium-channel blocker) [35]. Therefore, it was considered interesting to investigate the effect 
of β-Carotene, as a competitor for light absorption, on the photostability of DBZ. 
 
 
Fig 9.8: (Left) Absorption spectra of Dacarbazine (DBZ) and β-Carotene (β-Ca). (Right) 
Photokinetic trace of 0.001 mg/mL DBZ, irradiated monochromatically at 330nm (9.96 x 10-7 
eintsien-1 s-1 dm-3, 22°C, stirred) compared with that in the presence of 0.088 mg/mL β-
carotene. 
 
Although β-Carotene itself was found to be slightly photoactive in the irradiation conditions 
used for DBZ, the idea of spectral overlay and competition for light was used. That is by using a 
higher concentration of β-Carotene (0.88 mg/mL) than DBZ (0.01 mg/mL), less light would be 
absorbed by DBZ and so reducing its photodegradation rate.  
Unfortunately, photostabilization of DBZ was not observed. Instead, a major drop in 
absorbance at wavelength 330 nm was seen, as shown in Fig. 9.8.  
In order to understand this observation better, the effect of DBZ on β-Carotene was studied.  
Thus, a constant concentration of β-Carotene (0.88 mg/mL) was added to increasing 
concentrations of DBZ (0, 0.010, 0.027 and 0.044 mg/mL) and the initial velocity (𝜈𝜈0(𝑚𝑚𝑡𝑡𝑑𝑑.)
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determined by differential equation of the model equation describing AB(2Φ) Φ-order kinetics 
at t=0 (eq. 12, Annex A5.3). 
It was found that as the concentration of DBZ increased, the rate at which β-Carotene 
degraded increased as well (Fig. 9.9, Table 9.3). Thus, it can be concluded that β-Carotene is 










For the first time, two new ways of modelling and quantifying the effect of excipients on drugs’ 
photodegradation has been reported. Application of Φ-order kinetics and RK treatment has 
been found very useful and successful.  
The methods used here are shown to be much more appropriate and effective in quantifying 
the effect of excipients on drug photodegradation than those used in the literature - providing 
a clear indication of an excipient’s effectiveness. 
 
Fig. 9.9: Effect of increasing DBZ concentrations 
of (0 - 0.044 mg/mL) on the photostability of β-
Carotene (0.88 mg/mL). λirr = 330 nm (9.96 x 10-7 


























Table 9.3: Initial velocities of β-Carotene 
(0.88 mg/mL) in water in the presence and 
absence of DBZ and the percentage of 
degradation observed.  
 
λirr = 330 nm (9.96 x 10
-7 eintsien-1 s-1 dm-3, 22°C, 





𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜⁄ / s-
1 
Ratio % Degradation 
0 1.70 x 10-4 1 25.6 
0.01 2.32 x 10-4 1.37 38.4 
0.027 2.92 x 10-4 1.72 56.5 
0.044 3.42 x 10-4 2.01 73.4 
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The effect of excipients on the reduction of the rate of DBZ, AXI and SUT degradation has been 
found to depend markedly on the absorbance of the excipient at the irradiation wavelength. 
While VAN and TRZ have been found to completely photostablize DBZ and SUT (respectively) in 
water solution, SSY has been shown to increase AXI’s photostability by 13-fold. 
These results has shown the importance and requirement of a systematic study on the effects 
of excipients on pharmaceutics’ degradation since different excipients have different effects 
on photostability and some might show unexpected behaviour (SSY and β-Carotene). While 
some are limited by their recommended daily intake (SSY, TRZ and OHCl). 
Nonetheless, the use of pharmaceutical excipients in drug photostabilization has been shown 
to be very useful. This opens up the possibilities of liquid formulations AXI and SUT (both of 
which are currently only available as solid dosage forms) for alternative routes of 
administration. 
Alternatively, a solution containing a combination of various excipients may have an increased 
photostabilizing effect of the drugs than they do on their own (see Chapter 10). 
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10.1. INTRODUCTION 
The lack of commercially available oral liquid dosage forms is an on-going problem in the 
pharmaceutical industry [1] – limiting their availability to paediatric patients, adults unable to 
swallow tablets or capsules and patients receiving medicines via nasogastric or gastrostomy 
tubes [1]. However, a range of problems are encountered when developing drugs into a stable 
liquid formulations, from the drug’s solubility, photo- and thermal-stability to the stability of 
the excipients and packaging [2,3].  
As most drug substances and excipients absorb in the UV and visible range, exposure to light 
could potentially lead to photochemical reactions. These reactions may cause the drug 
substance or components of the formulation to degrade and reduce the efficacy of the 
formulation or give rise to a toxic formulation [4]. Therefore, initial solutions would be to 
package the drug in a protective material. However, this is not the only solution and it is 
known that some types of protective packaging is not sufficient enough in preventing 
photodegradation – as in the case of DBZ [5].  
AXI and SUT are commercially only available as solid dosage forms and when required, liquid 
dosage forms are prepared extemporaneously [1,6,7]. However, extemporaneously prepared 
oral suspensions are susceptible to caking, making the suspension excessively thick and un-
pourable [8]. In addition, there is a lack of stability data available [9,10]. 
Thus, this chapter presents and explores for the first time, new stable liquid formulations for 
DBZ, AXI and SUT based on nanosponges. 
There are two main goals of pharmaceutical formulation development [11,12]. First, to 
produce a drug that is stable to ensure that efficacy and safety characteristics of the active 
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substance are maintained. Second, to make drug administration easier and convenient to the 
patient who will use it, whilst keeping the use of excipients at a safe and minimal level [13].  
 
10.2. CYCLODEXTRIN-BASED AXI FORMULATION 
10.2.1. Water solubility 
Solubility of the active drug in aqueous solution is critical in the design of formulation [14-16]. 
Many poorly soluble drugs can be made more water soluble by modifying their chemistry, such 
as introducing a hydrophilic group on the molecule [15]. Salts and derivatives of poorly soluble 
drugs are very common, but great care is required with modifications like these because 
different salts and forms may not have the same chemical stability and the biologic activity 
may be modified [15]. 
Furthermore, the very low water solubility limit of many anticancer drugs is the greatest 
challenge in the pharmaceutical industry, drug delivery in particular – limiting their use in 
clinical practice [17]. Nanosponges, such as cyclodextrin polymers, have been shown to 
improve solubility of some cancer drugs by incorporating drugs within their structure via 
complexation [17-19]. Yet, no such studies have been reported for DBZ, AXI or SUT. 
As shown in previous chapters, of the three drugs studied, cyclodextrins (CD) complexes well 
with AXI. Since its use in pharmaceutical products, cyclodextrins have shown to be very 
effective in solubilising hydrophobic drugs – allowing solution-based dosage forms such as 
intravenous parenteral or oral solutions [27-29]. With increasing interest in nanoparticles and 




182 | P a g e  
 
Table 10.1: Examples of the maximum increase in solubility observed for various CD and 
drugs. 
 
It is common practice to use the phase solubility diagram described to determine the solubility 
of drug and CDP complexes [27,30]. The method is based on the assumption of 
monomolecular inclusions (1:1, 1:2, 1:3, etc) and is perform with excess drug in solution. Not 
only can this process be costly, it does not give the solubility limit of the complex, the 
minimum water and CD required to solubilize the drug at its required dosage. Thus, an 
alternative method have been employed here for determining the solubility of the AXI/CDP 
complex. 
 











AXI 5 0 2 x 10-4 0 
AXI/α-CDP 5 300 10 50,000 
AXI/β-CDP 5 770 5 25,000 
a amount of AXI (mg) that can be dissolved by 1 mL of water 
 
CD Drugs Increase in Solubility Reference 
α-CD Cyclosporine A 10 20 
β-CD Carvedilol 110 21 
γ-CD Nystatin 103 22 





DM-β-CD Estradiol 214,900 24 
HE-β-CD Estradiol 92,250 24 
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AXI has very poor solubility in water, 2 x 10-4 mg/mL [31]. One dose of Inlyta® contains 5 mg 
AXI [32]. Therefore, to dissolve and administer this drug as a liquid formulation, 25000 mL (25 
L) of water would be required. For any patient, this is completely impractical. 
Yet, with the addition of α-CDP and β-CDP, a single 5 mg dose of AXI can be solubilized with 
just 0.5 – 1 mL of water (Table 10.2). The original solubility of AXI in water (2 x 10-4 mg/mL) has 
now significantly improved to 5 mg/mL through complexation with cyclodextrin polymers. That 
is, an impressive 25,000 times increase with β-CDP and 50,000 times increase with α-CDP.  
Because only 1 mL or less is required, great potential for other routes of administration to be 
considered (such as a parenteral to be injected intravenously and oral liquid formulation) and 
so making the drug available to paediatrics, elderly and patients who have difficulty swallowing 
tablets.  
Current commercially available AXI (Inlyta®) tablets, containing the anhydrous form of AXI, has 
a bioavailability of only 58% - partly due to low solubility [33]. This means that only 2.9 mg of 
the 5 mg enters the bloodstream. Studies have shown that complexation with cyclodextrins 
improves a drug’s bioavailability through the improvement of its solubility [27-29]. Therefore, 
the AXI/α-CDP and AXI/β-CDP formulations has the potential to demonstrate higher 
bioavailability than the current Inlyta formulation marketed by Pfizer. If the bioavailability is 
improved through complexation with CDPs, then the current 5 mg dose administered may be 
reduced without comprising the drug’s efficacy. 
 
10.2.2. Thermal stability 
In the absence of any CDPs, AXI completely thermally degrades within an hour (See Chapter 6). 
Complexation with β-CDP showed complete stabilization for at least 5 hours. The changes in 
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absorbance observed at 330 nm remained within ± 1 standard deviation of the average 
absorbance reading (Fig. 10.1). Complexation with α-CDP also showed substantial 
improvement to AXI’s thermal stability. Thermal degradation of AXI/α-CDP was found to have 
slowed down significantly from completion within 1 hour to requiring over 9 hours to 
complete. 
The difference in the stabilizing effect of the two CDPs may be due to the fact that the amount 
of β-CDP (770 mg) present in the AXI/β-CDP formulation is more than twice that of α-CDP (300 
mg) in the AXI/α-CDP formulation. It should be noted that the amount used in this study is the 
minimum required to completely solubilise 5 mg AXI.  
 
 
Fig 10.1: Thermaldegradation kinetic trace of (left) 2.16 x 10-5 M Axitinib (AXI) in 2.5 % (v/v) 
ethanol/water solution, as AXI/α-CDP formulation and (right) as AXI/β-CDP formulation, 
where circles represent experimental data and the mean values (0.097 ± 8.85 x 10-3) 
represented as a line, with only four data points out of the range. Kept 22°c, stirred, 
observed at 330 nm 
 
10.2.3. Photostability 
10.2.3.1. Monochromatic Irradiation 
As seen in previous chapters, irradiation of AXI in aqueous solution forms a new peak at 380 
nm, which belongs solely to the photoproduct since an increase in absorption at 380 nm is not 
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The evolution spectra and kinetic trace obtained (Fig. 10.2) for both formulations is proof that 
the thermal reaction has been completely stopped through the inclusion of CDPs and a plateau 
has been reached - indicating the end of a reaction.   
Therefore, the Φ-Order kinetic model equation (as seen in Chapter 5) can be used to calculate 
the rate constant (k) of the reaction. The rate constant of AXI/α-CDP and AXI/β-CDP 
formulations were determined to be 2.4 min-1 and 12 min-1 (144 s-1 and 720 s-1, respectively) - 
AXI/α-CDP being 5 times slower than β-CDP. In water, AXI’s k was determined to be 0.004 s-1 
(0.24 min-1) at low concentration. Thus, neither formulations photostabilized AXI in UV light.    
 
 
Fig. 10.2: Evolution of the electronic absorption spectra of AXI/α-CDP and AXI/β-CDP 
formulations in water and the photokinetic traces obtained at 330 nm (circles) and 380 nm 
(triangles), where open shapes represent experimental data and the solid lines are the fitting 
of the traces to the Φ-order kinetic model (kAB = 2.4 min-1 and kAB = 12 min-1, respectively), 
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10.2.3.1. Polychromatic Irradiation 
Photokinetic traces obtained for AXI/β-CDP at 330 nm and 380 nm (Fig 10.3) showed that a 
majority of the absorbance values remained within ± 1 standard deviation of the mean 
absorbance value for both throughout the experiment, i.e. there is very little change in 
absorbance throughout testing and the photoreaction is very stable for at least 7 hours. The 
formulation has extended the shelf life of AXI by an additional 6 hours because as shown 




Fig 10.3: Kinetic traces of AXI/α-CDP (left) and AXI/β-CDP (right) formulations in water 
solution when exposed to polychromatic irradiation and ambient room temperature, stirred, 
obtained at 330 nm (circles) and 380 nm (triangles). Traces obtained for AXI/β-CDP, the 
mean values are represented as a line (0.0865 ± 6.49 x 10-3 for 330 nm and 0.0217 ± 2.55 x 
10-3 for 380 nm), with only three data points out of range (dotted lines = mean ± SD). 
 
AXI/α-CDP on the other hand, demonstrated that over 8 hours will be required to completely 
degrade AXI under ambient conditions. An increase in absorption at 380 nm was not seen. The 
reaction observed here was comparable to that recorded earlier for thermal degradation 
(section 10.2.2). Consequently, it can be inferred that the reaction recorded here was 
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Although, looking at the formulation under polychromatic conditions whilst being continuously 
stirred is useful as it gives an indication of a situation where it is being agitated. It would be 
interesting to see if the formulation was made up a period of time before administration 
(without agitation). Therefore, tests have been conducted on the complex under 
polychromatic conditions unstirred (Fig 10.4).  
In comparison to the complex tested in polychromatic stirred conditions, the absorbance 
readings in the unstirred conditions are shown to be just as stable over a period of 4 hours (Fig 
10.4). Readings for the absorbance values observed at 330 nm and 380 nm are within ±1 
standard deviation meaning that there is no change in absorbance for 4 hours.  
 
 
Fig 10.4: (Left) Evolution of the electronic absorption spectra of AXI/β-CDP formulation in 
water solution when exposed to polychromatic irradiation and ambient room temperature, 
not stirred. (Right) Photokinetic traces obtained at 330 nm (circles) and 380 nm (triangles), 
circles represent experimental data and the mean values (0.0493 ± 2.85 x 10-3 and 0.0123 ± 
1.44 x 10-3, respectively) represented as a line, with only  data points out of the range 
(dotted lines = mean ± SD). 
 
During dosage form design, many pharmaceutical characteristics must be addressed 
depending on the drug and delivering system. Liquid formulations must be palatable (if taken 
orally), soluble and stable, whilst ensuring efficacy and safety [2,3,11-13].  Improving a drug’s 
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AXI/α-CDP and AXI/β-CDP formulations meets these criteria, they are simple in comparison to 
the current Inlyta® tablet formulations [32].   
Manufacturing liquid formulations is generally less complex than a tablet. However, it must be 
noted that any form of heat and light needs to be avoided during the manufacturing process of 
the complexes, due to AXI’s high degradation lability. Thus, the sensitivity of the drug to 
degradation by these routes needs to be held with the utmost importance. The risk of 
developing impurities in the formulation must be avoided. 
Another issue to consider is the palatability as patients may be concerned with the palatability 
of the formulation. If the formulation is not pleasant tasting then this could be an issue with 
patient compliance. However, α-CDP and β-CDP come from a family of cyclodextrins which are 
made up of sugar molecules that are bound in a ring together. Therefore, the CDPs in AXI/α-
CDP and AXI/β-CDP complexes are also playing the role of taste-masking agents. The use of 
cyclodextrins in this manner is not unknown. For example, Zinc acetate dihydrate used in 
lozenge formulations carries a bitter taste; it is masked by the use of anethol-β-cyclodextrin 
complex [34]. The high quantity of CDPs in the formulation allows the bitter taste of AXI to be 
masked. 
It is recommended that AXI tablets are swallowed whole with a glass of water [31]. However, 
pharmacist and nurses frequently encounter patients with nasogastric tube or those unable to 
swallow oral medications for other reasons [6]. Even though it is advised against, current 
practice is to crush the tablet and administering it as a suspension [6]. This method can impact 
on the drug’s stability, especially when exposed to light, and the safety of pharmacists and 
nurses who would require protection from inadvertent exposure.  
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An alternative preparation method which does not involve the crushing of the tablet, outlined 
by Pfizer for healthcare professionals, is to prepare a suspension by placing the tablet in an 
amber oral syringe with 15 mL of United States Pharmacopeia (USP) graded water and waiting 
10 minutes for the tablet to disintegrate [6]. This then must be keep away from light and 
administered via nasogastric tube within 15 minutes of preparation. As shown in this study, 
AXI degrades rapidly in water even in the absence of light. The method described here has at 
least a 25 minutes gap between placing AXI in water and absorption. Thus, by that time, half of 
AXI would have already thermally degraded, as shown by our findings. 
 In this aspect, the new AXI powder formulation is especially useful and convenient as it is 
thermally stable and easily reconstituted. As well as, providing flexibility when other routes of 
administration, such as parenteral preparations, are required. 
Furthermore, it is known for renal cell carcinoma metastases to develop in the neck. 15% of 
renal cell carcinoma cases report metastases to the head and neck regions [35] and for 
patients to develop painful swellings in the neck and head [36].  In these circumstances, it is 
advantageous that AXI the drug used to treat this condition can be administered as a solution 
instead of being administered as a tablet such as Inlyta, which is more likely to cause 
discomfort towards the patient [37]. 
 
10.2.4. AXI/α-CDP and AXI/β-CDP Formulation As  Parenteral Injections  
For a drug be administered parenterally, the drug must be non-toxic and readily dissolved [38]. 
Bioavailability is defined as the proportion of drug or substance that has entered the 
circulation in order to have an active effect in the body [39]. Here, a single dose of AXI (5 mg) 
was readily dissolved in 0.5 mL and 1 mL of double distilled water as a formulation with α-CDP 
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and β-CDP, respectively. Also, intravenously administering AXI/α-CDP and AXI/β-CDP 
formulation avoids first pass metabolism as opposed to the oral route of administration [40].  
α-CDP and β-CDP has been approved by the FDA as being safe to be use in pharmaceutical 
formulations [41]. It is also known that orally administered cyclodextrins are not toxic; this is 
due to the fact that they are not absorbed well in the gastrointestinal tract. But it is also 
important to assure that the use of CDP in parenteral is safe and suitable. 
Nanosponges like CDP have been shown to be safe, biodegradable materials with negligible 
toxicity on cell cultures that were well-tolerated after injection with no apparent side effects 
[20,29]. In Swiss albino mice, nanosponges were found to be safe up to 5000 mg/kg without 
showing any signs of toxicity or adverse reactions [42].  
Accordingly, the newly developed AXI/α-CDP and AXI/β-CDP formulations can potentially be 
used parenterally. Currently, AXI cannot be administered intravenously and there are no 
studies reporting to have attempted. Thus, the two new formulations presented here could 
possibly provide healthcare professionals and patients an alternative route of administration 
which may be more ideal for some patients. 
A final point to consider when looking at the formulation as a parenteral to be injected is that 
it is possible to deliver the effective dose of drug; in the event of an emergency where a 
patient becomes unconscious, providing the drug instantly via the parenteral route would 
become inevitable. 
 
10.2.5. Characterisation of the Formulations 
The variation of the IR spectrum can provide information of the occurrence of inclusion 
between the drug and CD [43-45]. Fig 10.5 shows the IR spectra of AXI, α-CDP, AXI/α-CDP 
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formulation, AXI/α-CDP physical mixture, β-CDP, AXI/β-CDP formulation and AXI/β-CDP 
physical mixture.  
For both α- and β-CDP, a wide band at 3000-3610 cm-1 is seen due to OH bonds stretching. Due 
to C-O- bonds stretching, a strong absorption band at 900-1170 cm-1 is also observed.  
Whilst the former band remains relatively unchanged after complexation, a decrease in 
intensity of the latter band in both AXI/α-CDP and AXI/β-CDP formulation is seen. This 
indicates inclusion of AXI within the CDPs. The lack of change in band intensity seen in the 
physical mixtures strongly suggests this conclusion. 
The greater decrease in band intensity observed for AXI/α-CDP is indicative of a strong guest-
host interaction and a better inclusion complex formed between AXI and α-CDP than β-CDP 
[43-45]. This collaborates well with the enhanced water solubility and stabilising effect found 
for AXI/α-CDP. 
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Fig. 10.5: The IR spectra of AXI, α-CDP, AXI/α-CDP formulation, AXI/α-CDP physical mixture, 
β-CDP, AXI/ β-CDP formulation and AXI/β-CDP physical mixture 
 
Evaluation of surface morphology the powder of AXI/α-CDP and AXI/β-CDP formulations using 
Scanning Electron Microscope (SEM) showed the change in the crystallinity of AXI in the 
inclusion complex compared to the other. AXI powder consists of irregular rod-like crystals (Fig 
10.6). Microphotographs of α-CDP and β-CDP shows large sheet-like structures. 
In the powder of AXI/α-CDP and AXI/β-CDP formulations the morphology of the original AXI 
and CDPs disappeared and it was not possible to differentiate the two. The change in surface 
morphology is indicative of a new solid-state (most likely amorphous), which may be due to 
the encapsulation of AXI within α-CDP and β-CDP [46,47]. Whereas, the physical mixture 
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Fig 10.6: Scanning electron microphotographs  
 
AXI Powder             α-CDP      β-CDP 
α-CDP Rotary Evaporate        AXI/α-CDP Formulation         AXI/α-CDP physical mixture 
β-CDP rotary evaporated           AXI/β-CDP Formulation    AXI/β-CDP physical mixture 
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10.3. FORMULATIONS FOR DBZ AND SUT 
The usefulness and requirement of liquid formulations of drugs cannot be denied. Yet, no 
liquid formulation of sunitinib malate is commercially available and no stable liquid 
formulation of DBZ exist.  
DBZ is administered by intravenous bolus injection or by short term intravenous infusion due 
to poor oral bioavailability [48]. The use of an opaque infusion set suggested by Shükla & 
Koriech [49,50] and Baird & Willoughby [51] shows to be effective but are simply inconvenient 
due to the inability to see and follow the infusion. On the other hand, the light filtering 
administration set developed by Kirk [52] enables the user to see and follow the infusion 
clearly and protect DBZ from photodegradation; thus preventing the formation of the vascular 
pain causing agent.  
To the best of our knowledge, only Islam and Asker [53] attempted to photoprotect DBZ 
solutions with the use of excipients. Even though the method was found to be effective, it is 
not commercially employed due to the fact that glutathione inhibits DBZ-induced cell 
apoptosis [54]. Thus, a suitable photoprotective excipient is still yet to be discovered.   
In this study, a photostable liquid formulation for DBZ has been found (Fig 10.7). Besides 1 
mg/mL DBZ, the formulation contains Sunset Yellow (0.02 mg/mL, SSY) and Tartrazine (100 
mg/mL, TRZ) and Odansetron (2 mg/mL, OHCl). SSY and TRZ are azo-dye commonly used in 
food and pharmaceuticals which are both deemed safe for injections by European Food Safety 
Authority [55,56], while OHCl is a drug co-administered with DBZ to prevent nausea and 
vomiting. This formulation was shown to provide a 10 times increase in photostability (Table 
10.3), making the solution practically photostable when irradiated monochromatically for 
more than an hour at its maximum peak (330 nm).  




Fig 10.7: (Left) Changes in absorbance observed for 1 mg/mL DBZ alone and in liquid 
formulation containing Sunset Yellow (0.02 mg/mL) and Tartrazine (100 mg/mL) and 
Odansetron (2 mg/mL), when monochromatically irradiated at 330 nm (4.69 x 10-6 einstein s-
1 dm-3) (Right) Effect of a combination of α-Cyclodextrin monomer (25 mg/mL), Sunset 
Yellow (0.16 mg/mL)  on the degradation of AXI (0.008 mg/mL) observed at 332 nm, when 
kept in the dark at 22°C and monochromatically irradiated at 360 nm (3.08 x 10-6 einstein s-1 
dm-3) 
 
This DBZ formulation will enable standard infusion sets to be used without the need to 
photoprotect the content. It should be noted that this is the first time DBZ is shown to be 
completely photostabilized through the use of pharmaceutical excipients. 
As shown in the previous chapter, TRZ is serves as a good competitive light absorber for SUT. 
In liquid form TRZ’s Maximum Permit Level (MPL) is 100 mg/mL [56].  The amount of TRZ 
permitted for 1.88 x 10-4 M SUT (0.1 mg/mL) was then calculated based on the person taking a 
single dose of 50 mg. This was determined to be 0.2 mg/mL. 
This was then subjected to polychromatic irradiation and monitored by HPLC. The results 
found showed at high drug concentrations a decrease in photodegradation rate is observed, as 
with the other drugs. Addition of TRZ to solutions of SUT hindered the formation of its 
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Table 10.3: Initial velocities of DBZ, AXI and SUT degradation in different media 
Sample 
𝑷𝑷𝝀𝝀𝒊𝒊𝒊𝒊𝒊𝒊 
x 10-6 einstien-1 s-1 dm-3 
Condition 
Initial Velocity  
s-1 , x 10-4 
Dacarbazine (λ irr = 330 nm, 22°C) 
DBZ (0.001 mg/mL) 1.96 Light 6.55 
DBZ + SSY (0.078 mg/mL) 2.03 Light 1.45 
DBZ + TRZ (0.18 mg/mL) 2.03 Light 2.90 
DBZ + OHCl (0.18 mg/mL) 1.05 Light 1.29 
DBZ (1 mg/mL) 4.69 Light 10.03 
DBZ (1 mg/mL) + SSY (0.02 mg/mL) 




Axitinb (λ irr = 360 nm, 22°C) 
AXI (0.008 mg/mL) 0.00 Dark 1.76 
AXI (0.008 mg/mL) 3.05 Light 7.23 
AXI + SSY (0.16 mg/mL) 3.06 Light 5.55 
AXI + α-CD (25.5 mg/mL) 3.07 Light 5.20 
AXI + α-CD (27.4 mg/mL)+SSY (0.16 
mg/mL) 3.04 Light 0.26 
Sunitnib (λ irr = 430 nm, 22°C) 
SUT (0.01 mg/mL) 0.00 Dark 3.00 
SUT (0.01 mg/mL) 5.67 Light 2.40 
SUT + TRZ (0.02 mg/mL) 5.67 Light 0.13 
SUT (0.1 mg/mL) -a Light 2.0 
SUT + TRZ (0.2 mg/mL) - Light 1.0 
a Polychromatic ambient light was used 
 
 
197 | P a g e  
 
 
Current practice for patients requiring liquid doses of SUT is to use a mortar and pestle to mix 
the contents of SUT capsules with a 1:1 mixture of ORA-PLUS®:ORA-SWEET® and store in an 
amber plastic bottle [57].  
This new SUT oral liquid formulation containing TRZ offers a quicker and simpler preparation 
method for busy clinical environments. Since, both TRZ and SUT come as powders, the 
formulation can simply be reconstituted by the addition of water when required. However, the 
solution must be administered immediately or be kept refrigerated. 
 
10.4. COSTS 
The current Inlyta formulation is very costly to purchase at approximately £62.80 a tablet 
(containing 5 mg AXI) [59]. While the money used to develop this formulation throughout the 
project approximates the cost of one dose to be less than £30 (Table 10.4). Table 10.4 shows 
the approximate price of one dose of 5 mg based on the pricing of each component used in the 
formulation.  
To produce one 5 mg dose of the AXI/α-CDP and AXI/β-CDP formulation it costs only ~£11.14 
and ~£27.17, respectively. The vast difference in price of the new AXI formulation using α-CDP 
and β-CDP will make AXI more readily available as costs are lower for the manufacturer, NHS 
and patient. 
As for SUT, the price for a pack of 50 mg capsules (30 capsules per pack) is £3363.00 (excluding 
VAT) [58]. That is £112.10 per capsule. Whereas, 50 mg of SUT costs £79 from SelleckChem 
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AXI Selleckchem 83.00 50 mg 1.66 5 mg 8.30 
α-CDP CycloLab 94.6 10000 mg 0.01 300 mg 2.84 
β-CDP Sigma Aldrich 
122.5
0 5000 mg 0.02 770 mg 18.87 
Ethanol Sigma Aldrich 38.90 500 mL 0.08 -
b - - 
Purified 
Water Amount not specified. During complex formation, the purified water and ethanol are evaporated. 
Total cost per dose (£) 
AXI-β-CDP 27.17 
AXI/α-CDP 11.14 
 a Includes cost of compound and shipping 
b not applicable 
 
10.5. CONCLUSION 
The prime objective of this study was to develop aqueous formulation for our three drugs 
(DBZ, AXI and SUT) that present improved thermal and/or photochemical stabilities compared 
to their solution ones (i.e. in ethanol, water or ethanol/water as discussed in chapters 5 and 6). 
For the case of AXI, there was an extra challenge to achieve a liquid formulation as this 
molecule is naturally very poorly soluble in water.  
The results obtained in chapter 8 demonstrates that AXI was complexed with CD monomers 
and polymers at low concentration (2 x 10-5 M). The test of such complexation at high AXI 
concentration in this chapter proved its solubility in water could be improved by 2500-times in 
the presence of β-CDP and 5000-times with α-CDP. It meant that now the concentration of AXI 
could get to 5 mg/mL in 10 mg/mL in water; which represents the dosage of the drug in Inlyta® 
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tablets. Such high concentration cannot be achieved by the CD monomers due to their own 
relatively low solubility limits in water, compared to the polymers. 
One of the primary consequence of AXI/CDP complex, in addition to increasing AXI’s solubility 
in water, was the total disappearance of the significant thermal degradation of this molecule, 
observed earlier in ethanol/water (v/v, 2.5/97.5) solutions, as been proven for low AXI 
concentration in chapter 6. This might suggest that the results obtained at low drug 
concentration could well be representative of what occurs at high drug concentration. This 
point is true for AXI, but this needs to be supported by more experimental evidence as the 
literature lacks a discussion about this issue. Its importance comes from the fact that the 
studies performed at low concentration of the drug are less time consuming and cheaper than 
those leading to the optimization/definition of the solubility limit of AXI/CDP complex. 
The improvement of SUT thermal stability in water was suggested here to be obtained by 
leaving SUT solution in the fridge at ~4-6°C. DBZ is naturally thermally stable at room 
temperature in water. The photostability of their formulation was proven to considerably 
improve by using the same strategy that involves light absorption competitors represented by 
selected excipients (chapter 9). 
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CONCLUSION   




Photodecomposition of unstable drug formulations could lead to undesirable side effects. A 
loss of potency of the drug and the development of adverse effects may be due to the 
formation of photoproducts during storage or administration. Therefore, photostability testing 
of drug substances is important for the evaluation of the overall photosensitivity of the 
material for development. Hence, the photostability of drug substances has developed into an 
important area of research, especially as increasing number of drugs are considered 
photolabile.  
The ICH made provision of photostability data for all new drug licence applications 
compulsory. A guideline was established to regulate photostability test conclusions from 
different laboratory but it lacked protocols for the treatment and analysis of kinetic data of 
drug photodegradation. Often photokinetic data of drugs are treated using thermal zero-, first- 
and/or second-order thermal kinetic models. They were used irrespective of the 
photochemical mechanism governing the drug and its photoproducts, and the fact that the 
equations were originally developed for pure thermal reactions. So, in many cases, only part of 
the kinetic data of the photodegradation trace was used. In addition, poor fittings and data 
equally well fitting more than one reaction-order model were achieved. 
The photokinetic traces of DBZ, AXI and SUT were all well described by the newly proposed Φ-
order model for unimolecular and photoreversible reactions obeying an AB mechanism, even 
when subjected to non-isosbestic irradiation. These and previous results presented by our 
team strongly suggests that photodegradation of drugs are better described by Φ-order than 
the classic thermal reaction orders. 
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The application of Φ-order here to determine the quantum yields (the only physical parameter 
capable of indicating the photoreactivity of a drug) and develop drug-actinometers are not 
only straightforward to implement, but they also allow the generation of reliable and 
quantitative data on the photodegradation reaction. 
Drug actinometers developed using Φ-order kinetic equations here can be used without prior 
knowledge of the reaction attributes, such as quantum yields. The proposed procedure and 
actinometers should work well for monochromatic irradiations. But, it is not advised to be 
used for polychromatic light as quantum yield values are shown in this study to be wavelength 
dependant and so are their 𝛽𝛽𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  factors. Therefore, the average quantum yield values 
obtained using polychromatic irradiations, as reported on by many studies in the 
pharmaceutical literature, must be considered with caution. However, Φ-order was also 
shown to be applicable to data obtained by polychromatic irradiation – even those of complex 
drug mechanism. 
Analysis of complex degradation mechanisms can be circumvented by the use of mathematical 
software procedures. However, current methods do not provide a unique answer and require 
chromatographic data to determine the component spectral profiles and concentrations. More 
importantly, these models are based on the thermal differential equations - which are 
completely different to that of photokinetic.  
Thus, the successful application of the new Runge-Kutta numerical treatment proposed here 
for analysis of spectrokinetic data of complex drug photoreaction is the first of its kind. It 
helped elucidate complex drug mechanisms (number of species and occurrence of thermal and 
photochemical steps). It enabled the determination of the quantum yields and absorption 
coefficients, not only of the mother compound but of all photoactive degradation products, in 
addition to showing the evolution of the species respective concentrations during reaction 
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time. Such a performance cannot be expected from chromatography techniques, especially 
when thermally unstable products are concerned. 
Until now, stable liquid dosage forms of DBZ, AXI and SUT do not exist in water. For the case of 
AXI, there was an extra challenge to achieve a liquid formulation as this molecule is naturally 
very poorly soluble in water.  
Our results demonstrate that formation of AXI/CDP complexes significantly increased its 
solubility in water by up to 5000-times. It meant that now the concentration of AXI could get 
up to 5-10 mg/mL in water, which represents the dosage of the drug in Inlyta® tablets. Such 
high concentrations cannot be achieved by the CD monomers due to their own relatively low 
solubility limits in water, compared to the polymers. 
In addition to increasing AXI’s solubility in water, formulation of AXI with CDP yield a total 
disappearance of the significant thermal degradation of this molecule observed earlier in 
ethanol/water (v/v, 2.5/97.5) solutions.  
The improvement of SUT thermal stability in water was suggested here to be obtained by 
leaving SUT solution in the fridge at ~4-6°C. DBZ is naturally thermally stable at room 
temperature in water. The photostability of their formulations were proven to considerably 
improve by using the same strategy that involves light absorption competitors represented by 
selected excipients (chapter 8). 
In drug development, knowledge of the complexation efficiency is useful. However, even with 
increased interest in CDP due to advances in nanotechnology, only few studies have reported 
on the fluorimeteric characterisation of nanosponge-drug complexes. 
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The new mathematical framework proposed in this study for characterisation of such 
complexes enabled a reliable determination of the true complex stoichiometry without 
imposing preselected values (i.e. 1:1, 1:2, etc) – as with current methods.  
In addition to not requiring the precise knowledge of the relative molar mass, the method 
gives information on both stoichiometry and association constant of the complex. 
Some of the problems often encountered in photostability testing and liquid formulation 
development had been addressed here in this study. The successful application of the methods 
proposed to the model anti-cancer drugs has set out new approaches that might be found 
useful for future treatments of photodegradation data, development of drug-actinometers and 
liquid formulations of drugs. 
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A5.1. Φ-Order Kinetic Model for non-isosbestic irradiations 
The model equation describing Φ-order kinetics for the photoreversible degradation of initial 








































𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(∞) are the total 
absorbance of the reaction medium at reaction time (t), at the start of the reaction (t = 0) and 
at infinity (∞), when irradiated at a certain wavelength and observed at the same wavelength 
(λ irr/λ irr) or irradiated and observed at different wavelengths (λ irr/λobs). 
The rate constant 𝑘𝑘𝐴𝐴⇋𝐵𝐵






𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖� × 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(∞) =  𝛽𝛽𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖            Eq.2 
where Φ𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  and Φ𝐵𝐵→𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  are the forward and reverse quantum yields at the irradiation 
wavelength (λ irr), 𝜀𝜀𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖and 𝜀𝜀𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  the extinction coefficients of A and B, 𝑃𝑃𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  the light intensity 
received, 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  the path length of the irradiation light and 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(∞) the photokinetic factor 
expressed as: 











    Eq.3 
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It is possible to use Eq.1 to describe the kinetic behaviour of any AB photoreaction at any 
observation/irradiation conditions. Thus, for an AB(2Φ) system where both species absorb at 
the irradiation wavelength , the absorbance at infinity will be represented by the 
photostationary state (pss). As a result,  𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜(∞) and 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(∞) becomes  𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜(𝑝𝑝𝑝𝑝𝑝𝑝) 
and 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(𝑝𝑝𝑝𝑝𝑝𝑝). For an unimolecular AB(1Φ) system where only the A absorbs at the 
irradiation wavelength, 𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜(∞) , Φ𝐵𝐵→𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  and 𝜀𝜀𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  = 0 and 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(∞) = ln(10) = 2.3. This 
returns Eq.1 to the model equations obtained through closed-form integration for this AB(1Φ) 
system [1].  
The 𝛽𝛽𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  in Eq.2 is a proportionality factor between the overall rate-constant and the 
radiant power. 
 
A5.2. Equations for isosbestic irradiations 
The equation expressing the time-based variation of the total absorbance observed for 
monochromatic irradiation at an isosbestic point (𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 = 𝜆𝜆𝑖𝑖𝑚𝑚𝑡𝑡𝑚𝑚) can be obtained by closed-form 






𝜆𝜆𝐶𝐶𝑝𝑝𝐶𝐶𝑝𝑝×𝑡𝑡   Eq.4 
where 𝑘𝑘𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜can be worked out from Eq. 2 with the time-dependent photokinetic factor 
as 𝐹𝐹𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜  instead of 𝐹𝐹𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(𝑝𝑝𝑝𝑝𝑝𝑝) and 𝐹𝐹𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜  calculated using Eq. 3 with the absorbance measured 
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A5.3. Photokinetic Elucidation Method 
By fitting experimental data with the Φ-order kinetic equations for non-isosbestic and 
isosbestic irradiation above, the rate-constant of the reaction can be determined.  
For an AB(1Φ) system, a simple rearrangement of eq.2 (into eq. 5) enables Φ𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  to be 
calculated: 





               Eq.5 
For an AB(2Φ) reaction, determination of the rate-constant of the reaction alone is not 
sufficient to work out the unknown parameters of the reactions, i.e. the forward quantum 
yield (𝛷𝛷𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 ), the reverse quantum yield (𝛷𝛷𝐵𝐵→𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 ) and the absorption coefficient of the 
photoproduct (𝜀𝜀𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖) at the irradiation wavelength.  
For an AB(2Φ) reaction, the original compound (A) and its product (B) reach equilibrium, and 
so the final absorption spectrum recorded is in fact that of both A and B. Thus, determination 
of 𝜀𝜀𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  is not possible with just spectrographic data. Without knowing the concentration of 
species B at pss, 𝛷𝛷𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  and 𝛷𝛷𝐵𝐵→𝐴𝐴
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖  cannot be calculated. As a result, further information is 
required to determine the values of these three unknown parameters. 
This problem can be solved in three steps: (i) determine the reaction quantum yields at 
isosbestic irradiation; (ii) reconstruct the whole spectrum of the photoproduct (PP); and (iii) 
determine the reaction quantum yields for any non-isosbestic irradiation. 
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Firstly, the photodegradation reaction is subject to a monochromatic irradiation at the 
isosbestic point where  𝜀𝜀𝐴𝐴
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜 = 𝜀𝜀𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜. Hence, reducing the number of unknowns to two 
(𝛷𝛷𝐴𝐴→𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜 and 𝛷𝛷𝐵𝐵→𝐴𝐴






 ×  (𝐶𝐶𝐴𝐴(0)−𝐶𝐶𝐴𝐴(𝑝𝑝𝑚𝑚𝑚𝑚))
𝐶𝐶𝐴𝐴(0)







𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖                                   Eq.7 
Where 𝑘𝑘𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜  can be determined by fitting the concentration profiles (obtained using 
the HPLC) with Eq.4. 
The equilibrium constant (𝐾𝐾𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜, Eq.8) - which expresses the species’ concentrations at pss for 








           Eq.8 
The ratio of the concentrations of species A and B at equilibrium, independent of the 
wavelength, corresponds with the ratio of the quantum yields at the isosbestic wavelength. It 
is also important to note that 𝐾𝐾𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜  is independent of the concentration of the initial species. 
This is important as the concentration used for HPLC experiment is often too high for 
quantitative spectrophotometric measurement of the reaction. Hence, a lower concentration 
of the initial species can be used for the second elucidation step – reconstruction of the full 
spectrum of the photoproduct. 
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Using the value of 𝐾𝐾𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜, the total absorption spectra of the initial species and that of the 
reactive medium at pss (from an isosbestic irradiation experiment), the whole spectrum of the 






𝜆𝜆𝑥𝑥  × 𝐶𝐶𝐴𝐴(0) × 𝑠𝑠𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜
𝐾𝐾𝐴𝐴⇋𝐵𝐵
𝜆𝜆𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜  × 𝐶𝐶𝐴𝐴(0) × 𝑠𝑠𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜
         Eq.9 
Once the absorption coefficients of the photoproducts are known for all wavelengths, the 
photochemical quantum yields at any irradiation wavelength can readily be determined, by 




















                   Eq.11 
Where the numerical value of the reaction’s initial velocity (𝜈𝜈0(𝑚𝑚𝑡𝑡𝑑𝑑.)
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜⁄ ) can be obtained  
















𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖/𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖(0)�×�𝑠𝑠𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝑠𝑠𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜� � −
1�       Eq.12 
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A5.4. Determination of the Reaction Quantum Yields for an Isosbestic Irradiation 
Table A5.1:  Changes in DBZ, AXI, SUT and their photoproduct’s peak area and concentration over the irradiation period determined by HPLC 
 
Table A5.2: First-order equations for the three drugs and their products and the rate-constant determined for isosbestic irradiation 
 Change in Concentration of A Change in Concentration of B 𝒌𝒌𝑨𝑨⇋𝑩𝑩









 × log �1 + �10𝐴𝐴𝑡𝑡𝑜𝑜𝑡𝑡
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖⁄ (0)×𝑠𝑠𝑖𝑖𝑖𝑖𝑖𝑖𝑠𝑠𝑜𝑜𝑜𝑜𝑜𝑜 − 1�� 𝐶𝐶−𝑘𝑘𝑡𝑡 𝐶𝐶𝐵𝐵(𝑡𝑡) =  𝐶𝐶𝐶𝐶𝐵𝐵𝐷𝐷(𝑡𝑡) − 𝐶𝐶𝐶𝐶𝐵𝐵𝐷𝐷(0) 4.72 x 10
-3 1.02 x 10-6 
AXI 𝐶𝐶𝑡𝑡−𝐴𝐴𝑋𝑋𝐴𝐴(𝑡𝑡) =  𝐶𝐶𝑡𝑡−𝐴𝐴𝑋𝑋𝐴𝐴(∞) + �𝐶𝐶𝑡𝑡−𝐴𝐴𝑋𝑋𝐴𝐴(0) − 𝐶𝐶𝑡𝑡−𝐴𝐴𝑋𝑋𝐴𝐴(∞)�𝐶𝐶−𝑘𝑘𝑡𝑡 𝐶𝐶𝐶𝐶−𝐴𝐴𝑋𝑋𝐴𝐴(𝑡𝑡) =  𝐶𝐶𝐶𝐶−𝐴𝐴𝑋𝑋𝐴𝐴(∞) + �𝐶𝐶𝐶𝐶−𝐴𝐴𝑋𝑋𝐴𝐴(∞)�𝐶𝐶−𝑘𝑘𝑡𝑡 2.78 x 10
-3 3.12 x 10-6 
SUT 𝐶𝐶𝐷𝐷−𝑆𝑆𝑆𝑆𝑆𝑆(𝑡𝑡) =  𝐶𝐶𝐷𝐷−𝑆𝑆𝑆𝑆𝑆𝑆(∞) + �𝐶𝐶𝐷𝐷−𝑆𝑆𝑆𝑆𝑆𝑆(0) − 𝐶𝐶𝐷𝐷−𝑆𝑆𝑆𝑆𝑆𝑆(∞)�𝐶𝐶−𝑘𝑘𝑡𝑡  𝐶𝐶𝐸𝐸−𝑆𝑆𝑆𝑆𝑆𝑆(𝑡𝑡) =  𝐶𝐶𝐸𝐸−𝑆𝑆𝑆𝑆𝑆𝑆(∞) + �𝐶𝐶𝐸𝐸−𝑆𝑆𝑆𝑆𝑆𝑆(∞)�𝐶𝐶−𝑘𝑘𝑡𝑡  2.83 x 10
-3 2.19 x 10-6 
Time 
/mins 
Concentration / M Time 
/mins 
Concentration / M Time 
/mins 
Concentration / M 
DBZ PP t-AXI c-AXI Z-SUT E-SUT 
0 1.32 x 10-4 0 0 8.13 x 10-5 0 0 7.51 x 10-5 0 
10 8.60 x 10-5 4.59  x 10-5 2 6.21 x 10-5 1.92 x 10-5 5 6.51 x 10-5 1.01 x 10-5 
24 5.35 x 10-5 7.84  x 10-5 5 5.14 x 10-5 2.99 x 10-5 10 6.07 x 10-5 1.44 x 10-5 
36 1.48 x 10-5 1.17 x 10-4 10 3.16 x 10-5 4.97 x 10-5 20 5.91 x 10-5 1.60 x 10-5 
49 0 1.32 x 10-4 15 2.00 x 10-5 6.13 x 10-5 30 5.78 x 10-5 1.73 x 10-5 
63 0 1.32 x 10-4 20 1.82 x 10-5 6.31 x 10-5 40 5.68 x 10-5 1.83 x 10-5 
92 0 1.32 x 10-4 30 1.79 x 10-5 6.34 x 10-5 50 5.22 x 10-5 2.29 x 10-5 
104 0 1.32 x 10-4 40 1.57 x 10-5 6.56 x 10-5 60 5.73 x 10-5 1.78 x 10-5 
120 0 1.32 x 10-4 60 1.82 x 10-5 6.31 x 10-5 - - - 




1. Maafi M and Brown R.G. (2007) The kinetic model for AB(1Φ) systems: A closed-form 
integration for the differential equations with a variable photokinetic factor, Journal of 
Photochemistry and Photobiology A: Chemistry, 187:319-324    
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A6.1. SUNITINIB’S ABSORPTION SPECTRUM IN WATER 
 
Fig. 6.1:  Native absorption spectra of sunitinib in water and ethanol (SUT, 8.97 x 10-6 M and 
8.94 x 10-6 M respectively).  
 
A6.2. DIFFERENTIAL EQUATIONS OF AXI AND SUT 
 








∆ × 𝐶𝐶𝐶𝐶2 + 𝑘𝑘𝐴𝐴2→𝐶𝐶2




∆ × 𝐶𝐶𝐶𝐶2                         Eq.3 
 




∆ × 𝐶𝐶𝐴𝐴3 + 𝑘𝑘𝐵𝐵3→𝐴𝐴3
∆ × 𝐶𝐶𝐵𝐵3 − 𝑘𝑘𝐴𝐴3→𝐶𝐶3
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A6.3. SUNITINIB’S PHOTOSTABILITY IN AQUEOUS SOLUTION 
 
Fig 6.4: Evolution of the electronic absorption spectra of 1.92 x 10-5 M SUT in water, when 
irradiated continuously with a monochromatic beam at 430 nm (4.90 x 10-6 einstein s-1 dm-3, 
22°C) 
 
A6.4. RATE LAWS OF THE SYSTEMS 
 




∆ × 𝐶𝐶𝐴𝐴2 − 𝑘𝑘𝐴𝐴2→𝐵𝐵2
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹𝜆𝜆𝐼𝐼𝐶𝐶𝐶𝐶(𝑡𝑡) × 𝐶𝐶𝐴𝐴2+𝑘𝑘𝐵𝐵2→𝐴𝐴2
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐵𝐵2 +
𝑘𝑘𝐶𝐶2→𝐴𝐴2




∆ × 𝐶𝐶𝐵𝐵2 + 𝑘𝑘𝐴𝐴2→𝐵𝐵2
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹𝜆𝜆𝐼𝐼𝐶𝐶𝐶𝐶(𝑡𝑡) × 𝐶𝐶𝐴𝐴2 − 𝑘𝑘𝐵𝐵2→𝐴𝐴2
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐵𝐵2 +
𝑘𝑘𝐹𝐹2→𝐵𝐵2
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐹𝐹2 − 𝑘𝑘𝐵𝐵2→𝐸𝐸2




∆ × 𝐶𝐶𝐴𝐴2 − 𝑘𝑘𝐶𝐶2→𝐶𝐶2
∆ × 𝐶𝐶𝐶𝐶2 − 𝑘𝑘𝐶𝐶2→𝐴𝐴2
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐶𝐶2 − 𝑘𝑘𝐶𝐶2→𝐹𝐹2
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹λirr(𝑡𝑡) ×
𝐶𝐶𝐶𝐶2 + 𝑘𝑘𝐹𝐹2→𝐶𝐶2
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐹𝐹2 + 𝑘𝑘𝐶𝐶2→𝐶𝐶2




∆ × 𝐶𝐶𝐶𝐶2 − 𝑘𝑘𝐶𝐶2→𝐶𝐶2








∆ × 𝐶𝐶𝐵𝐵2 − 𝑘𝑘𝐹𝐹2→𝐺𝐺2
∆ × 𝐶𝐶𝐹𝐹2 − 𝑘𝑘𝐹𝐹2→𝐵𝐵2
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐹𝐹2 − 𝑘𝑘𝐹𝐹2→𝐶𝐶2
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹λirr(𝑡𝑡) ×
𝐶𝐶𝐹𝐹2 + 𝑘𝑘𝐶𝐶2→𝐹𝐹2
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐶𝐶2 + 𝑘𝑘𝐺𝐺2→𝐹𝐹2
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐺𝐺2      Eq.18 





∆ × 𝐶𝐶𝐹𝐹2 − 𝑘𝑘𝐺𝐺2→𝐹𝐹2
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐹𝐹λirr(𝑡𝑡) × 𝐶𝐶𝐺𝐺2       Eq.19 
 
SUT’s were written to scheme 6.2: 
𝑑𝑑𝐶𝐶𝐴𝐴3
𝑑𝑑𝑡𝑡
(𝑡𝑡) =  −𝑘𝑘𝐴𝐴3→𝐵𝐵3
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐶𝐶𝐴𝐴3  × 𝐹𝐹𝜆𝜆𝐼𝐼𝐶𝐶𝐶𝐶(𝑡𝑡) + 𝑘𝑘𝐵𝐵3→𝐴𝐴3
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐶𝐶𝐵𝐵3  × 𝐹𝐹𝜆𝜆𝐼𝐼𝐶𝐶𝐶𝐶(𝑡𝑡)− 𝑘𝑘𝐴𝐴3→𝐵𝐵3
∆ × 𝐶𝐶𝐴𝐴3 +
𝑘𝑘𝐵𝐵3→𝐴𝐴3
∆ × 𝐶𝐶𝐵𝐵3 − 𝑘𝑘𝐴𝐴3→𝐶𝐶3




𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐶𝐶𝐴𝐴3  × 𝐹𝐹𝜆𝜆𝐼𝐼𝐶𝐶𝐶𝐶(𝑡𝑡)− 𝑘𝑘𝐵𝐵3→𝐴𝐴3
𝜆𝜆𝑖𝑖𝑖𝑖𝑖𝑖 × 𝐶𝐶𝐵𝐵3  × 𝐹𝐹𝜆𝜆𝐼𝐼𝐶𝐶𝐶𝐶(𝑡𝑡) + 𝑘𝑘𝐴𝐴3→𝐵𝐵3
∆ × 𝐶𝐶𝐴𝐴3 −
𝑘𝑘𝐵𝐵3→𝐴𝐴3
∆ × 𝐶𝐶𝐵𝐵3 − 𝑘𝑘𝐵𝐵3→𝐶𝐶3
∆ × 𝐶𝐶𝐵𝐵3          Eq.21 
𝑑𝑑𝐶𝐶𝐶𝐶3
𝑑𝑑𝑡𝑡
(𝑡𝑡) =  𝑘𝑘𝐴𝐴3→𝐶𝐶3




∆ × 𝐶𝐶𝐵𝐵3         Eq.23 
 
A6.5. RUNGE-KUTTA ANALYSIS OF THE PHOTODEGRADATION REACTION 
 
Fig 6.9: Fitting of 2.03 x 10-5 M AXI in 2.5 % (v/v) ethanol/water solution when 
monochromatically irradiated at 330 nm (6.99 x 10-7 einstein s-1 dm-3, 22°C) and observed at 
230nm, 280 nm, 300 nm, 330 nm, 360 nm and 380 nm. Experimental kinetics traces (open 
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A6.6. DETERMINATION OF AXITINIB’S DEGRADATION REACTION IN AQUEOUS 
MEDIA 
 
In ethanoic solution, both AXI was shown to be thermally stable. However, this was not the 
case in water. AXI’s absorption spectrum decreased simultaneously at every wavelength (Fig 
A6.1).  
 
Fig A6.1: Changes in the spectrum of (left) 1.97 x10-4 M AXI 2.5% v/v ethanol/water solution, 
stirred and thermalstatically maintained at 22°C. (Right) Kinetic trace obtained when 
observed at 430 nm 
 
Looking at Fig A6.1, the decrease in absorbance under thermal conditions within the first 60 
seconds is relatively quick in comparison to the rest. It is clear that the reaction is not 
unimolecular, but maybe an A to B to C reaction involving three species. 
The small change in absorbance can be seen in the first reaction suggesting that the first 
thermal product (C) has an epsilon that’s very similar to AXI (A) and very possibly a similar 
chemical structure as well.  On the other hand, the epsilon of the final thermal product (D) is 
significantly lower and hugely different to A and C.  A consecutive reaction mechanism 
involving three species is proposed (scheme A6.1): 
 
A C DD D  
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The thermal reaction seems to deplete A in less 500 s while the photochemical reaction in the 
same conditions looks like it does not allow A to react thermally, this supported by the 
variation of the spectra since in the latter case we observe a similar behaviour to that obtained 
in ethanol and not the decrease of the whole spectrum as observed during the thermal 
reaction (Fig. A6.1). This further suggests the formation of different products. 
 
 
Fig. A6.2: Irradiation of 2.03 x 10-5 M AXI in 2.5 % (v/v) ethanol/water solution continuously 
with a monochromatic beam at 360 nm (1.15 x 10-6 einstein s-1 dm-3, 22°C); (left) spectral 
evolution;  (right) kinetic traces obtained when observed at 330 nm and 380 nm. 
 
As seen in Fig. A6.2 (right), the photodegradation of AXI is very fast in the first 800 s (broken 
line) of the reaction (S1) and then slows down (S2). The absorbance at 330 nm in S1 changes 
by 0.2 AU in just 800 s, whereas in S2 only 0.03 AU change in absorbance is observed over 
3000 s. The change in absorbance in the latter section is of the same magnitude of that in 
thermal reaction (0.03 AU) from 800 s onwards. Coinciding with the fact that thermal reaction 
continues to occur, even when the solution is exposed to light, the slower reaction in S2 at 330 
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The difference in the spectral evolution and increase in absorbance observed at 380 nm (peak 
established in ethanol as belonging to the photoproduct, Z-AXI) points to the occurrence of 
photoreaction.  
The significant difference in the evolution of the thermal and photo-degradation strongly 
suggests that the products produced are different. A comparison of AXI’s spectra and the 
spectra obtained at the end of the photo- and thermal reaction further supports the idea that 
these reaction produce different end products (Fig. A6.3). 
 
 
Fig. A6.3: The spectra of E-AXI, the last spectra of the photoreaction (λ irr = 330 nm, 6.99 x 10-7 
einstein-1 s-1 dm-3, 22°C, stirred) and the last spectra of the thermal reaction (22°C, stirred).   
 
Therefore, AXI’s reaction in water can deemed to involve at least 4 species: 
 
Scheme A6.2: proposed reaction mechanism for the degradation of AXI in water involving 4 
species 
 
Comparison of the thermal and photokinetic traces (Fig. A6.4) suggests that during 
photoreaction, the formation of Species C is hampered as the change in absorbance recorded 
is significantly different. This may be because less C is formed than B and so the absorbance at 






















224 | P a g e  
 
photo- and thermal kinetic traces do not finish at the same point. If the formation of species C 
is constant, A and B will require to re-equilibrate to compensate for the loss of A to C. 
Therefore, species C must photochemically reverse to A. 
               
Fig. A6.4: Thermal and photokinetic traces of E-AXI in water.  
 
This also indicates that during the thermal degradation the double bond at which 
photoisomerisation occurs is not broken. Accordingly, it is highly probable that species C is also 
photochemically active, transforming into its isomer equivalent (Species F). Because A and B 
are similarly structured and thermal degradation does not occur at the double bond, it can be 
deemed that B thermally degrades into F and then G to F as well (scheme A6.3). 
 
Fig. A6.5: Irradiation of the solution at the end of the thermal 
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Irradiation of the solution at the end of the thermal reaction induced a very slow increase of 
absorbance (Fig. A6.5) at all wavelength, indicating a slow reverse photoreaction of species D 
to C -  and so G to F. 
Closer inspection of the photokinetic trace at 380 nm revealed that a plateau is not reached 
and a small change in absorbance can be observed pointing to the presence of a very slow 
reaction which is not reversible.  
Finally from these data, AXI’s degradation mechanism in aqueous medium is proposed 
(Scheme A6.4). 
 
A6.7. SPECIES’ CONCENTRATIONS 
 
 
Fig. 6.10: Concentration profiles obtained for 1.12 x 10-5 M Z-SUT and its products when 
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A6.8. ELECTRONIC ABSORPTION SPECTRA OF SUNITINIB AND ITS PRODUCTS 
 
Fig 6.11: Estimated electronic absorption spectra of SUT and its products 
 
A6.9. PHOTOCHEMICAL QUANTUM YIELD VALUES OF AXITINIB 
 
 
Fig 6.14: Photochemical quantum yield values of Axitinib and its products determined at 
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A6.10. POTENITAL DEVELOPMENT OF ACTINOMETERS  
 
Table 6.5: Equations for the recalculation of radiant power (P) for three irradiation 
wavelengths obtained using the theoretical (theo) and Φ-order kinetics model (fit) equations  
λ irr  /nm 300 330 360 
Ptheo 
P300 = 880.17 x Ptheo – 
2x10-5 
P330 = -302.21 x Ptheo + 
1x10-6 
P360 = 199.67 x Ptheo – 
3x10-7 
r2 1 1 1 
Pfit 
P300 = -208.33 x Pfit – 
2x10-5 
P330 = -397.8 x Pfit – 2x10-
6 
P360 = -269.41 x Pfit – 
2x10-5 
r2 0.99 0.98 0.97 
 
 
A6.11. THE EFFECT OF POLYCHROMATIC LIGHT  
 
 
Fig 6.16: Evolution of the electronic absorption spectra of 5.38 x 10-6 M DBZ in water 
 
 
Fig 6.16: Kinetic traces obtained for AXI in water when subjected to ambient polychromatic 
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A7.1. THE MATHEMATICAL BACKGROUND FOR A Gn:(CDp)m COMPLEX 
The association of “n” (one or more) guest species with a polymer “m” (one or more) 
cyclodextrin chain-molecules that may encompass each up to “p” cyclodextrin monomer–
units, form a type of complex that will be labelled here as 𝐺𝐺𝑛𝑛: �𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚 (Scheme 7.1). Hence, 
for monomer cyclodextrins, p = 1. Such a complex is supposed to instantaneously occur in the 
solution medium with a unique stoichiometry for the guest/nanosponge complex (irrespective 
of the specific type of binding that may include an inclusion, non-inclusion, clustering or 
aggregation).  
The overall association reaction is given by 
n G  + m CDp   ⇌ Gn:(CDp)m 
Scheme 7.1: Association reaction of n guest molecules with m  
cyclodextrin nanosponge units (CDp). 
 
The thermodynamic association (or binding) constant of the complex at equilibrium for a given 






𝑚𝑚              Eq. 1 
 
Here, we consider the most general case where the experiment “i” is performed by keeping 
constant the guest (drug) molecule concentration throughout, [𝐺𝐺]0,𝑖𝑖, and gradually increasing 
the concentrations of the host-nanosponge, �𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑖𝑖,𝑗𝑗, in a set of “j” separate solutions.  
For each solution, the mass balance for CD is given by 
�𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑖𝑖,𝑗𝑗 = �𝐶𝐶𝐶𝐶𝑝𝑝�𝑖𝑖,𝑗𝑗 + 𝑛𝑛 × �𝐺𝐺𝑛𝑛: �𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚�𝑖𝑖,𝑗𝑗
           Eq. 2 
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where �𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑖𝑖,𝑗𝑗  is the actual initial concentration of 𝐶𝐶𝐶𝐶𝑝𝑝 in the j
th solution for experiment “i”; 
�𝐶𝐶𝐶𝐶𝑝𝑝�𝑖𝑖,𝑗𝑗 and �𝐺𝐺𝑛𝑛: �𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚�𝑖𝑖,𝑗𝑗
 are respectively the concentrations of free and complexed 
nanosponge molecules in the medium at equilibrium for a given temperature.    
If we assume that the concentration of the guest molecule is very small compared to that of 
CD then Eq. 2 becomes 
�𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑖𝑖,𝑗𝑗 ≅ �𝐶𝐶𝐶𝐶𝑝𝑝�𝑖𝑖,𝑗𝑗               Eq. 3 
 
We also consider the mass balance relative to the guest species, as 
[𝐺𝐺]0,𝑖𝑖 = [𝐺𝐺]𝑖𝑖,𝑗𝑗 + 𝐶𝐶 × �𝐺𝐺𝑛𝑛: �𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚�𝑖𝑖,𝑗𝑗
            Eq. 4 
 
where [𝐺𝐺]0,𝑖𝑖 is the constant initial concentration of the guest for the i
th experiment (used for 
the “j” solutions). [𝐺𝐺]𝑖𝑖,𝑗𝑗  and �𝐺𝐺𝑛𝑛: �𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚�𝑖𝑖,𝑗𝑗
 are respectively the concentrations relative to 
free and complexed guest molecules in the medium at equilibrium for the jth  solution of 
experiment “i”.  
Each of the j solutions of an experiment i, is individually analysed by fluorimetry.  
The total fluorescence intensity (𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 ) recorded for the medium, for each individual solution 
“j” at a given observation wavelength (𝜆𝜆𝑡𝑡𝑜𝑜𝑚𝑚, e.g. at the maximum of the emission spectrum of 




𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜             Eq. 5 
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The measured fluorescence intensities of free guest �𝐹𝐹𝐹𝐹𝐺𝐺,𝑖𝑖,𝑗𝑗




� are proportional to the respective species 
concentrations ([𝐺𝐺]𝑖𝑖,𝑗𝑗 and �𝐺𝐺𝑛𝑛: �𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚�𝑖𝑖,𝑗𝑗
, respectively), according to the Beer-Lambert law, 
where the proportionality factors are the fluorescence molar coefficients (𝜎𝜎𝐺𝐺  and 𝜎𝜎𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
, 
respectively [1]).  
Therefore, 𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜  can be re-written as  
𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 = 𝜎𝜎𝐺𝐺 × [𝐺𝐺]𝑖𝑖,𝑗𝑗 + 𝜎𝜎𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
× �𝐺𝐺𝑛𝑛: �𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚�𝑖𝑖,𝑗𝑗
          Eq. 6 
 
Rearranging Eq. 4 for [𝐺𝐺]𝑖𝑖,𝑗𝑗 and introducing its expression in Eq. 6, yields 
𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 = 𝜎𝜎𝐺𝐺 × [𝐺𝐺]0,𝑖𝑖 + �𝜎𝜎𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
− 𝐶𝐶 × 𝜎𝜎𝐺𝐺 � × �𝐺𝐺𝑛𝑛: �𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚�𝑖𝑖,𝑗𝑗
        Eq. 7 
 
Since the native fluorescence of the guess (i.e. measured in the absence of the host) is 
expressed as 𝐹𝐹𝐹𝐹0,𝐺𝐺,𝑖𝑖








            Eq. 8 
 
Introducing the resulting rearranged equation from combining Eqs. 8 and 4, in the resulting 
equation from introducing Eq. 8 in Eq. 1 gives a new expression for the association constant 
𝐾𝐾𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
 (Eq. 9) which is exclusively dependent on experimentally accessible quantities. 
 
























        Eq. 9 
 
Assuming that at high 𝐶𝐶𝐶𝐶𝑝𝑝 concentrations (�𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑖𝑖,𝑗𝑗 ≅ ∞), every molecule of the guest is 
complexed �[𝐺𝐺]0,𝑖𝑖 = 𝐶𝐶 × �𝐺𝐺𝑛𝑛: �𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚�𝑖𝑖,𝑗𝑗
∞
�, therefore the fluorescence intensity of the 
medium is  
 
𝐹𝐹𝐹𝐹0,(𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚)





× [𝐺𝐺]0,𝑖𝑖 × 𝜎𝜎𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
   Eq. 10 
 
 
Hence, combining the latter Eqs. 9 and 10, leads to a general equation for the variation of the 
medium total fluorescence intensity (𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 ) with nanosponge concentration (�𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑖𝑖,𝑗𝑗) for a  


















𝑚𝑚                      Eq. 11 
 
If the relative molar mass of the CD polymer (𝑅𝑅𝑀𝑀𝑀𝑀(𝐶𝐶𝐶𝐶𝑝𝑝)) is not known with accuracy (which 
is indeed the case for a majority of nanosponges), then it would be useful, from an 
experimental point of view, to employ a g/L unit for concentrations (instead of the molarity 






















𝑚𝑚         Eq. 12 
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where, RMM(G) and RMM(CDp) are the relative molar masses of guest (G) and nanosponge 
(CDp), respectively (expressed in g/mol); and in Eq. 12, the species concentrations ([𝐺𝐺]0,𝑖𝑖 and 
�𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑖𝑖,𝑗𝑗) are expressed in g/L, mg/mL or equivalent. 
The unit of the association constant, 𝐾𝐾𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
, that can be worked out from either Eq. 11 or 
12, is expressed either in molarity or g/L units as 𝑀𝑀1−𝑚𝑚−𝑛𝑛 or (𝐿𝐿/𝐿𝐿)1−𝑚𝑚−𝑛𝑛, respectively. In the 
cases were the relative molar mass of the nanosponge is not known with precision, it is 
possible to work with an alternative “pseudo–association” constant, 𝐾𝐾𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
ʹ  (Eq. 13), which 
will be expressed in �𝐿𝐿2/(𝑛𝑛𝐶𝐶𝐹𝐹 × 𝐿𝐿)�1−𝑚𝑚−𝑛𝑛 or equivalent.  
 
𝐾𝐾𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
′ =  𝐾𝐾𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
× [𝑅𝑅𝑀𝑀𝑀𝑀(𝐺𝐺)]0,𝑖𝑖1−𝑛𝑛 × �𝑅𝑅𝑀𝑀𝑀𝑀�𝐶𝐶𝐶𝐶𝑝𝑝��0,𝑖𝑖
−𝑚𝑚                Eq. 13 
 
It is clear that Eq.11 is non-linear relative to the variation of the medium fluorescence 
intensity, 𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 , with increasing nanosponge concentration, �𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑖𝑖,𝑗𝑗, in the solution. This 
mean that is impossible to derive a classical formulation for the isotherm, i.e. where the 
fluorescence intensity is directly expressed as a function of CD concentration, 𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 =
𝑓𝑓 ��𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑖𝑖,𝑗𝑗�, for the general case where n has any given values higher than 1.  
However, it is possible to derive from Eq.11 a general expression for the isotherm 
corresponding to complexes involving a single guest molecule (n = 1) associated to m 
nanosponge host-molecules (𝐺𝐺1: �𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚), as: 
 












𝑚𝑚           Eq.14 
 
Eq.14 reduces down to the equations that have been previously proposed in the literature for 
complexes involving CD monomers [2,3]. 
The limit value of the first term of Eq.11 tends to 0 (i.e. 𝐹𝐹𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑖𝑖,𝑗𝑗
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 ≅ 𝐹𝐹𝐹𝐹0,(𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚)
𝜆𝜆𝑜𝑜𝑜𝑜𝑜𝑜 ) when the CD 
concentration tends to infinity. This means that in all cases, irrespective of n and m values, the 
isotherm ends with a plateau that indicates the occurrence of a saturation (where the majority of 
guest molecules are involved in a complex). It is then evident that any variation to the final part of 
the curve (by an increase or a decrease of the medium total fluorescence intensity after the plateau 
region) for given experimental data would strongly suggest the occurrence of another phenomenon.  
According to a great number of simulations we performed on Eq.11, the isotherms can have one of 
two general shapes (Fig. A7.1); they are either exponential-like (as for the usual isotherms observed 
for 1:1 complexes) when m = 1 and any n values, or an S-shaped curves if m > 1 for any n (even for a 
1:2 complex). Therefore, the shape of the isotherm can inform on whether m is equal to unity.       
 
 


























when m > 1 and
any n values
when m = 1 and
any n values
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� of Eq.11 against 1
�𝐶𝐶𝐶𝐶𝑝𝑝�0,𝑖𝑖,𝑗𝑗
𝑚𝑚  will 
always yield a straight line. However, in practice this means that the stoichiometry of the 
complex (i.e. parameters n and m) must be known or pre-selected.  
This relationship may nevertheless be used either for confirmation of the results of the 
parameters found by another method, or for successive iterations on preconceived 
stoichiometries of the complex (iterations run with imposed values for n and m, until a good 
linear fit is obtained).  
The latter strategy is generally adopted in the literature for monomers (p = 1) where a linear 
treatment is sought, by assuming that a single parameter (e.g. 𝐾𝐾𝐺𝐺𝑛𝑛:�𝐶𝐶𝐶𝐶𝑝𝑝�𝑚𝑚
) is unknown; an 
approach that can be applied for Eq.11, where several options might be proposed until a good 
fit is found. Generally, one starts with n = m = 1, defines the equations to which the data will 
be fitted to, for instance, the Benesi-Hildebrand equation for 1:1 complexes [4,5]. If a poor 
fitting is found then n and/or m is incremented by one unit at a time to define the appropriate 
equations and proceed to the fitting. This procedure is repeated until a good fitting is found, 
hence defining the couple n and m. This strategy would be tedious if the stoichiometry of the 
complex involves a high number of species.  
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